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Mitochondria: life and death of a cell 
In eukaryotes, many energetic functions, such as cellular respiration and energy 
production, take place in double membrane cytoplasmic organelles, containing their 
own genome, the mitochondria. These organelles are the main players in many cellular 
processes, not only the energy production, but also thermogenesis, apoptosis, reactive 
species of oxygen (ROS) production and calcium homeostasis. In the last 20 years 
several neurodegenerative diseases, aging and cancer have been associated with 
mitochondrial impairment and mitochondrial DNA (mtDNA) mutations.1,2 
The origin of mitochondria is explained by the endo-symbiont theory, which proposes 
that these organelles originated from aerobic bacteria, incorporated into an oxidative 
proto-eukaryote host cell and maintained during evolution.3 
 
Morphology and dynamics 
Mitochondria are delimited by two membranes, the outer mitochondrial membrane 
(OMM), very permeable, and the strictly selective inner mitochondrial membrane 
(IMM), characterized by the presence of cristae. These ‘mitochondrial units’ have a 
major axis of 2–5 µm, as observed in classical electron microscopy images of isolated 
mitochondria. In the cytosol of a living cell, these organelles display an elongated, 
tubular morphology.4 Mitochondria can be considered dynamic organelles in two ways: 
their shape is continuously remodelled by cycles of fission and fusion events and they 
must be strategically distributed to meet cellular needs and signals from outside.5 
The fission/fusion process is regulated to respond to specific cellular needs, such as the 
transport of mitochondria at specific subcellular sites or the equal mitochondrial 
distribution between the two daughter cells during mitosis.6 Moreover mitochondrial 
morphology changes drastically during the early steps of apoptosis (fragmentation of 
the reticulum and remodelling of the cristae) and this process is required to insure the 
release of apoptogenic factors and the progression of the apoptotic cascade.7  
 
 
 
  
The proteins involved in the fission/fusion process are usually large GTPases belonging 
to the dyn
- 
- 
- 
Although seve
identified, the knowledge of the mechanisms and the regulation of fusion and fission is 
still not completely clear.
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Mitochondria are travelling powerhouses that need to be located within the cytoplasm 
according to the local metabolic needs of the cell. Mitochondrial movements within 
neuronal axons occur as a bi-directional, antero-retrograde flux, traveling with the so-
called “fast component” of axonal transport.23,24 The mitochondrial distribution within 
the cytoplasm depends on their interaction with the cytoskeleton, in particular with the 
microtubules (MT) and the motor proteins. Thus, MT-based motility is supported by 
kinesin for anterograde transport, and by dynein for retrograde transport. Mitochondria 
can also use actin microfilaments, most likely representing an auxiliary system involved 
in local transport.25 Both kinesin and dynein are associated with an ATPase activity that 
is activated by microtubule binding and so, mitochondrial axonal transport is an ATP-
dependent process. 26,27 
 
The respiratory chain 
Mitochondrial respiration is driven by a chain of sequentially organized redox reactions 
fed by reducing equivalents derived from the oxidative degradation of carbon substrates. 
Embedded in the lipid bilayer of the IMM, the oxidative phosphorylation (OXPHOS) 
system is the final biochemical pathway in energy production of the cell. The 
respiratory chain consists of five multimeric enzyme complexes (I-V) together with two 
mobile electron carriers, ubiquinone (CoQ) and cytochrome c (cyt c) (Fig. 2).  
Complex I (NADH:ubiquinone oxidoreductase), the first site of the respiratory chain, 
transfers electrons from nicotinamide adenine dinucleotide (NADH) to CoQ, generating 
ubiquinol (CoQH2), which then shuttles two electrons to complex III 
(ubiquinol:ferricytochrome c oxidoreductase, cytochrome bc1 complex).28  Complex I is 
composed approximately of 45 subunits, 7 mtDNA-encoded.29 Ubiquinol is also 
produced by complex II (succinate:ubiquinone oxidoreductase), which, in a pathway 
parallel to that of complex I, transfers electrons from flavin adenine dinucleotide 
(FADH2) to CoQ. Complex II is the only respiratory enzyme completely encoded by 
nDNA (4 subunits).30 A third, further source that transfers electrons to CoQ to generate 
ubiquinol is glycerol 3-phosphate dehydrogenase. 
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 Fig. 2 Mitochondrial respiratory chain. From Zeviani M, Di Donato S. Brain (2004) 127:2153-2171. 
 
Complex III has only one mtDNA-encoded subunit, cytochrome b; the other 10 
subunits are nDNA-encoded, and at least one nDNA-encoded protein has been reported 
to be essential for the enzyme assembly.31,32 Complex III, the middle segment of the 
respiratory chain, transfers two electrons from CoQH2 to cyt c, which in turn shuttles 
the electrons to complex IV (ferrycytochrome:oxygen oxidoreductase, cytochrome c 
oxidase). Complex IV, the terminal component of the respiratory chain, transfers 
electrons to molecular oxygen, the final acceptor, producing water. The three largest 
subunits out of the 13 that make up complex IV are encoded by mtDNA, but at least 
five nDNA-encoded genes have been identified as essential to the enzyme assembly.32,33  
All the respiratory complexes containing mtDNA-encoded subunits (complexes I, III, 
and IV) couple the electron transfer with the proton translocation across the inner 
mitochondrial membrane from the matrix side to the intermembrane space. According 
to the chemiosmotic theory, proposed by Mitchell,34 the electrochemical gradient (∆µH) 
drives the reverse flow of protons back to the matrix through the membrane portion of 
complex V (ATP synthase, F1Fo-ATPase), which then catalyzes the ATP synthesis, 
phosphorylating ADP to ATP. Complex V has two subunits encoded by mtDNA 
(ATPase6 and ATPase8), that take part to the membrane-bound portion (Fo) of the 
enzyme, and about 13 other subunits encoded by nDNA.35 The ATP synthesized in the 
mitochondrial matrix is transported across the inner mitochondrial membrane with an 
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exchange mechanism, importing cytosolic ADP by the adenine nucleotide translocator 
(ANT).  
 
Complex I structure, function and assembly 
Complex I, the largest of the five OXPHOS complexes, binds and oxidizes NADH to 
free electrons via a non-covalently bound flavine mononucleotide (FMN). Then the 
electrons are transferred via a cascade of up to nine iron–sulfur clusters to electron 
acceptor ubiquinone and then through the OXPHOS system to reduce molecular oxygen 
at complex IV. Enzymes from different organisms have different numbers of iron-
sulphur clusters, most of which share the same midpoint potential and are called 
“isopotential” clusters. The energy released during this process is used to drive proton 
translocation across the IMM. The redox reaction of complex I can be summarized in 
the following scheme:36,37  
 
NADH + H+ + Q + 4H+matrix → NAD+ + QH2 + 4H+intermembrane space 
 
The way in which the electron transfer is coupled to proton translocation is still debated: 
it could be directly coupled via close proximity of the ubiquinone binding site to proton 
translocation, or indirectly via conformational changes of the enzyme. This latter 
hypothesis is supported by recent data obtained for bacterial and Y. lipolytica 
enzymes.38   
Complex I is L-shaped, consisting of two arms: a hydrophobic membrane region which 
resides in the IMM and a hydrophilic peripheral or matrix region which protrudes into 
the mitochondrial matrix (Fig. 3).39-41 Recently the crystal structure of the peripheral 
arm of T. thermophylus complex I elucidated the exact arrangement of the iron–sulfur 
clusters within the complex,42,43 but the structure of the transmembrane arm is still 
unknown. 
Three functional modules can be distinguished for human complex I: 
1. the dehydrogenase module, which is responsible for the oxidation of NADH and 
consists of at least the NDUFV2, NDUFV1 and NDUFS1 subunits  
2. the hydrogenase module, which guides the released electrons to ubiquinone and 
consists of at least the NDUFS2, NDUFS3, NDUFS7 and NDUFS8 subunits 
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3. the proton translocation or transporter module, which consists of at least the 
ND1, ND2, ND3, ND4, ND4L, ND5 and ND6 subunits. 38 
 
 
Fig. 3 Complex I structure and protein composition. From Vogel RO et al. Biochim Biophys Acta. (2007) 
1767:1215-1227. 
 
The “minimal” functioning structure is considered the bacterial complex I, composed by 
the 14 most conserved subunits, also known as core subunits. Several phylogenetic 
studies have revealed a high degree of conservation of certain modules in different 
organisms and have led to models describing the modular evolution of complex I.38,44 
These models proposed that complex I is originated from an ancestral soluble nickel-
iron hydrogenase (sharing homology with the NDUFS2 and NDUFS7 subunits). This 
hydrogenase has gained a quinone binding site and has become membrane bound upon 
acquisition of a protein of unknown function (NDUFS3), a ferrodoxin-type (NDUFS8), 
ion translocating (ND5) and quinone-binding (ND1) subunits. This structure was 
subsequently expanded by triplication of ion translocating subunits (ND2 and ND4). 
Then the complex has lost its nickel-iron active site and its ability to react with 
molecular hydrogen, finally, membrane subunits (ND3, ND4L and ND6) and the 
NADH dehydrogenase module (NDUFS1, NDUFV1 and NDUFV2) are acquired.38 
Several subunits are necessary for a correct assembly of complex I: all the mitochondrial 
proteins, with the only exceptions of ND3 and ND4L, if mutated lead to many different 
species of subcomplexes. Moreover, mutations in many nuclear subunits, such as 
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NDUFA1, NDUFA6, NDUFA9, NDUFS1, NDUFS3, NDUFS4, NDUFS8 and 
NDUFV1, generate an incomplete assembly of complex I.38 
 
 
Fig. 4 General model proposed for complex I assembly in human. From Vogel RO et al. Biochim 
Biophys Acta. (2007) 1767:1215-1227.  
 
Four different models were proposed for the assembly mechanism in human.45-48 These 
models agree in that 100/200kDa intermediate, containing at least NDUFS2 and 
NDU4S3, is anchored to the membrane by at least ND1 prior to addition of remaining 
membrane, hydrogenase and NADH dehydrogenase subunits (Fig. 4). This first stage is 
follow by the assembly of a 400/500 kDa membrane bound intermediate, probably 
containing NDUFS1, NDUFS7, NDUFS8, ND2, ND3 and ND6. Subsequently an 
800/850 kDa intermediate is generated, most likely due to the addition of NDUFB8, 
NDUFA9, NDUFV1, NDUFV3 and NDUFS6. Finally the addition of at least NDUFV2 
and NDUFS4 leads to a fully assembled complex I.38 This extremely complex process 
probably regulated and coordinated by different chaperone proteins; some of them are 
recently identified, such as B17.2L and AIF.49-51 
 
Reactive Oxygen Species (ROS) production 
The mitochondrial respiratory chain is also the principal cellular source of ROS. ROS 
are generated by loose electrons spilling from complex I and III, and reacting with 
molecular oxygen to form the superoxide anion (O2.-). The O2.- is rapidly converted into 
hydrogen peroxide (H2O2) by manganese superoxide dismutase (MnSOD, SOD2); H2O2 
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is further metabolized by glutathione peroxidase (GPx) into H2O. Alternatively, H2O2 
may also generate the hydroxyl radical (OH.) in the presence of transition metals 
through the Fenton reaction. Furthermore, O2.- may react directly with nitric oxide (NO.) 
to produce peroxynitrite (ONOO.). Compared to O2.-, H2O2 is much more stable and can 
diffuse through biological membranes, giving it the potential to act as a long-range 
signaling molecule.52-54 A recent work has shown that ROS can be used by the cell as 
regulated and specific second messengers to propagate signals in multiple settings.55 
Being the major generator of ROS, mitochondria could also be the principal target of 
ROS damage, which could affect DNA, proteins and/or lipids. 
Oxidative damage to DNA causes modification of the bases, the deoxyribose backbone, 
single and double strand breaks, as well as cross-links to other molecules. DNA 
modifications are potentially mutagenic, contributing to cancer, premature ageing and 
neurodegenerative diseases.56 Moreover mtDNA is especially susceptible to attack by 
ROS due to the close proximity to the respiratory chain and the lack of protective 
histones; the level of modified bases in mtDNA is 10- to 20-fold higher than that in 
nuclear DNA. In this way, ROS induced oxidative damage is probably a major source 
of mitochondrial genomic instability leading to respiratory dysfunction and this 
instability is thought to be one of the most important factors in ageing.57  
Excessive ROS production may cause local damage to the Fe-S clusters of respiratory 
enzymes (complexes I, II and III), as well as to tricarboxylic acid cycle enzymes 
(aconitase).58,59 Moreover, peroxynitrite can nitrate tyrosine residues or thiolic groups of 
nearby proteins  and both complex I and MnSOD have been reported to be  damaged by 
this process.60-63 Oxidized proteins are recognized by proteases and degraded. 
Lastly, another important damaging process is lipid peroxidation; this affects vital 
mitochondrial functions, such as respiration and oxidative phosphorylation, inner 
membrane barrier properties, maintenance of mitochondrial membrane potential (∆ψm), 
and mitochondrial Ca2+ buffering capacity.64-66  
 
Apoptosis 
Apoptosis is a major pathway of programmed cell death (PCD) and is extremely 
important in several physiological conditions, such as embryonic development, tissue 
generation and the immune system development. This process is involved also in many 
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pathological events, included neurodegenerative, cardiovascular and immunological 
disorders.67 Apoptosis is characterized by a cascade of controlled events that leads to 
specific morphological changes in the cell: loss of adhesion, cell shrinkage, plasmatic 
membrane blebbing, chromatin condensation, DNA fragmentation, proteolytic cut of 
specific substrates and exposure of phosphatidylserine on the external surface of the 
cell.68-70 The final event of this cascade is the phagocytosis of the apoptotic cell, without 
any release of cytoplasmic content into the extracellular matrix or inflammatory 
response induction. 
Apart the granzyme B pathway, there are other two apoptotic cascades: the “extrinsic” 
or death receptor pathway, and the “intrinsic” or mitochondrial pathway (Fig. 5). The 
extrinsic pathway is activated by the binding of ligands to a specific death receptor, 
such as Fas, TNF or TRAIL receptors. This step is followed by the receptor 
oligomerization, which induce the recruitment of adaptor proteins and upstream 
procaspases. The proteolytic cut of inactive procaspases induce their direct activation 
and triggers the apoptotic cascade.71 The mitochondrial pathway is a complex signaling 
cascade, regulated by the Bcl-2 family proteins, that needs the release of apoptogenic 
factors from mitochondria for the caspase activation. The intrinsic pathway can be 
divided in three well defined phases: induction, mitochondrial and execution phases. 
During the induction phase external and internal stimuli activate different signaling 
pathways and this signal is transduced to mitochondria by Bcl-2 family proteins. This 
protein family includes several proteins sharing a common feature: the presence of one 
or more BH (Bcl-2 homology) domains. There are four different BH domains (BH1-
BH4), composed by α-helices, that allow the formation of homodimers and eterodimers 
between different members of the family.72 A subgroup of these proteins, including Bcl-
2, Bcl-XL, Bcl-w, Mcl-1, has an anti-apoptotic function is characterized by the BH1-2 or 
the BH1-4 domains and a transmembrane domain presence. Instead, there are two 
subgroups with pro-apoptotic functions: the Bax type proteins (Bax, Bak and Bok) with 
BH1-3 and transmembrane domains and the “BH-3 only” type (Bid, Bim and Bad). 
The second apoptotic step is the mitochondrial phase characterized by an alteration of 
the OMM and the release of apoptogenic factors to the cytosol. How this happens is still 
debated and actually there are at least two hypothesis to explain this phenomenon, 
involving two distinct channels. These channels are the permeability transition pore 
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PTP in the inner membrane and the mitochondrial apoptosis-induced channel MAC in 
the outer membrane. 
 
 
Fig. 5 Cellular signaling pathways involved in apoptosis. From Taylor RC, Cullen SP, Martin SJ. Nat 
Rev Mol Cell Biol. 2008; 9:231-241. 
 
The most probable model proposes that MAC is generated on the OMM thanks to the 
direct pore forming properties of some pro-apoptotic Bcl-2 proteins. Bax, a monomeric 
soluble cytosolic factor, oligomerizes, translocates, and inserts in the OMM upon 
induction of apoptosis.73,74 Together with Bak, Bax is supposed to form tetrameric 
channels regulated by BH3-only proteins, such as Bid. These proteins induce the 
conformational change of Bax and regulates the MAC formation, functioning as sensors 
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for cellular integrity and activity, cytoskeleton integrity, growth factor presence, and 
death domain receptor signaling.75 Anyway, the exact molecular composition of MAC 
and its regulation are still not completely explained. 
The second model propose the opening of the PTP, an unselective and high conductive 
channel, in the IMM in response to apoptotic stimuli. This event induces an alteration of 
the IMM permeability, causing a depolarization of the IMM, a matrix swelling and 
OMM break.76  Recent studies demonstrates that the first step of mitochondrial 
permeabilization could be the transient opening of MAC, and that PTP has a role in the 
amplification of the apoptotic signaling. Whatever is the mechanism of the 
mitochondrial permeabilization, the final result is the release of apoptogenic factors 
(cytochrome c, AIF, endonuclease G, Smac/DIABLO and Omi/HtrA2). (Fig. 6) 
 
 
Fig. 6 Apoptogenic factors released from mitochondria during apoptosis. From Vila M, Przedborski S. 
Nat Rev Neurosci. 2003; 4:365-375. 
 
The most important and well known apoptotic factor is cytochrome c (12.3 kDa) that is 
able to trigger the assembly of the apoptosome. The apoptosome is a complex 
composed of cyt c, Apaf-1, and dATP. Cyt c binds Apaf-1 at WD-40 repeats domain in 
the presence of ATP, and allows the conformational change of Apaf-1 from a closed 
monomeric configuration to a platform for procaspase-9 assembly (Fig. 7). Procaspase-
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9 binds Apaf-1 at a conserved amino acid sequence called the caspase recruitment 
domain or CARD, leading to the activation of procaspase-9.77 
 
 
Fig. 7 Apoptosome assembly and caspase-9 activation. From Reed JC. Trends Mol Med. 2001; 7:314-
319. 
 
AIF (Apoptosis Inducing Factor, 57 kDa) is a flavoprotein confined to the mitochondria 
in normal conditions but able to translocate to the nucleus in response to apoptogenic 
stimuli.76 The exact function of AIF under normal physiological conditions is still not 
clear, but it has been reported to be an important part of the antioxidant machinery. 
Overexpression of AIF induces chromatin condensation, dissipation of the 
mitochondrial transmembrane potential, exposure of phosphatidylserine on the plasma 
membrane, and high molecular weight (50 kbp) DNA fragmentation.78 The molecular 
mechanism of AIF functioning in apoptosis is also unknown. It has no intrinsic nuclease 
activity and its oxidoreductase activity is not required for its apoptogenic function. 
Probably AIF acts together with endonuclease G in a caspase-independent apoptotic 
mechanism.79,80 
Endonuclease G (endoG, 30 kDa) is a non-specific nuclease released from mitochondria 
in apoptotic cells. Probably this endonuclease has a role in the normal mitochondrial 
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nucleic acid metabolism, but this role is still unclear. During apoptosis in mammalian 
cells, endoG translocates to the nucleus and digests nuclear DNA in the absence of 
caspase activity or the caspase-activated deoxyribonuclease CAD/DFF. Probably endoG 
acts in concert with both exonucleases and DNase I in the nucleus to generate DNA 
cleavage products.76  
Recently, a new protein, Smac/DIABLO (23 kDa) has been discovered.81,82 This protein 
is released from the mitochondria along with cyt c during apoptosis and promotes 
caspase activation by associating with the apoptosome and by inhibiting IAPs. 
Smac/DIABLO relieves the inhibition on caspases by binding to the BIR domains 
(Baculovirus IAP Repeats) of IAPs proteins (Inhibitors of Apoptosis Proteins) and by 
disrupting their association with caspase-9. In this way, Smac/DIABLO allows caspase-
9 to activate caspase-3, causing apoptosis.83  
Omi/HtrA2 (37kDa) is a serine protease identified because of its homology to the 
bacterial endoprotease HtrA (high-temperature requirement). Omi/HtrA2 seems to be 
upregulated in conditions of cellular stress.83,84 The proapoptotic feature of Omi/Htra2 
was first identified through its ability to bind and antagonize IAPs, similar to 
Smac/DIABLO.85,86 Omi/Htra2 is released from mitochondria during apoptosis and 
contributes to caspase-dependent and independent PCD.76 
The last step in apoptosis is the executive phase and the major players are specific 
proteases called caspases (cysteine aspartyl-specific proteases) that cleaves their 
substrates at aspartic acid (Asp) residues.87,88 This family of intracellular proteases is 
composed in human at least of 12 members, even if not all directly involved in 
apoptosis, sharing an high sequence homology and substrates specificity. (Fig. 8)  
Caspases are produced as inactive zymogens with three domains: a regulatory N-term, 
and two highly conserved catalytic domains. They can be activated by proteolytic 
cleavage at conserved Asp residues and can collaborate in proteolytic cascades, where 
caspases activate themselves and each other, and finally cleave their substrates. 
Caspases are often divided in upstream ‘initiator’ caspases or downstream ‘effector’ 
caspases.89 The upstream pro-caspases have long N-terminal pro-domains that function 
as protein interaction modules, by associating with proteins that trigger caspase 
activation. By contrast, downstream effector caspases contain short N-terminal pro-
domains, and are largely dependent on upstream caspases for their proteolytic 
Introduction 
 
15 
 
processing and activation. Upstream pro-caspases are not completely inactive and, if 
brought into close apposition through protein interactions, they can trans-process each 
other, producing fully active proteases (induced proximity mechanism).90 
Caspases have as substrates several proteins with structural and enzymatic functions 
(collected in caspase substrates database, http://www.casbah.ie) that have to be cleaved 
to  continue the apoptotic process.91 
1. the cell cytoskeleton is degraded causing rounding of cells and membrane 
blebbing; caspases’ substrates are proteins involved in microfilaments, 
microtubules and intermediates filaments formation, such as actin, myosin, 
spectrins, gelsolin, filamin, tubulin, vimentin, keratins. 
2. nuclear envelope and fragmentation is maily due to degradations of laminins. 
3. loss of adhesion is caused by dismantling of cell-matrix focal adhesion sites, 
cell-cell adhesion complexes and desmosomes (substrates are focal adhesion 
kinase FAK, p130cas, tensin, catenins and cadherins) 
4. mitochondrial, Golgi and endoplasmic reticulum fragmentation is actuated in 
order to block any cellular function and metabolism 
5. DNA condensation and fragmentation is necessary to prevent any replication or 
transcription, to block the immune response and any kind of possible rescue 
mediated by new protein synthesis. The fragmentation process is mainly due to 
activation of CAD endonuclease, through degradation of its inhibitor ICAD, 
while the condensation mechanism is mediated by degradation of MST1 kinase 
(mammalian sterile-20), that prevent the histon H2B phosphorylation.  
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Fig. 8 Mammalian caspases: function and structure. From Taylor RC, Cullen SP, Martin SJ. Nat Rev Mol 
Cell Biol. 2008; 9:231-241. 
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Mitochondrial genetics 
Human mtDNA is a double-stranded, circular molecule of 16569bp, completely 
decoded,92 containing 37 genes: 13 genes encoding for subunits of the respiratory chain  
and 22 tRNA and 2 rRNA necessary for translation of these proteins (Fig. 9). Based on 
their nucleotide composition, the two strands are distinct in heavy (H), rich in guanine, 
and light (L), rich in cytosine. 
The mammalian mtDNA shows a high level of economy, in terms of sequence 
organization. In fact, there are essentially no repetitive sequence families, introns or 
intergenic regions. Some respiratory protein genes overlap, and protein coding and 
rRNA genes are interspersed with tRNA genes, that represent the signal for cleavage 
sites of RNA processing. The major non-coding region is the D-loop (displacement 
loop), characterized by the presence of a triple strand structure due to the association of 
the new H-strand in this region. The D-loop contains the origin of H-strand DNA 
replication and is also the site of transcription from opposing heavy and light strand 
promoters.93,94 The second non-coding region is composed by 30 nucleotides and 
represent the replication origin for the L-strand. (Fig. 9) 
Mitochondrial genetics follows its specific rules and differs from mendelian genetics at 
least in three main aspects:95 
1. Heteroplasmy and threshold effect. A somatic mammalian cell contains 1000-
10000 mtDNA copies; if all mtDNA molecules are identical (wild type or 
mutant), this condition is called homoplasmy, whereas if different molecules 
coexist, this condition is known as heteroplasmy. In case of heteroplasmic 
pathogenic mutations, a minimal critical load of mtDNA molecules have to be 
mutated to exert the pathogenic effect of the mutation (threshold effect). This 
threshold is also dependent on the tissue energy requirement. Thus, the threshold 
is unsurprisingly lower in high energy demand tissues and they are more 
vulnerable to mtDNA mutations. 
2. Maternal inheritance. Every mitochondrion and so, every mtDNA molecule, in 
the zygote derives from the oocyte, because after the fecundation process all 
mitochondria from the spermatocytes are degraded in a ubiquitin-dependent 
fashion.96,97 Thus, mtDNA molecules and, if present, mtDNA mutations are 
transmitted in the progeny, along the maternal lineage. Anyway, a heteroplasmic 
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mutation can be transmitted with different mutation load, because during the 
oogenesis there is a preferential amplification of only few mtDNA molecules 
(bottleneck).98 The bottleneck phenomenon explain the rapid shift of some 
heteroplasmic mutation to homoplasmy, in few generations. 
3. Mitotic segregation. During the cellular division, the proportion of mutated 
mtDNA may vary with time, because the replication of mtDNA and nDNA are 
not coordinated and  the distribution of mitochondria during the mitotic process 
is casual. Segregation of heteroplasmic mutations may occur during the cell 
division or during the mtDNA content of a post mitotic cell is renewed. This 
phenomenon explains the mosaic distribution of mutated mtDNAs and the 
reaching of a certain mutation load in some tissues. 
  
These rules are complicated by the different tendency of certain mutations to be 
transmitted (heteroplasmic point mutation are frequently transmitted, whereas deletions 
are rare) and by the mutation levels in the maternal germ line.99 
The distribution of mtDNA molecules in the progeny depends on a bottleneck 
mechanism during oogenesis. A mammalian oocyte contains many copies of mtDNA, 
probably derived by just a few mtDNA molecules in a precursor cell. How this 
mechanism is actuated and regulated is still unexplained, but it seems like its purpose is 
to reset the mtDNA mutation rate between generations.99 
Mitochondrial DNA molecules are organized, in association with several proteins, in 
distinct particles, called nucleoids. These particles are dynamic structures able to divide 
and redistribute in the mitochondrial network and may be single units of inheritance.100  
Their distribution could be important for the mitotic segregation of certain genomes in 
heteroplasmy condition and explain why the segregation of mtDNA mutants is faster 
than expected, with so many mtDNA genomes per cell. The major nucleoid component 
is Tfam, that acts probably as a key regulator of the mtDNA copy number, but many 
other proteins were identified, such as mtSSB, TWINKLE, ANT1 and prohibitin.99 
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Fig. 9 Map of human mtDNA. From Falkenberg M, Larsson NG, Gustafsson CM. Annu Rev Biochem. 
2007; 76:679-699.  
 
Mitochondrial DNA variability 
Due to its peculiar uniparental maternal inheritance, mtDNA has been extensively used 
to study population genetics by phylogenetic analysis. Moreover, mtDNA 
recombination in identical molecules does not influence the genetic assessment and is 
able to accumulate mutation at higher rate, compared to nuclear DNA.101-103 Thus, a 
great number of mtDNA variants have been fixed and accumulated characterizing 
different maternal lineages. These mtDNA lineages have diverged from the first ‘Eve’ 
and colonized different geographical regions. Based on different clusters of population-
specific polymorphisms, present both in coding and control regions, we can now define 
the mitochondrial haplogroups. Many phylogenetic studies defined the occurrence of 
specific haplogroups in the different continents. In Africa, haplogroup L is present in 
80-100% of mtDNAs; in Asia the most representative haplogroups are A, B, F and M, 
divided in sub-classes C, D, E and G.102-104 Asian haplogroups are also present in Native 
Introduction 
 
20 
 
Americans populations, whereas four European haplogroups (H, J, K and I) are the most 
representative in the general nothern american population.105  
Among Europeans, 95% of the population belongs to 1 of 10 haplogroups: H, I, J, K, M, 
T, U, V, W, and X.106 Given the central role of mitochondria in cellular metabolism, 
many studies have investigated the association between mtDNA haplogroups and sub-
haplogroups and multifactorial diseases and aging, based on the assumption that the 
many non-synonymous variants may have functional relevance. 
 
Mitochondrial replication, transcription and translation 
Mitochondrial DNA replication is independent from cell cycle (the so called relaxed 
replication) and some mtDNA molecules are preferentially replicated while others do 
not replicate at all.107,108  
The enzyme responsible for mtDNA replication is polymerase γ (POLγ), an RNA 
dependent DNA polymerase, discovered in human HeLa cells.109 In human this enzyme 
is an heterotrimer composed by a catalytic subunit (POLγA, 140kDa), with polymerase, 
3’-5’ exonuclease, and 5’-deoxyribose phosphate lyase activities, and two smaller 
accessory subunits (POLγB, 55kDa), able to increase the catalytic activity of 
POLγA.110-113 Other two proteins are necessary for mtDNA replication: the helicase 
TWINKLE and the mitochondrial single-stranded DNA-binding protein (mtSSB). 
Together with POLγ, they form a processive replisome, able to replicate the entire 
mtDNA.99 
The mtDNA replication mechanism is still unclear and at least two models has been 
proposed and currently debated. The first model proposes a strand-asymmetric and 
asynchronous replication, in which the primers for the H-strand (leading strand) 
replication are provided by the transcription mechanism.114 When H-strand synthesis 
has reached 2/3 of the DNA molecule, it exposes the origin of L-strand DNA replication 
(OL), and lagging-strand DNA synthesis then initiates in the opposite direction. New 
complete mtDNA molecules are finally ligated.99 
Another model has been more recently proposed and suggests that mtDNA replicates 
symmetrically, with leading and lagging strands synthesis progressing from multiple, 
bidirectional replication forks, in a precise initiation zone that includes cyt b and ND5-6 
genes.115-117 
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Moreover, a novel major replication origin has been found at position 57 in the D-loop 
region, probably responsible for mtDNA maintenance under steady-state conditions. In 
this paper the autors suggested that the previously characterized origins may be more 
important for recovery after mtDNA depletion and to improve the DNA synthesis in 
response to certain stimuli.118  
Mitochondrial transcription starts from three different transcription origins, one for the 
L-strand and two for the H-strand (H1 and H2), producing three polycistronic 
molecules.119  The H1 site (nt 561) is the most frequently used and is responsible for the 
synthesis of the two rRNAs, tRNAPhe and tRNAVal. The second transcription unit is less 
frequently used than the previous one, starts at the initiation site H2 (position 646) and 
produces a polycistronic molecule, that is subsequently processed in 12 mRNAs and 14 
tRNA.114 The L-strand generates a single polycistron starting at position 407, from 
which 8 tRNAs and the ND6 mRNA are derived.119 
The primary transcripts are processed, according to the “tRNA punctuation” model, to 
generate the mature RNAs after an endonucleolytic cleavage, triggered by the 
maturation of tRNAs secondary structure.120,121 The 5′- cleavage occurs first, by a 
mitochondrial RNaseP, then the 3’- end is cleaved by a tRNAase Z. 
The minimal machinery required for mtDNA transcription includes the RNA 
polymerase mtRPOL (similar to that from T7 and T3 bacteriophages), the initiations 
factors Tfam, TFB1M, and TFB2M and the termination factor mTERF (Fig. 10). The 
human mtRPOL gene encodes a protein of 1230 amino acid residues with a series of 
conserved motifs in the C-term (520-1230 aa).122  
Tfam (10q21, 202 aa) was the first mitochondrial transcription factor identified and 
contains two HMG-boxes (High Mobility Group) with DNA binding activity, separated 
by a linker region and a basic C-terminal tail required for promoter-specific 
transcription.123 Tfam is able to wrap, bend and unwind DNA in vitro with a low 
sequence specificity.124,125 Moreover, Tfam is also able to bind mtDNA in a nonspecific 
manner, and probably is responsible for its stabilization and maintenance.125,126 
Interestingly, Tfam levels correlate well with mtDNA copy number, suggesting that this 
protein can function as a limiting determinant of mtDNA abundance.94 
Two isoforms of human mt-TFB, named TFB1M and TFB2M, have been identified but 
the first one exhibits about 1/10 the transcriptional activity of TFB2M. Both factors 
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seem to interact directly with the RNA polymerase forming a heterodimer, and, in 
addition to TFAM, are required for the accurate initiation from H- and L-strand 
promoters in vitro.119  
Mitochondrial encoded mRNAs are translated in the matrix with a specific translational 
machinery, represented by the mitoribosomes. These ribosomes are particular being 
composed by two mitochondrial rRNAs (12s and 16s) and nuclear encoded proteins. 
The genetic code of mtDNA is also slightly different. Thus, UGA in mitochondrial 
translation does not specify for a tryptophan amino acid, but a stop codon; moreover 
AUA represent an isoleucine and not a methionine and AGA/AGG are not stop codons 
but specify for arginine. Moreover, mitochondrial translation has a more simplified 
codon-anticodon recognition mechanism (22 tRNAs are sufficient to specify for all the 
amino acid, a single tRNA specifies for both methionine and N-formyl methionine and 
AUA/AUU codons are often used as a start signal).127    
 
 
Fig. 10 Schematic representation of the mammalian D-loop and transcription termination regions, 
showing the main elements and factors involved in transcription and in replication initiation. From 
Fernandez-Silva P, Enriquez JA, Montoya J. Exp Physiol. 2003; 88:41-56. 
 
Mitochondrial-nucleus communications: mitochondrial biogenesis 
Mitochondrial biogenesis is a complex and regulated process that involves the 
coordinated expression of mitochondrial and nuclear genes. This process has been 
intensively studied in the last 20 years and it is now known that mitochondrial 
biogenesis is finely tuned by different signaling cascades that involve transcription 
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factors and coactivators that regulate the expression of genes coding for mitochondrial 
components.128 
These include nuclear encoded mitochondrial proteins participating in OXPHOS, heme 
biosynthesis, mitochondrial protein import, and mtDNA transcription and replication. 
The most important transcription factors activating promoters of mitochondrial genes 
are Tfam, NRF-1, NRF-2 and ERRα (estrogen related receptor), together with 
transcriptional coactivators belonging to the peroxisome proliferator-activated receptor 
γ-coactivator-1 (PGC-1) family (Fig. 11).129-131 
 
PGC-1 protein family 
This family is composed by at least three members sharing a sequence homology and 
regulating several metabolic pathways such as cellular respiration, adaptative 
thermogenesis and hepatic glucose metabolism. These coactivators stimulate the 
mitochondrial biogenesis in general, even if PGC-1α is mainly involved in the 
regulation of gluconeogenesis, PGC-1β in the regulation of fatty acid oxidation and 
PRC seems to be responsible for the coordination of nuclear and mitochondrial DNA 
replication during the cell cycle progression.132,133  
These proteins have conserved domains with well characterized features (Fig. 11):  
- the N-terminus contains a transcriptional activation domain, includes the major 
nuclear hormone receptor-interacting motif (LXXLL), and is important for 
interactions with proteins capable of remodeling chromatin.  
- the C-terminal contains an RNA-binding motif (RMM), that enhances the RNA 
splicing, and a serine-arginine-rich (RS) domain.  
These domains are extremely conserved from fish to mammals, suggesting that these 
coactivators play a major role by regulating some important functions in eukaryotes.134 
It is still unclear if the biological functions of PGC-1α are overlapped with the functions 
of the other two family members, and further studies are necessary.  
The first member of this family, PGC-1α (92 kDa), was discovered as an interacting 
partner of the adipogenic nuclear receptor PPARγ in brown adipose tissue (BAT) where 
is responsible for the regulation of adaptative thermogenesis and adipocyte 
differentiation.135  
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The N-terminal 200 amino acids of PGC-1α contain a powerful transcriptional 
activation domain, rich in acidic amino acids (Fig. 11). Even if this protein lacks an 
intrinsic histone-modifying activity, this domain allows PGC-1α to recruits several 
cofactors with chromatin remodeling functions, such as p300/CBP (CREB Binding 
Protein) or SRC-1. 
 
 
 
Fig. 11 The PGC-1 protein family, conserved domains and protein homology. From Puigserver P and 
Spiegelman BM. Endocrinol Rev. 2003; 24:78-90. 
 
Moreover, in this region there is an LXXLL sequence (amino acids 142–146), 
responsible for ligand-dependent interaction of other coactivators with nuclear hormone 
receptors.134,136 The presence of this motif on PGC-1α is necessary for the ligand-
dependent interaction with ER, PPARα, RXRα, glucocorticoid receptor, and probably 
other nuclear hormone receptors.134 PGC-1α also uses different non-LXXLL domains to 
interact with certain other transcription factors: a domain between amino acids 200 and 
400 interacts with PPARα and NRF-1 and a region between amino acids 400 to 500 that 
interacts with MEF2.136 The binding of proteins with HAT (histone acetyl transferase) 
activity is driven by the presence of a specific association with a transcription factor (for 
example PPARγ or NRF-1).137 This event induces a conformational change in PGC-1α 
structure that recruits SRC-1 and CBP/p300 into the transcriptional complex. Moreover, 
the C-terminal domain is the docking site of a second activating complex formed by 
TRAP/DRIP.138 
The C-terminal region contains also the RS domain (aa 565-631), that has been shown 
to interact with the C-terminal of RNA polymerase II,139 and the RMM domain (aa 677-
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709). This region is also involved in the recruitment and the docking of several splicing 
factors, such as SC35, SRp75, 55 and 40, suggesting that PGC-1α can participate in the 
RNA splicing process.134 
In general transcriptional coactivators are expressed in a stable manner and their 
activation depends on the associated transcription factor. Indeed, PGC-1α is strongly 
induced by cold exposure and prolonged exercise.135,140,141  
Ectopic overexpression of  PGC-1α causes the increase of mtDNA content at the steady 
state and transcriptional activation of several genes involved in respiration, ROS 
detoxification machinery, energy metabolism, fatty acid β-oxidation and glucose 
uptake. 142,143 During mitochondrial biogenesis the most important action of this protein 
probably is the transcriptional activation of NRF1 and 2 and its interaction with the 
same proteins that leads the transcription of many nuclear encoded mitochondrial genes, 
especially Tfam, TFB1M and TFB2M. PGC-1α is also able to interact with PPARα, 
causing the stimulation of fatty acid β-oxidation, with PPARγ, inducing UCP-1 and the 
adaptative thermogenesis, and many other nuclear transcription factors (HNF4, FOXO1, 
MEF2, SRBP1, SOX9).135,144-149 A list of transcription factors activated by this 
coactivator is provided in table 1. 
 PGC-1α gene expression can be modulated by several mechanisms in response to 
different stimuli and cell type (Fig. 12).  
1. In adipocyte, in response to cold exposure, β-adrenergic receptors are activated. 
This causes the signal transduction via protein Gs (a subtype of protein G) and 
adenylate cyclase, associated with an increase of cAMP concentration. The 
subsequently PKA (Protein Kinase A) activation induces the phosphorylation of 
CREB or ATF2 (Activating Transcription Factor 2), factors able to stimulate 
PGC-1α transcription. 
2. During fasting, the activation of CREB and the subsequent PGC-1α increase, 
can induce the gluconeogenetic pathway in mouse liver.150  
3. It also has been shown a strong activation of PGC-1α transcription after a 
prolonged exercise in vivo or an increase in Ca2+ levels in myotubules. In the 
first case, a chronic energy deficit is associated with an increase in AMP/ATP 
ratio and the activation of AMPK.151 The same kinase can be activated by CamK 
(Ca2+/calmodulin dependent protein kinase) as a consequence of the intracellular 
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Ca2+ levels increase. AMPK is involved in CREB phosphorylation and/or direct 
PGC-1α transcriptional activation. Lastly, MEF2 induction via calcineurin A is 
also involved in PGC-1α activation in skeletal muscle.152 
4. Another signaling pathway is mediated by NO generation and involves the 
cGMP signaling. The final event is the increase in coupled respiration mediated 
by PGC-1α transcription.153,154  
 
 
Tab. 1 Transcriptional partners of the PGC-1 coactivators. Modified from Lin J, Handschin C, 
Spiegelman BM. Cell Metab. 2005; 1:361-370. 
 
PGC-1α exhibits a very short half life (2-3 hours),155 but it can be increased by p38 
mediated phosphorylation in three sites (Thr262, Ser265, Thr298).156 This process 
causes also the dissociation of the transcriptional repressor p160 myb-binding 
protein.157 Lastly, PGC-1α presents also 13 Lys that can be deacetylated by Sirt1, in 
fasting conditions, in a NAD+ dependent reaction. In this pathway PGC-1α is able to 
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switch on the hepatic glucose production without affecting mitochondrial protein 
content.158 
The second family member, PGC-1β, is larger but shares sequence similarity with PGC-
1α along its entire length. Like its homolog, the protein is particularly expressed in 
tissue with high energy demand, such as brown fat, heart and skeletal muscle, where is 
able to coordinate mitochondrial biogenesis, inducing NRF1-target genes.131,159 In 
contrast with PGC-1α, PGC-1β is not induced in BAT after cold exposure and is a poor 
inducer of gluconeogenesis in liver, due to the lack of interaction with HNF4 and 
FOXO1.160 
 
 
Fig. 12 Integration of different signaling pathways in mitochondrial biogenesis regulated by PGC-1α. 
From Scarpulla RC. Physiol Rev. 2008; 88:611-38. 
 
Another homologue is PRC (PGC-1α Related Coactivator), identified through a 
database search for sequence similarities. PRC is significantly longer than PGC-1α, and 
the protein contains an LXXLL consensus, an acid N-terminal activation domain and a 
C-terminal RS domain.161 The main difference with the other two family members is the 
low expression of PRC in tissues with high energy demand.94 However, PRC is rapidly 
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induced after serum treatment of quiescent fibroblasts and is expressed more abundantly 
in proliferating cells compared with growth-arrested cells. The transcription pathway is 
similar to that previously described, involving the induction of NRF-1, NRF-2, Tfam, 
TFB1M and TFB2M, as well as genes encoding for nuclear and mitochondrial 
respiratory subunits.94  
 
Nuclear respiratory factors (NRF1 and NRF2) 
NRF1 is a transcription factor that recognizes directly a palindromic sequence           
(5’-YGCGCAYGCGCR-3’) in the promoter of several nuclear encoded mitochondrial 
genes.162,163 This transcription factor binds the recognition site as an homodimer and is a 
protein of 503 amino acids, with a N-terminal Ser-phosphorylation domain, a central 
DNA binding domain and a C-terminal transactivation domain.94 NRF-1 has been 
associated with the expression of many genes required for mitochondrial respiratory 
function, including the vast majority of nuclear genes that encode subunits of the five 
OXPHOS complexes.94 Moreover, there are several evidences supporting the idea that 
NRF1 could be an integrative factor that coordinates respiratory subunit expression with 
the mitochondrial transcriptional machinery.94 NRF-1 binds and activates not only the 
promoters of Tfam and TFB, but also genes of the respiratory chain complexes, heme-
biosynthesis, mitochondrial transmembrane transporters.94  
Human NRF2 is comprised of five subunits, a DNA-binding α subunit and four others 
accessory subunits (β1, β2, γ1 and γ2) that form a complex with α subunit do not bind 
DNA alone. All the accessory subunits contain a transcriptional activation domain. 
NRF2 binding sites contain the GGAA core motif, found in many mitochondrial genes 
promoters, such as all 10 nucleus encoded cytochrome oxidase subunits, Tfam, the two 
isoforms of TFB and three subunits of SDH.94,164-166 
 
Nuclear receptors 
There are several nuclear receptors involved in mitochondrial biogenesis, such as 
PPARs (peroxisome proliferator associated receptors) and ERRs (estrogen related 
receptors). Nuclear hormone receptors generally function as ligand-activated 
transcription factors that regulate the expression of specific genes and they usually share 
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conserved functional domains (the DNA binding domain, the ligand binding domain 
and the N- and C-terminal transcriptional activation domains).167  
Many mitochondrial oxidative pathways converge into the respiratory chain, and one of 
the most important is the fatty acid oxidation pathway, which consists of a series of 
reactions that oxidize fatty acids to acetyl-CoA, due to mitochondrial enzymes. PPARs 
have been implicated as transcriptional regulators of this metabolic pathway. This 
family of adopted orphan receptors consists of three isoforms: PPARα, PPARβ/δ and 
PPARγ, sharing a highly conserved structure and mode of action. They act as 
transcriptional regulators through their direct binding to specific nucleotide sequences 
(PPREs, peroxisome proliferator response elements), present in the promoter or, 
sometimes, in an intron, of target genes.168  
Their transcriptional activity is expressed only after the binding of their ligands; some 
of them are shared by the three isoforms, such as polyunsaturated and oxidized fatty 
acids. Other ligands, specific for PPARα, are long-chain unsaturated, branched, 
conjugated and oxidized fatty acids (linoleic acid, phytanic acid, eicosanoids and 
leukotrienes), while some prostaglandins are specific ligands of PPARγ.169 Moreover 
PPARs are activated by two classes of agonists, the thiazolidinediones for PPARγ 
(TZDs) and the fibrates for PPARα. TZDs are mainly used in the treatment of diabetes 
mellitus type 2 and related diseases; activating PPARγ, they cause a decrease in insulin 
resistance and in VEGF induced angiogenesis and changes in adipocyte differentiations. 
Instead, fibrates are hypolipidemic agents, commonly used in the therapy of metabolic 
disorders coupled with hypercholesterolemia. Interestingly, one of those drugs, 
bezafibrate, is a well known PPARs pan-activator, and is also used as treatment against 
insulin resistance.167 PPARs bind the promoter only as an heterodimer with the receptor 
for 9-cis retinoic acid, RXR (retinoid X receptor).170,171 This heterodimer can be 
activated by the PPARs ligand alone, but the coordinated binding of both ligands is 
much more potent.169 
PPARα controls the expression of several genes involved in fatty acid metabolism. 
After fasting, when fatty acids are more used for energy production, PPARα expression 
and activity increase, inducing the β-oxidation. Furthermore, PPARα is induced, 
coordinating its target genes, in skeletal muscle after exercise172 and also in the heart, 
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where the main energy source derives from lipids, especially during the fetal-adult 
transition.173 
Whereas PPARα is the main player in the catabolism of fatty acids in the liver, PPARγ 
influences their storage in adipose tissue and is essential for adipocyte survival. There 
are two isoforms of PPARγ: PPARγ1 mainly expressed in colon, spleen, blood cells, 
liver, skeletal muscle and retina, and PPARγ2 expressed in the adipose tissue. Both 
these isoforms respond to the same stimuli and activate the same target genes.167 
Lastly, PPARβ/δ is linked to colon cancer and regulates the expression of acyl-CoA 
synthetase 2 in the brain, but this member received only little attention to date, probably 
because no diseases seem associated with this factor.169 
Another family of nuclear receptor involved in the regulation of mitochondrial 
biogenesis and oxidative metabolism is the estrogen-related receptor family (ERRs). 
This is a family of orphan nuclear receptors resembling the estrogen receptor without 
binding estrogens or other ligands.167 The three family members (ERRα, β and γ) have 
the typical structure of nuclear receptors, as PPARs. The central zinc finger DNA-
binding domain recognizes the response element (ERREs) characterized by the 
nucleotide sequence 5’-TNAAGGTCA-3’.174 The conserved C-term domain should be 
the one responsible for interactions with corepressors and/or coactivators and for the 
ligand binding, but putative ligands are still unknown. These receptors are constitutively 
present in an active conformation, even in the absence of ligand.175-177  
ERRα, the most extensively studied, is ubiquitously expressed and is more abundant 
compared to the other two family members, reaching the highest levels in tissues with 
high metabolic needs (heart, skeletal muscle, kidney, BAT and central nervous system). 
Several studies have revealed the strict connection between ERRs and PGC-1α/β in the 
regulation of energy metabolism genes.178-181 These two proteins interact directly 
through their specific domains: in PGC-1α there are three nuclear hormone receptor-
interacting motifs and one of these (L3) is exclusively used for the interaction with 
ERRα ligand binding domain. This interaction improves dramatically the transcriptional 
activity of ERRα, suggesting that PGC-1α/β could be a “protein ligands” of ERRs.174 
Furthermore, PGC-1α regulates not only the activity, but also the expression of ERRα in 
an auto-regulatory loop, in which high levels of PGC-1α induce the increase of ERRα 
transcriptional activity at the level of its promoter.182-184 Taken together, the coactivator 
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and the nuclear receptor coordinate the expression of several genes involved in fatty 
acid oxidation, tricarboxylic acid cycle, oxidative stress defense, mitochondrial 
biogenesis and dynamics and oxidative phosphorylation.174 A list of genes probably 
regulated by the complex PGC-1/ERRs is reported in table 2. 
 
Other nuclear factors 
Many other nuclear factors have been implicated in the expression of respiratory genes 
and in the control of mitochondrial biogenesis. For example, the cytochrome c promoter 
contains cis-elements that recognize transcription factors ATF/CREB, c-Myc and Sp1, 
while muscle-specific complex IV subunits are regulated by MEF-2 and/or YY1 
(YingYang1).167 
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Tab. 2 Genes encoding mitochondrial proteins with ERREs in their promoter, probably regulated by 
ERRs. Modified from Giguere V. Endocr Rev. 2008; 29:677-696. 
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Mitochondrial disorders 
 
The term “mitochondial medicine” was introduced for the first time by Rolf Luft in 
1994 and now is commonly used to indicate that branch of medicine interested in 
studying mitochondrial dysfunctions.185 Historically, the first mitochondrial patient is 
considered to be a women described by Luft in 1962, suffering of severe 
hypermetabolism, heat intollerance, profuse perspiration, muscular wasting and 
weakness, polyphagia and resting tachycardia.186 This phenotype, now known as Luft’s 
syndrome, is caused by a deregulated mitochondrial respiration, consuming an excess of 
energy, possibly due to a profound uncoupling, even if the molecular cause is still 
unknown.186 In 1988, 25 years later, the first pathogenic mtDNA point mutations and 
deletions were reported in association with Leber’s hereditary optic neuropathy (LHON) 
and mitochondrial myopathies.187,188 After these seminal reports, a multitude of mtDNA 
mutations were discovered associated with several maternally inherited and sporadic 
disorders, most of them affecting the central and perypheral nervous system, as well as 
skeletal and cardiac muscle.  
Mitochondrial disorders can be divided in two classes: the first is due to mtDNA 
mutations or rearrangments, whereas the second comprise Mendelian diseases 
associated with nuclear DNA mutations or rearrangments in genes encoding 
mitochondrial proteins.189 Moreover, mitochondrial disorders can be also classified in 
those affecting the respiratory chain  function (directly, OXPHOS subunits, or 
indirectly, affecting ancillary proteins, lipid milieu, and mitochondial translation) and 
those affecting mitochondrial dynamics. Furthermore, a mitochondrial involvement has 
been proposed for several neurodegenerative diseases, such as Parkinson and Alzheimer 
disease.189 
 
Disorders of the mitochondrial respiratory chain 
In figure 13 is shown the mitochondrial respiratory chain, depicted with the major 
mitochondrial disorders affecting directly the respiratory chain and the genes 
involved.189  
To date, about 200 mtDNA mutations and several single and multiple deletions have 
been associated with human diseases, and novel mutations are still being reported. Due 
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to the very peculiar chracteristics of mitochondrial genetics, these disorders show often 
a phenotypic heterogeneity. 
 
 
Fig. 13 The mitochondrial respiratory chain: diseases associated with respiratory chain defect and relative 
mutated genes. From DiMauro S and Schon EA. Annu Rev Neurosci. 2008;31:91-123. 
 
The same genetic defect may result in different phenotypes in different individual 
belonging to the same family, and/or in different families. On the other hand the same 
phenotype can be associated with several different mutations.190 Furthermore, the 
treshold effect is generally critic for the expression of the pathology, but in some cases, 
such as LHON, homoplasmic mutations may have variable penetrance and different 
clinical severity, often within the same family. A related question concerns the  
functional significance of mtDNA background. It has been shown that different 
haplogroups may modulate the oxidative phosphorylation and the complex I assembly, 
predisposing or protecting individuals to/from certain disorders.191,192  
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Major rearrangements of mtDNA usually comes as deletions or duplications, even if 
deletions are most common. Multiple deletions are caused by defects in nuclear genes 
encoding for enzymes involved in mtDNA maintainance and nucleotide metabolism, 
whereas single deletions are usually sporadic.189 The main syndromes associated with 
single sporadic deletions are Kearns-Sayre Syndrome (KSS), Pearson marrow-pancreas 
Syndrome (PS) and some forms of Chronic Progressive External Opthalmoplegia 
(CPEO).  
PS is a fatal sideroblastic anemia complicated by the involvement of exocrine pancreas. 
Usually the patients die aronund 4 years of age, but in case of survival deletions are 
associated with the development of KSS.190  
KSS is charactherized by retinitis pigmentosa, external ophtalmoplegia and onset before 
age 20. Other symptoms are variously reported, such as cardiac conduction block, 
cerebella ataxia, short stature, cerebrospinal fluid proteins greater than 100mg/dL, 
hearing loss and muscle weakness.190   
CPEO (widely reviewed by Spinazzola and Zeviani)193,194 is clinically defined by 
palpebral ptosis, generalized weakness and progressive limitation of ocular movements. 
Additional symptoms can be ataxia, sensorineural hearing loss, cataracts, parkinsonism 
and peripheral polyneuropathy. Skeletal muscle histolological analysis, with modified 
Gomori trichromic stain, shows the presence of ragged-red fibers (RRFs) due to 
accumulation of aberrant mitochondrial. Biochemically, it has been shown a moderate 
reduction in the activity of respiratory chain complexes.195,196 Sporadic forms are 
reported but there are also inherited CPEO, that can be autosomal dominant (adCPEO), 
autosomal recessive (arCPEO) and maternally inherited.189 Maternally inherited forms 
are caused by point mutations in mitochondrial tRNA genes specifying for leucine, 
isoleucine and alanine, whereas autosomal forms are caused by mutations in POLG1, 
POLG2, Twinkle and ANT-1 (Fig. 14), all genes involved in mtDNA replication or 
nucleotide metabolism, and leading to multiple deletions.197-200 
Recently a new syndrome, characterized by dominant optic atrophy, sensorineural 
deafness, ataxia, axonal sensory-motor polyneuropathy, CPEO and mitochondrial 
myopathy with cytochrome c oxidase negative and RRFs, has been described.17,18,201 
These patients harbour missense mutations in the OPA1 GTPase domain and multiple 
deletions of mitochondrial DNA (mtDNA) in skeletal muscle, revealing an 
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unrecognized role of the OPA1 protein, previously known only as a regulator of 
mitochondrial fusion, in mtDNA stability.17,18,201  
A more complex syndrome is MNGIE (Mitochondrial NeuroGastroIntestinal 
Encephalomyopathy), an autosomal recessive disorder affecting young adults. This 
syndrome is charachertized by CPEO, peripheral neuropathy, leukoencephalopathy and 
gastrointestinal dysmotility.202 The gastrointestinal symptoms include gastroparesis, 
frequent diarrhea and intestinal pseudo-obstruction, that lead to cachexia and early 
death.18 MNGIE is caused by different mutations in the gene TP, encoding the enzyme 
thymidine phosphorylase (Fig. 14).203 This enzyme is necessary in the thymine 
metabolism, acting in the thymine recycle pathway. Mutations in this gene cause the 
lack of enzyme activity, inducing an accumulation of thymidine, that is promptly 
transformed in deoxythymidine triphosphate, by the enzyme TK2 (Thymidine Kinase 
2). This process causes an unbalancing in the nucleotide pool which interfers with 
mtDNA replication, and consequently induces mtDNA depletion and accumulation of 
multiple deletions and point mutations.202 
Other recessive disorders leading to mtDNA depletion and multiple deletions are 
Sensory-Ataxia Neuropathy, Dysarthria and Opthalmoplegia (SANDO), spinocerebellar 
ataxia epilepsy syndrome and Alpers’ syndrome, all associated with recessive mutations 
in POLG1 gene.194 
Mitochondrial DNA depletion syndromes are also recessive traits with various 
phenotypical expression, which are caused by mutations in several genes (Fig. 14). The 
degree of depletion may vary in different tissues.189,194 The two major syndromes are: 
- Hepatocerebral syndrome, caused by mutations in POLG1 (Alpers’ syndrome), 
DGUOK (deoxyguanosine kinase, involved in nucleotide metabolism) and 
MPV17 (an IMM protein with unknown function)189,194,204 
- Pure myopathic syndromes, due to mutations in TK2, SUCLA2 (encoding the β-
subunit of succinylCoA synthetase) and RRM2B (p53 inducible ribonucleotide 
reductase small subunit)189,205,206 
Mitochondrial DNA is also an hot spot for pathogenic point mutations 
accumulation, causing different pathologies. One of the most common disorder is 
MELAS (Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-like 
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episodes), a multisystem disorder carachterized by stroke-like episodes in young 
age, encephalopathy with seizures and/or dementia and mitochondrial myopathy 
with lactic acidosis and RRFs.207 Additional features are myoclonus, ataxia, basal 
ganglia calcifications, pigmentary retinopathy, optic nerve atrophy, short stature, 
hearing impairment and cardiomyopathy.207 At least 15 different mtDNA mutations 
have been associated with MELAS, but more that 80% of the patients harbour the 
common mutation A3243G in the tRNALeu gene. Other reported mutations affect 
other positions in the tRNALeu gene and other tRNA genes, but mutations in 
structural genes, such as COIII, ND1, ND5 and ND6, have been also reported.208 
The phenotype of these mutations is usually heterogeneous, and individuals 
belonging to the same family are often olygosymptomatics, and manifest only some 
features of MELAS.209 Mutations in tRNA cause an impaired protein synthesis and 
a generalized respiratory chain biochemical defect.210 
 
Fig. 14 Nucleotide metabolism for mtDNA synthesis and replication: genes in bold have been associated 
with diseases, mtDNA multiple deletions and/or depletion syndromes. From DiMauro S and Schon EA. 
Annu Rev Neurosci. 2008;31:91-123. 
 
Mitochondrial DNA is also an hot spot for pathogenic point mutations accumulation, 
causing different pathologies. One of the most common disorder is MELAS 
(Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-like episodes), a 
multisystem disorder carachterized by stroke-like episodes in young age, 
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encephalopathy with seizures and/or dementia and mitochondrial myopathy with lactic 
acidosis and RRFs.207 Additional features are myoclonus, ataxia, basal ganglia 
calcifications, pigmentary retinopathy, optic nerve atrophy, short stature, hearing 
impairment and cardiomyopathy.207 At least 15 different mtDNA mutations have been 
associated with MELAS, but more that 80% of the patients harbour the common 
mutation A3243G in the tRNALeu gene. Other reported mutations affect other positions 
in the tRNALeu gene and other tRNA genes, but mutations in structural genes, such as 
COIII, ND1, ND5 and ND6, have been also reported.208 The phenotype of these 
mutations is usually heterogeneous, and individuals belonging to the same family are 
often olygosymptomatics, and manifest only some features of MELAS.209 Mutations in 
tRNA cause an impaired protein synthesis and a generalized respiratory chain 
biochemical defect.210 
Another syndrome characterized by the presence of mitochondrial tRNAs point 
mutations is MERRF (Myoclonus, Epilepsy and Ragged-Red Fibers). The clinical 
manifestation of this disorder includes myoclonus, epilepsy, ataxia and RRFs in muscle 
biopsies.207 In many patients were also reported hearing loss, dementia, short stature, 
lactic acidosis, pheripheral neuropathy and exercise intollerance.207 In literature are 
described at least 6 different mutations in mitochondrial tRNAs genes, expecially in 
tRNALys (the most common A8344G, 80% of cases, T8356C, G8363A, G8361A), a 
mutational hot spot for MERRF. Other genes involved are tRNAPhe, tRNASer and 
tRNAHis.211 
Mutations can also occurr in structural mitochondrial genes and the major disorders 
associated with these mutations are LHON (Leber’s Hereditary Optic Neuropathy, that 
will be extensively described in the next section), NARP (Neuropathy, ataxia, retinitis 
pigmentosa) and MILS (Maternally Inherited Leigh Syndrome). 
NARP is a multisystem disorder affecting young adults. The main symptoms are 
sensory neuropathy, ataxia, dementia, seizures and retinitis pigmentosa.207 A sigle 
heteroplasmic point mutation in ATPase6 gene (T8993G/C) is the molecular cause of 
the pathology.208,212 The same mutations, at high levels of mutantional load may were 
associated with mild forms of MILS.213  
Lastly, Leigh syndrome is a complex, early-onset, disease with a heterogeous clinical 
manifestation, due to different mutations in several genes (nuclear and mitochondrial), 
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to difference in age of onset, progression and the frequency of epilepsy.207 The wide 
variety of symptoms includes developemental regression, hypotonia, CPEO, hearing 
loss, optic neuropathy or pigmentary retinopathy, nystagmus, ataxia, seizures. Other 
symptoms may involve respiratory and cardio circulatory apparatus.207 Mutations were 
discovered in several genes, both structural and assembly genes, essential for the 
respiratory chain function. The inheritance may be autosomal recessive, X-linked and 
maternal (MILS), with several mutations reported in the following genes:213-216 
- Complex I: mitochondrial structural genes ND1-ND6, with the only exception of 
ND4L 
- Complex II: nuclear structural gene SDHA 
- Complex III: BCS1L 
- Complex IV: mitochondrial structural gene COIII and nuclear assebly factors 
COX10, COX15, SCO2 and SURF1 
- Complex V: mitochondrial structural gene ATPase6. 
Moreover, LRPPRC mutations have been found in the French Canadian variant of 
Leigh syndrome.207 LS may be a feature of a deficiency of any of the mitochondrial 
respiratory chain complexes, but also of pyruvate dehydrogenase complex (PDCH), 
leading to an inappropriate ATP production and cellular energy impairment. 
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Leber’s hereditary optic neuropathy 
LHON is a maternally inherited form of acute or subacute loss of central vision 
affecting predominantly young males.217 This usually monosymptomatic disease was 
clinically defined by Leber and is now recognized as the most frequent mitochondrial 
disease.218 
 
Clinical features 
Clinically, LHON is characterized by rapid loss of central vision in one eye, followed 
by similar involvement of the other eye, usually in a short time laps.219,220 This 
condition is usually painless and associated with dyschromatopsia. Visual acuity 
reaches stable residual values at or below 20/200 within a few months, and the visual 
field defect involves the central vision in the form of a large centro-cecal absolute 
scotoma. Fundus examination during the acute/subacute stage reveals circumpapillary 
telangiectatic microangiopathy, swelling of the nerve fiber layer around the disc 
(pseudoedema), absence of leakage on fluorescein angiography.221,222 The 
microangiopathy may be present in a number of asymptomatic at-risk family members 
along the maternal line, in whom it may remain stable over the years.223 In the acute 
phase, axonal loss in the papillomacular bundle leads to temporal atrophy of the optic 
nerve, and the endpoint of the disease is generally, a full optic atrophy with permanent 
severe loss of central vision but with relative preservation of pupillary light 
responses.220 However, spontaneous recovery of visual acuity has occasionally been 
reported even years after onset.220, 224-226 A young age of onset is a favorable prognostic 
factor, and the rate of visual recovery is more frequent in the patients bearing the 
14484/ND6 mutation.220 Visual function may improve progressively or suddenly, with 
contraction of the scotoma or reappearance of small islands of vision within it 
(fenestration).220 In long-lasting LHON, cupping of the optic disc has frequently been 
reported as a sign of the chronic stage of the pathological process.227-229 
A recent study from our group has demonstrated that the optic disc area can be a 
prognostic marker for LHON patients, because LHON carriers (harboring the mutation, 
but unaffected) display a greater optic disc area and higher vertical disc diameter, 
compared to controls and affected LHON. Thus, the optic nerve head morphology may 
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have a protective role. Our hypothesis is reinforced by the observation that, among the 
LHON-affected, larger discs were correlated with visual recovery and better visual 
outcome.230 
Even if LHON is usually a monosymptomatic disorder, a subset of patients has a 
syndromic form of optic atrophy frequently referred as “Leber’s plus”,231,232 which may 
include central nervous system involvement and movement disorders frequently 
associated with basal ganglia lesions, Leigh-like syndrome, cerebellar atrophy, 
migraine, epilepsy and peripheral neuropathy, and also cardiac involvement with 
conduction abnormalities or skeletal deformities.232,233-237  
In some cases, the occurrence of “Leber’s plus” has been related to specific mtDNA 
mutations, different from the primary LHON mutations and expressing a syndromic 
form of LHON, such as 14459/ND6 which is associated with LHON and dystonia.238 
Recently, several mutations have been described in the ND1, ND6, and ND5 genes of 
complex I associated with syndromic forms of LHON (from Leber’s like optic atrophy 
to MELAS or MILS).239-241 In other cases the “Leber’s plus” phenotype has been linked 
to a combination of different mtDNA mutations, including the association of one 
primary LHON mutation and other putative pathogenic changes, multiple putative 
pathogenic mutations, and the co-occurrence of two primary LHON mutations.242-244  
 
Histopathology 
LHON is characterized by a very selective degeneration of a single cell type, the retinal 
ganglion cells (RGCs). Thus, RGCs are somehow particularly sensitive to the 
mitochondrial energy defect due to the presence of LHON pathogenic mutations. All 
1.2 million fibers of the optic nerve derive from the retinal ganglion cells (RGC) of the 
inner retina.220,245,246 These cells have to transmit under all optical conditions and ensure 
axoplasmic transport all the way to distant primary visual nuclei.245,247 Moreover, the 
retinal nerve fibers run a long course without the myelin sheet, so that there is not 
saltatory conduction of action potential until past lamina cribrosa. In order to maintain 
the optical transparency and the consequently good visual resolution, these axons 
become myelinated only after they have exited the eye and formed the optic nerve (Fig. 
15).244 Thus, the high dependence of these cells on mitochondrial oxidative 
Introduction 
 
42 
 
phosphorylation may explain the particular sensitivity of RGCs and the related visual 
loss due to mitochondrial dysfunction. In the perifoveal macula, the RGCs are 
concentrated, then from the fovea, the number of RGCs decreases, becoming relatively 
sparse in the periphery.220,245,246  In addition there are two different classes of RGCs: the 
magno (M)-cells and the parvo (P)-cells, probably belonging to different class of 
neurons.248 Recent studies of the intraretinal ganglion cell axons have shown that 
varicosities, very rich in mitochondria and in desmosome- and hemidesmosome-like 
junctions, are present in single axons.248 Probably, these are functional sites, with high 
energy demand, important  for signal transmission.249 Only a few LHON cases have 
been studied histopathologically, none during the acute stage of the disease and only 
three were molecularly defined and studied by both light and electron microscopy.220 A 
drastic loss of RGC and NFL was reported in all cases (one 11778/ND4, one 
14484/ND6 plus 4160/ND1, and one 3460/ND1, reviewed by Carelli et al., 2004).220 
The 11778/ND4 and 3460/ND1 cases displayed a complete loss of central fibers with 
various degrees of axonal sparing in the periphery and absence of inflammatory 
signs.250-252 A diffuse axons demyelination, accumulation of mitochondria, cellular 
debris and cytoskeleton rearrangements were found in both cases. Some evidence of 
remyelination was also observed, suggestive of a still ongoing low-grade degenerative 
process long after the clinical onset of LHON.220 The 14484/4160 case, a “LHON plus” 
patient, displayed some residual RGC with swollen mitochondria and double-membrane 
bodies with calcium inclusions.253 This case is peculiar because of the double mutation 
and the clinical phenotype, characterized by LHON and MELAS overlap 
syndrome.242,254 
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Fig. 15 Mitochondria distribution within the optic nerve. From Carelli V, Ross-Cisneros FN, Sadun AA. 
Prog Retin Eye Res. 2004; 23:53-89. 
 
Genetics 
LHON is transmitted with a maternal pattern of inheritance, due to the presence of point 
mutations on mtDNA. The most common pathogenic mutations are 11778/ND4, 
3460/ND1, and 14484/ND6, characterizing about 90% of LHON cases. Several 
putatively pathogenic mutations have also been reported in single cases or families and 
still need a confirmation. In table 3 are reported all the LHON pathogenic, confirmed 
and putative, mutations. All LHON reported mutations have been identified in 
mitochondrial genes encoding complex I subunits. Other mitochondrial polymorphisms, 
either common or rare, have been associated with LHON and are defined as “secondary 
mutations” by some authors.255 Their role is still debated, but recent findings 
demonstrated definitively that both 11778/ND4 and 14484/ND6 mutations are 
associated respectively with mitochondrial subhaplogroup J2b and J1c, and that the 
3460/ND1 mutation is associated with haplogroup K.191 Probably, accumulation of non 
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synonymous polymorphisms in ND subunits and the cytb, most of them being the 
previously defined secondary mutations, gene can increase the penetrance of LHON.191 
Other studies confirm that one particular sub-branch of haplogroup J is associated with 
a unique, very old founder event for the 14484/ND6 mutation.256 This founder is 
responsible for their tight association in some specific populations, such as the French-
Canadians and the Dutch.220,256,257 This combination seems to induce a very low 
penetrance in females (male-female ratio 8:1, compared to other mutations 4-6:1) and 
could be an explanation for the tendency of 14484/ND6 and 11778/ND4 mutations to 
persist longer within a population when associated with haplogroup J.220 
Tab. 3 LHON pathogenic mutations, with corresponding genes, amino acidic change and 
heteroplasmy/homoplasmy detection. 
 
However, this aspect does not explain completely the variable penetrance and the male 
prevalence, two LHON features that remain still unclear. Even if the majority of LHON 
families carry the mtDNA pathogenic mutation in the homoplasmic condition, many 
individuals belonging to the maternal lineage are not clinically affected. Thus, the 
existence of other genetic determinants, such as nuclear modifying genes, has been 
suggested and widely debated.258  
Chromosome X has been extensively investigated, but to date no modifying gene has 
been identified yet.258,259 Several approaches have been tried unsuccessfully, in order to 
find a modifying gene, such as linkage analysis, X-inactivation pattern analysis, or by 
directly sequencing of candidate genes.260-266 Only recently, two different loci have been 
identified on chromosome X.267,268  
Another factor that may influence LHON penetrance, triggering the pathological 
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features in previously unaffected mutation carriers, is the exposure to certain 
environmental factors. These includes not only tobacco smoking and alcohol 
consumption, but also exposure to n-hexane and other solvents, head trauma, non-
controlled diabetes, ethambutol, and antiretroviral therapy in HIV patients.220,269 
 
Biochemistry 
Primary LHON mutations generally induce moderate changes in the catalytic function of 
complex I, with the only exception of 3460/ND1 mutation, the most severe, which has 
been shown to decrease the electron transport activity of complex I.270,271 Different studies, 
based on the investigation of complex I specific activity on different tissue of LHON 
patients and cell lines, do not shown a visible reduction in complex I activity, at least with 
11778/ND4 and 14484/ND6 mutations.270-273  Interestingly, these mutations affect the 
overall mitochondrial respiration, driven by complex I substrates, and different percentages 
of reduction have been reported. Moreover, mitochondria carrying the three common 
LHON mutations show a decreased sensitivity to rotenone, a powerful complex I inhibitor, 
and the 14484/ND6 and 3460/ND1 mutations induce an increase sensitivity of complex I 
to myxothiazol and nonyl-benzoquinol.274,275 These results suggest that LHON mutations 
may influence the interaction between complex I and ubiquinone, and that the three 
subunits affected by LHON mutations may constitute part of the ubiquinone binding 
site.273  
Several biochemical analyses have been carried out on cellular model, mainly primary 
cultures of patients’ fibroblasts and transmitochondrial cytoplasmic hybrids (cybrids, Fig. 
16). Cybrids are generated from human immortalized cell lines, lacking their mtDNA (the 
so called Rho0), and repopulated with patients mitochondria, harboring mtDNA 
mutations.276 The result is a transmitochondrial cell line in which only the features 
dependent on the patient mtDNA are co-transferred, dissected from the original nuclear 
genome and placed in a “neutral” nuclear background. In this widely used cellular model 
the main biochemical features of LHON mutations have been reproduced.272 
The impairment of complex I may induce a partial decrease of net energy production and a 
slight chronic increase of oxidative stress. Both hypotheses have been tested and many 
evidences have been found. Baracca and coll., 2005, showed that complex I-driven ATP 
synthesis is consistently reduced with all three common LHON mutations, even though 
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cells may compensate this energy impairment by alternative pathways, such as glycolysis 
and complex II/glycerol 3-phosphate dehydrogenase.277 These results fit with the 31P 
magnetic resonance spectroscopy (MRS) results in LHON patients, indicating a defective 
ATP synthesis in skeletal muscle and/or brain.278,279 
 
 
Fig 16 Scheme of cybrids generation process. From Maechler P, de Andrade PB. Biochem Soc Trans. 
2006; 34:824-827. 
 
On the other hand, an increased ROS production and chronic oxidative stress may be 
relevant for LHON pathophysiology. A significant increase in ROS generation and 
glutathione depletion, have been indeed observed in NT2 neuronal differentiated LHON 
cybrids carrying the 11778/ND4 and 3460/ND1 mutations and in osteosarcoma 
cybrids.280-282 Drastic changes in the mitochondrial antioxidant enzymatic machinery 
were also observed culturing cells in glucose free/galactose medium, suggesting a 
possible burst of oxidative stress, which may be implicated in the apoptotic cell death 
observed in LHON cybrids under these conditions of forced oxidative metabolism.283,284 
Using a medium without glucose and containing only galactose, the slow metabolism of 
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galactose to glucose-1-phosphate is not sufficient for the cells to synthesize the ATP 
necessary by glycolysis, and cells are forced to rely on respiratory chain for ATP 
synthesis. Thus, cells with a respiratory chain defect are not able to grow in similar 
conditions. In fact, incubation of LHON cybrids in galactose medium cause cell death 
characterized by the typical apoptotic hallmarks, including changes in nuclear 
morphology, chromatin condensation and fragmentation of chromosomal DNA.285 The 
cell death characterization study revealed that, even if there was a significant release of 
cytochrome c from mitochondria, the galactose-induced death process was caspase-
independent, and involved AIF and EndoG.286,287 The early reduction of ATP levels 
observed under the galactose conditions possibly prevents the execution of apoptosis 
through the “classical” cytochrome c-mediated caspase-dependent pathway, whereas 
AIF and EndoG, once translocated to the nucleus, may account for the cell death 
process.287 Moreover, an increased sensitivity to cell death was also reported in LHON 
cybrid after treatment with Fas, a well-known activator of the extrinsic apoptotic 
pathway.288 Only recently it has been demonstrated that, even if the LHON mutations 
do not affect the steady state levels of respiratory chain complexes, an accumulation of 
low molecular weight subcomplexes is evident in LHON cybrids. Moreover, LHON 
mutants belonging to different haplogroups shows a differentially delayed assembly 
rates of complexes I, III and IV, revealing that specific mtDNA polymorphisms may 
modify the pathogenic potential of LHON mutations.192 
 
Therapy and experimental treatments 
Currently, none of the proposed treatments, such as vitamins, cofactors, steroids and 
surgical treatment, is effective.220,245 The clinical trial of the neuroprotective agent 
brimonidine, during the acute phase of LHON, did not reveal any protective effect in the 
involvement of the second eye, during the disease progression.289  
A partial improvement of visual recovery and of neurological symptoms have been 
described with the treatment with idebenone, a coenzyme Q analogue.290,291 
Another approach recently proposed is based on allotopic expression of corrected 
mitochondrial genes transferred to the nucleus and targeted to mitochondria. This 
approach has been used to rescue the biochemical defect, due to mutations 8993 in 
ATPase 6 gene (NARP/MILS) and 11778 in ND4 gene (LHON).292,293  However, the 
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use of this approach is still controversial, especially because of the lacking of complete 
and long-lasting rescue.294,295 Recently, an optimization of allotopic expression for 
mitochondrial genes ATPase6, ND1 and ND4 has been developed, obtaining a complete 
restoration of mitochondrial activity in mutated human fibroblasts.296,297 The same 
authors also demonstrated that the allotopic expression of the human mitochondrial 
ND4 prevents blindness in a LHON rat model. The LHON 11778/ND4 mutation was 
introduced in rat eyes in vivo by electroporation causing the RGCs degeneration. 
Subsequent electroporation with the wild-type ND4 gene prevented the degeneration 
and the impairment of visual function.298 Another similar approach, consists to 
complement the mitochondrial defect through the expression of a transgene with ND 
subunits from other species. This approach has been applied on human cybrids bearing 
the 11778/ND4 mutation, using the nuclear protein Ndi1, a rotenone sensitive NADH-
quinone oxidoreductase, from S.cerevisiae.299 Mutant cells expressing Ndi1 show a 
recovery in complex I specific activity and in complex I driven respiration, a partial 
increase in ATP synthesis, a decrease in ROS production and are able to grow in 
galactose medium.299  
The biochemical phenotype of LHON mutations includes an increase of cellular 
oxidative stress, due to the “electron leaking” of impaired complex I. Different 
strategies have been tested in order to reduce the chronic oxidative condition. Ghelli et 
al., 2008, demonstrated that exogenous glutathione is the only one, in an variety of 
antioxidant and antiapoptotic compounds, able to reduce the cell death induced by the 
exposure of LHON cybrids to oxidative stress.300 Moreover, the overexpression of 
human MnSOD is able to rescue the apoptotic cell death induced by galactose medium 
in mutant cells 11778/ND4.301 
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Leber’s hereditary optic neuropathy (LHON) is one of the most common mitochondrial 
diseases, characterized by a very rapid loss of central vision and optic atrophy, due to 
the selective degeneration of retinal ganglion cells. The age of onset is around 20, and 
the degenerative process is fast and usually the second eye becomes affected in weeks 
or months.  Even if this pathology is well known and has been well characterized, there 
are still open questions on its pathophysiology, such as the male prevalence, the 
incomplete penetrance and the tissue selectivity.  
Most, but not all the patients clinically characterized as LHON have a molecular 
diagnosis. This is due to the fact that the 90% of LHON cases are caused by one of the 
three common mtDNA mutations (11778/ND4, 14484/ND6 and 3460/ND1), but the 
remaining 10% is caused by rare pathogenic mutations, reported in literature in one or 
few families. Moreover, there is also a small subset of patients reported with new 
putative pathogenic nucleotide changes, which awaits to be confirmed. 
The first aim of this research project was the identification of new pathogenic mutation 
or the validation of rare known mutations in families with a clear clinical diagnosis of 
LHON, but negative at the screening for the three classic mutations. The assessment of 
pathogenicity for a mitochondrial mutation is still debated. Mitchell and coll., 2006, 
proposed a new score system for the assignment of pathogenic value of mtDNA 
mutations.302 This score system considers as parameters the presence of a biochemical 
defect in affected and non affected tissues, functional studies, the independent 
identification of the same mutation in unrelated cases, the heteroplasmy and the 
conservation through different species. Thus, our purpose was the generation of a 
complete alignment of ND1-ND6 and ND4L subunits of complex I and, being the 
structure of the hydrophobic core of this enzyme still not known, the elaboration of new 
models for the secondary structure of these proteins. Both these in-silico analysis may 
help us to better understand the possible impact of a non-synonymous nucleotide 
change on protein structure and function. Furthermore, these models may suggest a 
recurrent pattern of pathogenic mutations and clarify their genotype-phenotype 
correlation. Furthermore, they may be useful for the identification of a functional role 
for polymorphic variants fixed during evolution in different mtDNA haplogroups. 
LHON is usually a monosymptomatic disorder, but there is a subset of patients with a 
syndromic form of optic atrophy referred as “Leber’s plus”, which may include central 
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nervous system involvement with frequent movement disorders.231,232 The occurrence of 
“Leber’s plus” in certain cases has been related to specific mtDNA mutations, different 
from the common LHON mutations or has been linked to a combination of different 
mtDNA mutations, including the association of one primary LHON mutation and other 
putative pathogenic changes or the co-occurrence of two primary LHON mutations. The 
second aim of this research project was to understand if some particular polymorphisms 
of mtDNA may have a functional role in Leber’s plus cases, influencing the clinical 
expression of the primary mutations. In particular we analyzed the mtDNA sequence in 
two unrelated Italian families with LHON plus myoclonus, and evidence of maternal 
transmission.   
Probably, one of the most interesting and unclear aspect of LHON is the variable 
penetrance. This phenomenon is common in LHON families, most of them being 
homoplasmic mutant. Inter-family variability of penetrance may be caused by nuclear or 
mitochondrial ‘secondary’ genetic determinants or other predisposing factors. However, 
within-family variability of penetrance in pedigrees with homoplasmic mutation 
harbored by all maternal related individuals remains unexplained. Thus, our third aim 
was to identify some molecular markers that may clearly differentiate affected 
individuals from carriers. In several mitochondrial disorders, the respiratory chain 
impairment is followed by an increase in mitochondrial mass, a common cellular 
strategy to compensate the energy defect. The compensatory activation of mitochondrial 
biogenesis is particularly evident in MELAS and MERRF, in which there is a massive 
subsarcolemmal accumulation of aberrant mitochondrial (RRFs) in patients’ skeletal 
muscle fibers. In LHON this accumulation is less evident, but an increase in SDH 
staining in skeletal muscle has been shown. Thus, the focus of this part of the project 
was the investigation of mitochondrial biogenesis in LHON patients. This part of the 
project was carried out in collaboration with Dr. Carla Giordano and Prof. Giulia 
d’Amati, at the University La Sapienza, Roma.   
To date, there is no therapy for LHON and many approaches have been tried to rescue 
the energetic defect in LHON cell lines. The last aim of this project was to analyze the 
potential therapeutic role of molecules reported in literature able to induce 
mitochondrial biogenesis. To this end, we investigated in a cellular model the 
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biosynthetic pathway driving mitochondrial biogenesis, and how its activation may 
rescue the pathologic cellular phenotype of LHON. 
Materials and methods 
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Sequence alignment and conservation analysis 
The protein sequences of ND1-ND6, ND4L, ATPase6 and COII genes were obtained 
from the non-redundant SwissProt database (http://www.expasy.org/sprot). All the 
available complete mitochondrial sequences were downloaded and three sequence sets 
were created, corresponding to eukaryotes, vertebrates and mammals. These data sets 
were aligned with ClustalX ver. 2.1 maintaining the default parameters.303 The analysis 
of amino acid conservation of the aligned sequences was carried out by GeneDoc, a 
sequence editor able to calculate the percentage of amino acid conservation for each 
position in the query alignment.304 In this way we also identified the most representative 
amino acidic residues and calculates their prevalence at each position within the 
alignment, setting the value of 70% as conservation threshold. For cytochrome b protein 
we used the alignment from Degli Esposti M. available on-line in the “The bc1-
complex” home page (http://www.life.uiuc.edu/crofts/bc-complex_site/). 
 
Prediction analysis of pathogenicity of amino acid substitutions 
PolyPhen, SIFT and PMut (http://tux.embl-heidelberg.de/ramensky/polyphen.cgi, 
http://blocks.fhcrc.org/sift/SIFT.htmL, http://mmb2.pcb.ub.es:8080/PMut/) were used to 
predict the possible impact of amino acid substitutions on the protein.  
PolyPhen is a program based on sequence comparison with homologous proteins; 
profile scores (PSIC, Position-Specific Independent Counts) are generated for the allelic 
variants and represent the logarithmic ratio of the likelihood of a given amino acid 
occurring at a particular site relative to the likelihood of this amino acid occurring at 
any site. PSIC score differences above 2 indicate a damaging effect; scores between 1.5 
and 2 suggest that the variant is possibly damaging, whereas scores below 1.5 indicate 
that the variant is benign.305  
SIFT is a sequence homology-based tool that sorts intolerant from tolerant amino acid 
substitution, based on the premise that protein evolution is correlated with protein 
function. Positions important for function should be conserved in an alignment of the 
protein family, whereas unimportant positions should appear diverse in an alignment.306 
SIFT follows a multistep procedure that searches for similar sequences, chooses related 
sequences, obtains the alignment of these sequences, and calculates normalized 
probabilities for all possible substitutions from the alignment. Positions with normalized 
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probabilities less than 0.05 are predicted to be not tolerated, those greater than or equal 
to 0.05 are predicted to be tolerated. 
Also PMut is a tool for the prediction of disease-associated amino acid mutations, 
which uses only sequence-based information (amino acid properties, evolutionary 
information, secondary structure and accessibility predictions, and database annotations) 
but is based on neural networks.307 Mutations are predicted to be either pathological or 
neutral. The overall success rate is 83.5 %, with a 66.5 % improvement over random 
when only sequence-derived information is included, while when structure is available 
the success rate increases to 87.0 % and the improvement over random to 73.0%. Thus, 
this program has the best success rate compared to the other two (SIFT 70.3 % overall 
success rate and 37.0 % improvement over random, PolyPhen 73.5% success rate with 
41.4 % improvement over random). 
 
Generation of ND1-ND6 subunit structural models 
The alignments produced for ND1-ND6 subunits were used to generate a consensus 
sequence for each gene. The hydrophobicity profile of these sequences and the average 
hydrophobicity along each position in the alignments was generated using three 
different hydropathy scales: RAO-AR, based on membrane-buried-helix parameters, 
MPH, based on membrane propensity for haemoproteins, and AMP07, based on the 
average of seven different hydrophobicity scales, including RAO-AR and MPH. These 
scales have been widely described and validated by Degli Esposti and coll., 1989 and 
1990.308,309 The resulting hydrophobicity profiles define for each subunits the number of 
transmembrane helices (TMH). When helices were predicted at least 5/6 times they 
were considered reliable. The transmembrane models topology was assessed based on 
the net charge and positioning the positive side in the mitochondrial matrix and the 
negative side in the mitochondrial intermembrane space. 
 
Cell lines and cultures conditions 
Human transmitochondrial hybrids (cybrids) were grown in DMEM added with 10% 
fetal bovine serum (FBS), 2 mM L-glutamine, 100 units/mL penicillin, and 100 µg/mL 
streptomycin and 0.1 mg/mL bromodeoxyuridine (complete medium). Cell lines were 
grown in a humidified incubator at 37°C with 5% CO2. For incubations in galactose 
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medium it has been used DMEM glucose-free medium supplemented with 5mM 
galactose, 2 mM L-glutamine, 5 mM Na-pyruvate and 10% FBS (galactose medium). 
For incubations with bezafibrate (BF), complete medium was supplemented with BF 
100 µM (diluted in DMSO, stock 20 mM), or the corresponding volume of DMSO.  
 
Growth curve in galactose or bezafibrate medium 
Cells (3x104) were seeded into 24-well plates and, after 24 hours, were washed twice 
with PBS and incubated with galactose medium, or in complete medium with 
bezafibrate or DMSO. At the end of incubation cells were harvested and counted using 
the Z1 COULTER COUNTER® Cell and Particle Counter (Beckman Coulter).  
 
Cell viability measurements 
Cells (3x104) were seeded into 24-well plates and, after 24 hours, were washed twice 
with PBS and preincubated 24 hour in complete medium with bezafibrate or DMSO, 
and then incubated in galactose medium supplemented with bezafibrate or DMSO. The 
sulforodhamine B (SRB) assay was performed following the manufacturer’s conditions. 
Briefly, at the end of incubation time, cells were fixed with 50% trichloroacetic acid 
(TCA) for 1 hour at 4°C, washed 5 times with H2O and finally dried for 1 hour at room 
temperature. Cells were then stained with SRB 0.4% diluted in 1% acetic acid for 1 
hour at room temperature, washed 4 times with 1% acetic acid, and disrupted with 10 
mM Tris-HCl pH 9.8. The absorbance of SRB was detected with Victor3 plate reader 
(Perkin Elmer) at the wavelength of 560 nm. 
 
Total cellular lysates preparation 
Cells were seed into 78 cm2 dishes in complete medium, after 24h, cells were washed in 
PBS and incubated for 72h in medium with bezafibrate 100 µM or DMSO. At the end 
of incubation time cells were scraped in 100 µL of RIPA lysis buffer [PBS, 1% Triton 
X-100, 0.5 mM EDTA, 0.6 mM PMSF and 100 µL/mL protease inhibitors]. The lysate 
was incubated in ice for 15’, frozen and thawed in liquid nitrogen twice, sonicated in 
waterbath for 2’ and centrifuged at 12000rpm for 10’ at 4°C. The supernatant was then 
collected and protein content was assessed according to Bradford.310 
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Western blotting of mitochondrial proteins 
Total cellular lysates were resuspended in Laemmli buffer (20% glycerol, 4% SDS, 125 
mM Tris-HCl pH 6.8, 10% β-mercaptoethanol, 0.004% bromophenol blue). Samples 
were denatured at 100°C for 5’ before loading on the polyacrilamide gel. Fifty 
micrograms of protein were separated by SDS-PAGE (10% acylamide/bis-acrylamide) 
electrophoresis and transferred onto nitrocellulose membrane (BioRad). Antibodies 
used were: mouse antibodies for complex I, IV and V subunits, purchased in cocktails 
from MitoSciences; goat polyclonal antibody for β-actin purchased from Santa Cruz 
Biotechnology. Mouse antibodies for complex I, IV and V subunits were used 
according to the manufacturer’s instructions. Goat polyclonal antibody for β-actin was 
used at 1:1000 dilution. Incubation with secondary antibodies (dilution 1:5000) and 
subsequent detection by chemiluminescence were done with SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific) according to the manufacturer’s 
instructions. 
 
Spectrophotometric assays for respiratory chain complexes and citrate synthase 
activity. 
Spectophotometric assays for OXPHOS complexes and citrate synthase activity were 
performed using a double wavelength spectrophotometer (Jasco V550), under stirring 
and controlled temperature. 
Respiratory chain complexes activity (I, II+III, III and IV) were evaluated in platelet 
homogenate freshly prepared from 100 mL of venous blood as described by Carelli et 
al., 1997, and Degli Esposti et al., 1994.271,273  
Specific NADH ubiquinone oxidoreductase and cytochrome c oxidase activities were 
determined in cells grown in complete medium according to Benit et al., 2006.311 with 
minor modifications. Briefly, small aliquots of cells were deep-frozen in 50 µL PBS and 
then thawed in 1 mL of ice-cold medium 1 [0.25 M sucrose, 20 mM Tris (pH 7.2), 40 
mM KCl, 2 mM EGTA, 1 mg/mL BSA, 0.01% digitonin (w/v), 10% Percoll (v/v)]. 
Cells were incubated 10 minutes in ice, centrifuged for 5 min at 5000rpm and the 
supernatant was discarded. The pellet was then washed with 1mL of medium 1 devoid 
of digitonin and Percoll and centrifuged for 5 min at 8000rpm. Finally, the pellet was 
resuspended in 30 µL of medium 1 devoid of digitonin and Percoll. Complex IV activity 
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was determined following the absorbance of reduced cytochrome c at wavelengths 550 
nm and 540 nm (ε= 19.1 mM-1 cm-1, 37°C). The assay was performed in 1 mL of 
medium A [10 mM KH2PO4 (pH 7.2), 1 mg/mL BSA] and the reaction was blocked by 
addition of 0.3 M KCN. Complex I specific activity was determined following the 
absorbance of NADH at wavelengths 340 nm and 380 nm (ε= 4.87 mM-1 cm-1, 37°C). 
The assay was performed in 1 mL of medium B [50 mM Tris (pH 8.0), 5 mg/mL BSA] 
and the reaction was blocked by addition of 8 µM rotenone. Citrate synthase activity 
was determined as described by Trounce et al., 1996.312 and protein content was 
assessed according to Bradford.310 
 
ATP synthesis assay 
The measurements of mitochondrial ATP synthesis were done in cells grown in 
DMEM-glucose according to Manfredi et al. 2002.313 with minor modifications. Briefly, 
after trypsinization, cells were resuspended (7x106/mL) in buffer A [10 mM KCl, 25 
mM Tris-HCl, 2 mM EDTA, 0.1% bovine serum albumin, 10 mM potassium phosphate, 
0.1 mM MgCl2 (pH 7.4)], kept for 15 minutes at room temperature, and then incubated 
with 50 µg/mL digitonin for 1 minute. After centrifugation, the cells pellet was 
resuspended in buffer A and aliquots were taken to measure ATP synthesis, protein 
content, and citrate synthase activity. Aliquots of cells were incubated with 5 mM 
malate plus 5 mM pyruvate (complex I–driven substrates) in the presence or absence of 
10 µg/mL oligomycin, or with 10 mM succinate plus 2 µg/mL rotenone (complex II–
driven substrate), and 0.2 mM ADP for 1 and 3 minutes. The amount of ATP was 
measured as described.287 Adenosine 5′-triphosphate (ATP) Bioluminescent Assay Kit 
was from Sigma Aldrich. The rate of ATP synthesis was expressed as a ratio of citrate 
synthase activity.312 Protein concentration was determined according to Bradford.310 
 
Nucleic acid extraction 
DNA samples were extracted from different tissues (whole blood, skeletal muscle, 
urinary epithelium, platelet fraction and hair) using the standard phenol-chloroform 
method, resuspended in MilliQ water and stored at -20°C. Cells from a confluent 75 
cm2 flask were pelleted and washed once in PBS. PBS was removed and DNA extracted 
with the standard phenol-chloroform method. 
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Total RNA was extracted from human skeletal muscle bioptic fragments and cultured 
cells (cybrids). Approximately, 50 sections of 20 µm were obtained from frozen tissue 
samples and total RNA was extracted using the RNeasy Micro Kit (Qiagen) following 
the manufacturer protocol. Briefly, sections were disrupted with 150µL RLT buffer plus 
143 mM β-mercaptoethanol and vortexed. The lysis buffer is then diluted with 290 µL 
RNase-free water and treated with 10 µL of Proteinase K (10 mg/mL) at 55°C for 10 
minutes. The homogenate was subsequently centrifuged for 3 minutes at 10000g at 
room temperature with the purpose to eliminate any eventually present tissue debris. 
The sample was transferred in a new tube and 0.5 volumes of ethanol 100% were added 
and loaded in a MinElute Spin Column (Qiagen). After a series of washes the total RNA 
is finally eluted with 14 µL of RNase-free water. 
Cybrids were grown in a 78 cm2 cell culture dish; when the cells were confluent, total 
RNA was extracted with TRIzol (Invitrogen) following the manufacturer suggested 
protocol. RNAs samples were precipitated with isopropanol followed by centrifugation 
for 10 minutes at 4°C at 12000g, and then the pellets were washed, dried and 
resuspended in RNase-free water. All the RNA samples were treated with DNase I 
(Promega), to avoid any contamination with genomic DNA, at 37°C for 30 minutes, 
followed by enzyme inactivation at 65°C for 10minutes. 
Nucleic acid concentration and purity was evaluated measuring 1 µL of sample with 
Nanodrop 1000 Spectrophotometer (Thermo Scientific), at the wavelengths 260 nm and 
280 nm. 
 
Identification of LHON common mutations 
The PCR mixture contained 2 ng of DNA, 0.2 U Taq DNA Polimerase (Eppendorf), 1x 
Buffer Advanced (Eppendorf), 200 µM PCR nucleotide Mix (Roche), 200 µM each 
primer (Invitrogen), in a final volume of 25 µL. 
For the PCR reaction we used a GeneAmp PCR System 2700 (Applied Biosystems) 
thermal cycler. Primers sequences and PCR conditions are reported in appendix B. The 
PCR reaction was checked with an electrophoresis on agarose gel and ethidium bromide 
staining. The PCR fragments were of 119 bp (11778/ND4), 75 bp (14484/ND6) and 398 
bp (3460/ND1). 
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The PCR products were subsequently digested with the following restriction enzymes 
LweI (Fermentas) for the G11778A mutation, Bsp143I (Fermentas) for the G14484A 
mutation and Hin1I (Fermentas) for the T3460A mutation. LweI recognize a restriction 
site in the wild type DNA and generates two fragments of 64 bp and 55 bp; Bsp143I 
recognize a restriction site in the wild type DNA and produce two fragments of 64 bp 
and 21 bp; Hin1I recognize a restriction site in the mutant DNA and produce two 
fragments of 298 bp and 91 bp. 
The digestion mixture was composed by 5 or 8 µL of PCR product, 1 U/µL of 
restriction enzyme, 1x suggested Buffer, in a final volume of 10 µL, and was incubated 
for 16 hours at 37°C. Subsequently the fragments were separated with electrophoresis 
on Metaphor (BioSpa) gel at 3% or 4% and displayed with ethidium bromide staining. 
 
Mitochondrial DNA complete sequencing 
The complete mtDNA sequencing was carried out on DNA samples extracted from 
venous blood, in the Laboratory of Genetics, Dipartimento di Genetica e Microbiologia, 
Università di Pavia (Prof. Antonio Torroni), as previously described.314 
 
Restriction fragment length polymorphism (RFLP) assay for LHON rare 
mutations 
The PCR mixture contained 2 ng of DNA, 0.2 U Taq DNA Polimerase (Eppendorf), 1x 
Buffer Advanced (Eppendorf), 200 µM PCR nucleotide Mix (Roche), 200 µM each 
primer (Invitrogen), in a final volume of 25µL. 
For the PCR reaction we used a GeneAmp PCR System 2700 (Applied Biosystems) 
thermal cycler. Primers sequences and PCR conditions are reported in appendix B. The 
PCR reaction was checked with an electrophoresis on agarose gel and ethidium bromide 
staining. 
The digestion mixture was composed by 5 or 8 µL of PCR product, 1 U/µL of 
restriction enzyme, 1x suggested Buffer, in a final volume of 10 µL, and was incubated 
at the suggested temperature. The enzyme list, digestion conditions and fragment length 
are shown in table 4. Subsequently the fragments were separated with electrophoresis 
on Metaphor (BioSpa) gel at 3% or 4% and displayed with ethidium bromide staining. 
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Mutation Enzyme Temperature/Time Mutant fragments 
size (bp) 
Wild type fragments 
size (bp) 
14258 BamHI 37°C / 16h 575 446, 129 
14495 NlaIII 37°C / 3h 102, 98 130 
14459 MaeIII 55°C / 16h 139, 25 164 
3700 HhaI 37°C / 16h 479 258, 221 
14568 AciI 37°C / 16h 298 160, 138 
14568 BcgI 37°C / 16h 160, 138 298 
4172 BseMI 55°C / 16h 130, 20 150 
 
Tab. 4 LHON candidate pathogenic mutation, digestion conditions, enzyme list (Fermentas) and 
digestion fragment length.  
 
RFLP assay for rare polymorphisms 
The PCR mixture contained 2 ng of DNA, 0.2 U Taq DNA Polimerase (Eppendorf), 1x 
Buffer Advanced (Eppendorf), 200 µM PCR nucleotide Mix (Roche), 200 µM each 
primer (Invitrogen), in a final volume of 25 µL. 
For the PCR reaction we used a GeneAmp PCR System 2700 (Applied Biosystems) 
thermal cycler. Primers sequences and PCR conditions are reported in appendix B. The 
PCR reaction was checked with an electrophoresis on agarose gel and ethidium bromide 
staining. 
The digestion mixture was composed by 5 or 8 µL of PCR product, 1 U/µL of 
restriction enzyme, 1x suggested Buffer, in a final volume of 10µL, and was incubated 
at the suggested temperature. The enzyme list, digestion conditions and fragment length 
are shown in table 5. Subsequently the fragments were separated with electrophoresis 
on Metaphor (BioSpa) gel at 3% or 4% and displayed with ethidium bromide staining. 
Polymorphism Enzyme Temperature/
Time 
Mutant fragments 
size (bp) 
Wild type fragments 
size (bp) 
4136 NlaIII 37°C / 3h 74, 26 100 
9319 TaaI 65°C / 16h 380, 139 519 
15773 BsrI 65°C / 16h 1709 480, 1229 
 
Tab. 5 LHON candidate pathogenic mutation, digestion conditions, enzyme list (Fermentas) and 
digestion fragment length.  
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Analysis of the functional polymorphism G1444A in the PGC-1α gene 
The PCR mixture contained 2 ng of DNA, 0.2 U Taq DNA Polimerase (Eppendorf), 1x 
Buffer Advanced (Eppendorf), 200 µM PCR nucleotide Mix (Roche), 200 µM each 
primer (Invitrogen), in a final volume of 25 µL. 
For the PCR reaction we used a GeneAmp PCR System 2700 (Applied Biosystems) 
thermal cycler. Primers sequences and PCR conditions are reported in appendix B. The 
PCR reaction was checked with an electrophoresis on agarose gel and ethidium bromide 
staining. 
The PCR product (260 bp) was subsequently digested with the restriction enzyme HpaII 
(Fermentas). This enzyme recognize the palindromic sequence 5’-CCGG-3’, and is able 
to cut the allele G, producing two fragments of 111 and 149 bp, while the allele A 
remains uncut. The digestion mixture was composed by 5 or 8 µL of PCR product, 1 
U/µL of restriction enzyme, 1x suggested Buffer, in a final volume of 10 µL, and was 
incubated for 16 hours at 37°C. Subsequently the fragments were separated with 
electrophoresis on Metaphor (BioSpa) gel at 4% and displayed with ethidium bromide 
staining. 
 
Mitochondrial DNA copy number evaluation 
Absolute quantification of mtDNA relative to nuclear DNA (nDNA) was performed by 
a real-time PCR based method using the LightCycler480 (Roche). This method is a 
multiplex assay based on hydrolysis probe chemistry. A mtDNA fragment (ND2 gene) 
and a nDNA fragment (FasL gene) were co-amplified by multiplex polymerase chain 
reaction according to the primers, probes and conditions previously published.315 These 
two fragments were cloned tale to tale in a vector and serial dilutions were used to 
construct a standard curve, obtaining a ratio of 1:1 of the reference molecules. Primers 
and probes sequences and PCR conditions are available on request. 
 
Reverse transcription 
Reverse transcription was performed on extracted RNA, using Transcriptor First Strand 
cDNA Synthesis Kit (Roche) and following the manufacturer’s protocol. The cDNA 
was generated performing a reverse transcription of 2 µg of total RNA using random 
hexameric primers.  
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Relative quantitative PCR assays for mitochondrial biogenesis related genes 
Relative mRNA quantification was performed by a real-time PCR based method using 
the instrument LightCycler480 (Roche). This method is a singleplex assay based on 
SybrGreen I chemistry. The mRNAs amount relative to target genes (PGC-1α, PGC-1β, 
PRC and Tfam) was determined using the human β-actin as reference. Primer sequences 
and PCR conditions are reported in appendix B. 
 
Statistical analysis 
Statistical analysis was performed using the SigmaStat ver.3.5 software package, 
choosing the most appropriate test. For mtDNA copy number analysis within the 
Brazilian family, ANOVA Dunn’s test or Mann-Whitney test were performed, being the 
values from these samples not normally distributed. Linear regression analysis was 
performed to correlate mtDNA copy number and age.  For mtDNA copy number 
analysis in Italian families paired t-test was used for blood and ANOVA Holm-Sidak 
test for skeletal muscle. For analysis of PGC-1α genotypes, χ2 or Fisher’s exact tests 
were performed. For correlation of mtDNA copy number and PGC-1α genotypes, 
ANOVA was performed. For relative gene expression analyses paired t-test was used on 
raw ∆Ct data. For cellular analyses t-test or ANOVA were performed. Data were 
considered significantly different for p-values < 0.05. 
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Part 1 - Role of mtDNA variants in LHON: pathogenic mutations and 
synergistic polymorphisms 
 
Conservation analysis and structural models of complex I subunits 
In order to establish the pathogenic potential of mtDNA mutations and the possible 
functional role of some common polymorphic variants, a conservation analysis on ND1-
ND6 and ND4L protein sequences has been carried out. The number of complete 
sequences, for each protein, downloaded from the non-redundant SwissProt database is 
reported in table 6. Moreover, we have downloaded, aligned and analyzed complete 
protein sequences of COX2 and ATPase6 subunits (Tab. 6). These sequences have been 
divided in three subsets, corresponding to eukaryotes, vertebrates and mammals, and 
used to generate global alignments. 
 
Subunit Eukaryotes  Vertebrates Mammals 
ND1  140  106  81  
ND2  119  88  62  
ND3  137  89  67  
ND4  88  51  38  
ND4L  90  63  55  
ND5  96  51  38  
ND6  86  75  41  
ATP 6  97  58  38  
COX2 286 184 162 
 
Tab. 6 Number of complete mitochondrial protein sequences used for the generation of ND1-6, ND4L, 
COX2 and ATPase6 global alignments. 
 
For each position, the percentage of amino acid conservation has been calculated and a 
consensus sequence has been generated, identifying the most prevalent amino acid 
along each alignment. The average of protein conservation and the percentage of 
conserved amino acids have been calculated and reported in table 7. Considering both 
parameters, the most conserved ND subunit is invariably ND1 (average conservation 
from 70.95% in eukaryotes to 84.90% in mammals) , whereas the less conserved is ND6 
(average conservation from 55.89% in eukaryotes to 71.15% in mammals). The 
conservation among the other subunits varies in the three different data sets. As 
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expected, the average conservation and the percentage of conserved amino acid increase 
with the reduction of evolutionary distances, independently from the protein. However, 
considering each single amino acid position, this is not a general rule, being some 
amino acid position more conserved in eukaryotes and vertebrates than in mammals. 
 
Complex 
I 
subunit 
 
Eukaryotes Vertebrates Mammals 
Average 
conservation 
(%) 
Conserved 
amino acid 
(%) 
Average 
conservation 
(%) 
Conserved 
amino acid 
(%) 
Average 
conservation 
(%) 
Conserved 
amino acid 
(%) 
ND1  70.95  58.81  81.72  72.33  84.90  76.73  
ND2  57.55  33.43  67.27  45.82  75.01  59.65  
ND3  62.18  46.96  75.12  60.00  79.71  67.83  
ND4  60.30  34.86  76.83  63.18  82.68  74.73  
ND4L  60.03  38.78  72.33  55.10  80.24  66.33  
ND5  55.69  26.70  73.16  56.55  79.38  68.66  
ND6  55.89  28.16  60.05  29.31  71.15  54.02  
 
Tab. 7 Percentages of average conservation and conserved amino acids in the ND1-6 and ND4L 
alignments, for each data set. 
 
The analyses of consensus sequences hydrophobicity and average hydropathy along the 
alignments allow us to identify the putative transmembrane segments, characterized by 
α-helix secondary structure (TMH), and to generate a structural model for each ND 
subunit.  
The scales AMP07 and RAO-AR predict the same number of TMHs, for ND1, ND2, 
ND3, ND4L and ND6 subunits, considering the average or consensus sequences 
hydrophobicity. In the case of ND4 and ND5, the same TMHs are predicted for both 
scales, but this number varies if we consider average or consensus sequences 
hydropathy. 
MPH scale recognizes different TMHs using average or consensus sequences 
hydrophobicity and predicts an equal number or less α-helix compared to AMP07 and 
RAO-AR. This is due to the more restrictive assignment of hydrophobicity to each 
amino acid and to the higher MPH threshold of hydrophobicity (1.1 for MPH versus 1.0 
for AMP07 and RAO-AR). In order to consider the influence in the prediction analysis 
of each scale, each transmembrane domain has to be predicted at least by 5 analyses on 
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a total of 6 (considering the three scales for average and consensus sequences 
hydropathies).  
 
ND1 subunit 
In the ND1 subunit AMP07 and RAO-AR clearly predict 8 TMHs, whereas MPH 
predicts 7 α-helices using the average hydropathy and 6 α-helices using the consensus 
sequence. Figure 17A shows the hydropathy profile generated with MPH scale on the 
consensus sequence obtained from eukaryotes global alignment. Our model represents 
ND1 with 6 TMHs and 1 amphipathic helix (named helix E in figure 17) protruding in 
the mitochondrial intermembrane space. The boundaries of helix E are the amino acid 
positions 220-240 and this helix shows a peculiar double peak hydropathy plot, with a 
very profound decrease of hydrophobicity in the middle of the helix. The conservation 
analysis reveals that ND1 is extremely conserved in mammals (Tab. 7), presenting 115 
invariant residues (36% of the protein) and 8 invariant zones corresponding to extra-
membrane loops AB, CD, DE and FG. In vertebrates there are 77 invariant amino acids 
(24% of the protein) and 5 invariant regions in the previously cited loops. The 
alignment of eukaryotes sequences reveals the lack of invariant zones and only three 
invariant residues (Arg-134, Pro-197 and Phe-198), probably the most important for 
ND1 function.  
Mitomap reports 12 nucleotide changes associated with LHON or LHON plus other 
mitochondrial diseases in ND1 subunit (Fig. 17B). Only one of these is defined as 
confirmed (G3460A), whereas 2 are reported as unclear (G3316A and T3394C), 8 as 
reported (G3376A, G3496T, C3497T, G3635A, G3700A, G3733A, T4160C, C4171A) 
and one as possibly synergistic (A4136G). According to our model, ten of the reported 
variants are located in extra-membrane loops (AB, CD, and FG) on the membrane side 
facing the mitochondrial matrix. These loops are very conserved regions of ND1 
subunit and the presence of pathogenic mutations may underlie the importance of these 
regions for ND1 function. The nucleotide change G3316A, reported as unclear, is 
located in the N-terminal of the protein, whereas the possibly pathogenic mutation 
G3635A is located inside the TMH C. Common non-synonymous polymorphisms, 
associated with mtDNA haplogroups, are also present in ND1 gene (T3394C/J1c1, 
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A3505G/W, A3796G/H1b, C3992T/H4, A4024G/H4a and T4216C/R2-JT), affecting 
different positions of the polypeptide chain. 
 
ND2 subunit 
In the ND2 subunit AMP07 and RAO-AR predict 9 TMHs, whereas MPH predicts 8 α-
helices with average hydropathy and 7 α-helices with the consensus sequence. In figure 
18A is shown the hydropathy profile generated with MPH scale on the consensus 
sequence. In this model we propose 8 TMHs and a α-helix in the C-terminal of the 
polypeptide chain (helix I) that can be either amphipathic or embedded in the membrane 
(Fig. 18). ND2 is a moderately conserved protein. Along mammalian sequences 
alignment there are 73 invariant residues (21% of the protein) and two hyper-conserved 
regions (130-135 and 169-173). In vertebrates and eukaryotes there are no invariant 
regions and respectively 37 and 6 invariants amino acid positions (10% and 1% of the 
protein). Only one nucleotide change may have a pathogenic potential for LHON 
(G5244A), and affect an amino acid position located in the loop GH, facing the 
intermembrane space. Conversely, several haplogroups defining non-synonymous 
polymorphisms have been accumulated in the ND2 gene (T4561C/K2a, T4639C/V1, 
C4640A/U3b-K1a5, A4917G/R1-T, 4960/N1b, G5046A/N2, C5263T/V1a, G5460A/W-
J1b) affecting residues located both in extra-membrane loops and in membrane 
spanning regions. 
 
 ND3 subunit 
This very small protein is predicted to fold in 3 TMHs by all the scales used in this 
study, corresponding to three wide hydrophobic regions (Fig. 19). ND3 shows a high 
overall conservation along mammals (Tab. 7), with 37 absolutely conserved amino 
acids (32% of the protein) and two hyper-conserved regions in helix A (aa 22-25) and 
helix B (aa 54-57). In vertebrates the invariant residues represent the 20% of the entire 
protein (23 amino acids), but no invariant regions can be defined. The overall 
conservation decrease in eukaryotes and only two residues are absolutely conserved 
Gly-40 and Glu-68, both located in extra-membrane loops (respectively AB and BC). 
Even in the absence of invariant zones, a large region with high local conservation can 
be observed from amino acid 32 to 77, representing the subunit core and covering part 
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of loops AB and BC and the entire helix B. In this region resides the only one reported 
mutation associated with LHON (T10237, Ile60Thr), whereas the population non-
synonymous polymorphism A10398G, defining haplogroups L3, N1a, K1 and J, affects 
position 114 in the C-terminal of the protein. 
 
ND4L subunit 
Similar to ND3, ND4L is a very small protein in which three TMHs are recognized by 
every hydropathy scale. Moreover, this protein presents three wide hydrophobic regions 
and consequently the TMHs boundaries cannot be clearly defined (Fig. 20). In 
mammals 29% of the polypeptide chain is represented by absolutely conserved amino 
acids and there is an invariant region corresponding to helix B. In vertebrates this 
percentage decreases at 10% and there is only one invariant amino acid (Glu-34) in 
eukaryotes. Three LHON possibly pathogenic mutations are reported on Mitomap 
(A10543G, T10591G and T10663C), affecting helices B and C. A single non-
synonymous variant (A10506G) is associated with haplogroup U3a and hits Thr-13 in 
helix A.  
 
ND4 subunit 
The hydrophobicity analysis of ND4 consensus sequence using AMP07 and RAO-AR 
scales reveals the presence of 14 hydrophobic segments, whereas for analysis conducted 
on average hydropathy only 13 TMHs are recognized. The more restrictive MPH scale 
predicts only 9 and 8 α-helices, respectively for average and consensus hydropathy. We 
here propose a model of ND4 with 10 defined TMHs and 2 helices (named in figure 21 
A and J) with a controversial hydropathy plot that can be either membrane spanning or 
protrude in the intermembrane space. Moreover, the assignment of ND4 topology across 
the membrane is controversial, being both sides positively charged. In mammals 39% of 
amino acids results invariant and 8 hyper-conserved regions are present, including a 
very long stretch of 16 amino acids, from 214 to 229.  This stretch corresponds to the 
loop EF, facing the intermembrane space where mutations or polymorphisms have 
never been reported. Along vertebrates’ alignment, 106 amino acids (23% of the chain) 
and 3 extremely conserved regions can be identified. These regions include the 
previously reported long stretch divided in two zones (214-224 and 226-229). Finally, 
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in eukaryotes there are 13 invariant residues (3% of the protein), including 4 from the 
long hyper-conserved stretch (Trp-215, Leu-216, Hys-220 and Ser-228). At least 4 
nucleotide changes are reported in Mitomap to be associated with LHON, but only 
G11778A is confirmed. This mutation induces the amino acid substitution Arg340Hys, 
an extremely conserved position in the intermembrane space loop IJ. Another reported 
mutation, C11874A, affects the loop JK on the same membrane side, whereas mutations 
T11253C and G11696A affect respectively loop DE and helix I. Moreover, two 
polymorphic variants of haplogroup K2c (A11015G and A11172G) hit ND4 subunit, 
precisely in loops BC and CD. 
 
ND5 subunit 
The largest mitochondrial-encoded complex I subunit is ND5. This protein shows 13 
hydrophobic segments, considering the hydrophobicity of the consensus sequence, 
independently from the used hydropathy scale. If average hydrophobicity is considered, 
AMP07 and RAO-AR predict 15 TMHs, whereas MPH predicts only 13 TMHs. The 
proposed model represents ND5 with 13 membrane spanning segments (Fig. 22). 
Moreover, another hydrophobic region can assume a TMH structure or be an 
amphipathic helix outside the membrane on the matrix side (Fig. 22, helix I). The 
conservation analysis of ND5 reveals the existence of several conserved regions. In 
mammals 33% of the whole protein is represented by invariant amino acids and 9 
absolutely conserved regions, including a long stretch of 18 amino acids (236-253), can 
be identified. This stretch is also evident along vertebrates’ alignment and invariant 
amino acids cover the 18% of the polypeptide chain. In eukaryotes, 22 amino acids are 
absolutely conserved (3.6%) and there are two zones with high local conservation (143-
155 and 222-256), corresponding to helix I and extra-membrane loops DE and IJ (Fig. 
22).  
At least 7 non-synonymous variants in ND5 gene have been associated with LHON or 
LHON and other mitochondrial diseases, none of them reported on Mitomap as 
confirmed. All these variants hit extra-membrane loops on both sides of the membrane 
and define at least one region (loops DE and FG) with a possible functional role (Fig. 
22B). Several haplogroups defining variants induce changes in the ND5 polypeptide 
chain, most of them concentrated in loops LM and MN. 
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ND6 subunit 
Every hydropathy scale predicts clearly 5 TMHs for ND6 subunit with a clearly defined 
topology (Fig. 23). ND6 is the most divergent ND subunit but in mammals shows a 
hyper-conserved box (amino acids 59-70) in the helix C with 40 invariant residues (23% 
of the polypeptide chain). In vertebrates and eukaryotes this region is still highly 
conserved, with at least 4 absolutely conserved amino acids (Gly-61, Gly-62, Phe-67 
and Tyr-69). Mutations associated with LHON are concentrated in helix B, a moderate 
conserved region with high conserved amino acids, in helix C, especially in the 
invariant box, and in the loop DE (Fig. 23B). Some non-synonymous polymorphisms 
have been accumulated in ND6 in general population (T14307C/K2b, T14318C/C, 
C14365T/H4a and A14582G/H4a). These variants are located in helices B and D and in 
loop DE and they correspond to poorly conserved positions. 
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Fig. 17 Hydropathy plot, conservation analysis and protein model of ND1 subunit. A) Hydrophobicity 
profile of consensus sequence with MPH scale and percentage of conservation (blue bars) of each amino 
acid residue along the alignment of eukaryotic sequences. The conservation threshold of 70% is indicated 
with the light blue line. B) Structural model of ND1 subunit with corresponding nucleotide changes 
reported in Mitomap as associated with LHON. Possibly pathogenic mutations are in regular font, 
secondary and unclear variants are in italic, confirmed mutations are in the box and LHON plus or 
LHON/ other mitochondrial diseases overlap syndromes are underlined. 
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Fig. 18 Hydropathy plot, conservation analysis and protein model of ND2 subunit. A) Hydrophobicity 
profile of consensus sequence with MPH scale and percentage of conservation (blue bars) of each amino 
acid residue along the alignment of eukaryotic sequences. The conservation threshold of 70% is indicated 
with the light blue line. B) Structural model of ND2 subunit with corresponding nucleotide changes 
reported in Mitomap as associated with LHON. Possibly pathogenic mutations are in regular font, 
secondary and unclear variants are in italic, confirmed mutations are in the box and LHON plus or 
LHON/ other mitochondrial diseases overlap syndromes are underlined. 
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Fig. 19 Hydropathy plot, conservation analysis and protein model of ND3 subunit. A) Hydrophobicity 
profile of consensus sequence with MPH scale and percentage of conservation (blue bars) of each amino 
acid residue along the alignment of eukaryotic sequences. The conservation threshold of 70% is indicated 
with the light blue line. B) Structural model of ND3 subunit with corresponding nucleotide changes 
reported in Mitomap as associated with LHON. Possibly pathogenic mutations are in regular font, 
secondary and unclear variants are in italic, confirmed mutations are in the box and LHON plus or 
LHON/ other mitochondrial diseases overlap syndromes are underlined. 
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Fig. 20 Hydropathy plot, conservation analysis and protein model of ND4L subunit. A) Hydrophobicity 
profile of consensus sequence with MPH scale and percentage of conservation (blue bars) of each amino 
acid residue along the alignment of eukaryotic sequences. The conservation threshold of 70% is indicated 
with the light blue line. B) Structural model of ND4L subunit with corresponding nucleotide changes 
reported in Mitomap as associated with LHON. Possibly pathogenic mutations are in regular font, 
secondary and unclear variants are in italic, confirmed mutations are in the box and LHON plus or 
LHON/ other mitochondrial diseases overlap syndromes are underlined. 
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Fig. 21 Hydropathy plot, conservation analysis and protein model of ND4 subunit. A) Hydrophobicity 
profile of consensus sequence with MPH scale and percentage of conservation (blue bars) of each amino 
acid residue along the alignment of eukaryotic sequences. The conservation threshold of 70% is indicated 
with the light blue line. B) Structural model of ND4 subunit with corresponding nucleotide changes 
reported in Mitomap as associated with LHON. Possibly pathogenic mutations are in regular font, 
confirmed mutations are in the box and LHON plus or LHON/ other mitochondrial diseases overlap 
syndromes are underlined. 
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Fig. 22 Hydropathy plot, conservation analysis and protein model of ND5 subunit. A) Hydrophobicity 
profile of consensus sequence with MPH scale and percentage of conservation (blue bars) of each amino 
acid residue along the alignment of eukaryotic sequences. The conservation threshold of 70% is indicated 
with the light blue line. B) Structural model of ND5 subunit with corresponding nucleotide changes 
reported in Mitomap as associated with LHON. Possibly pathogenic mutations are in regular font, 
confirmed mutations are in the box and LHON plus or LHON/ other mitochondrial diseases overlap 
syndromes are underlined. 
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Fig. 23 Hydropathy plot, conservation analysis and protein model of ND6 subunit. A) Hydrophobicity 
profile of consensus sequence with MPH scale and percentage of conservation (blue bars) of each amino 
acid residue along the alignment of eukaryotic sequences. The conservation threshold of 70% is indicated 
with the light blue line. B) Structural model of ND6 subunit with corresponding nucleotide changes 
reported in Mitomap as associated with LHON. Possibly pathogenic mutations are in regular font, 
confirmed mutations are in the box and LHON plus or LHON/ other mitochondrial diseases overlap 
syndromes are underlined. 
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Prediction of pathogenic potential of amino acid substitutions 
In this section we have analyzed the pathogenic potential of amino acid substitutions, 
due to mutations reported on Mitomap associated with LHON and with haplogroup 
related mtDNA polymorphisms. Conservation along alignments and three prediction 
tools available on-line (PolyPhen, SIFT and PMut) were used to assess the 
pathogenicity of these variants. Different predictions for each variant were obtained, 
depending on the selected method. If a variant is predicted as pathogenic at least by 3/4 
methods, it is accepted as pathogenic, whereas if it is predicted by 2/4 methods it is 
considered uncertain. In tables 8 and 9 the analyzed variants with the corresponding 
pathogenicity prediction are reported. 
Concerning the conservation analysis, 29/39 variants with potential pathogenic effects 
involve highly conserved positions along mammals (17 of those are invariants) and 
27/39 along vertebrates (10 invariants).  In eukaryotes only 22 variants affect a 
conserved amino acid and none of them invariant positions, underlining the extremely 
important role of these amino acids. Comparing the on-line prediction tools, PolyPhen 
results the most restrictive and predicts as possibly or probably pathogenic only 19/39 
amino acid substitution with putative pathogenic role. SIFT predicts as non tolerated 
24/39 variants, whereas PMut predicts as pathogenic 31/39 variants. 
Every mutation cited on Mitomap as confirmed is predicted pathogenic by this 
integrated approach, with the only exception of C14568T/ND6 that has to be considered 
uncertain. The possibly synergistic variant A4136G/ND1 results pathogenic, whereas 
secondary mutations and unclear variants are predicted neutral or uncertain. Mitomap 
cites as ‘reported’ 28 variants; our analysis reveals that 19 may have a potential 
pathogenic role, 2 are uncertain and 7 are neutral. 
The same approach has been applied on common polymorphisms conserved in 
European mtDNA haplogroups. In this case all the polymorphisms were predicted as 
not pathogenic, in fact 83% are neutral and only 17% are uncertain, mainly due to the 
moderate conservation of the affected amino acids (Tab. 9). 
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Tab. 8 Prediction of functional role of amino acid substitution in ND1-ND6 and ND4L subunits. Variants 
list is downloaded from Mitomap and for each variant is reported the conservation analysis and the 
prediction of PolyPhen, SIFT and PMut. Confirmed mutations are in bold, variants predicted to be 
pathogenic are underlined and uncertain variants are in italic. (Abbreviations Cfrm: confirmed, Pos syn: 
possibly synergistic, Rep: reported, Sec: secondary) 
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Tab. 9 Prediction of functional role of amino acid substitution in ND1-ND6 and ND4L subunits. Variants 
are common polymorphisms retrived from the general population and associated with European mtDNA 
haplogroups. For each variant is reported the conservation analysis and the prediction of PolyPhen (PSIC 
score higher than 1.5 are considered possibly damaging), SIFT and PMut (scores higher than 0.5 are 
considered pathological). Variants predicted to be pathogenic are underlined and uncertain variants are in 
italic. 
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Identification of rare and putative new LHON pathogenic mutations 
In 90% of cases, LHON is caused by one of three mtDNA common mutations 
(11778/ND4, 3460/ND1, 14484/ND6 in complex I subunit genes). However, in many 
cases the molecular diagnosis results negative for these mutations, even if the patients 
show a full LHON clinical phenotype. In order to explain the molecular cause of some 
of these cases, we here investigate 6 LHON probands from 5 unrelated Italian families 
(for family trees see Appendix C). All these patients result negative at LHON common 
mutation screening. We completely sequenced the mtDNA from these patients and we 
found 4 rare LHON mutations, some of them reported only once, and 2 new nucleotide 
changes with pathogenic potential. The raw data of mtDNA sequencing are reported in 
Appendix D and the list of non-synonymous nucleotide changes is reported in table 10. 
Figure 24 shows the tree encompassing the complete mtDNA sequences observed in the 
investigated pedigrees. 
 
Family Locus Nucleotide 
change  
Amino acid 
position 
Amino acid 
change 
Homoplasmy/ 
Heteroplasmy 
mtDNA 
haplogroup 
Fam. 1 ND1 G3700A 132 Ala-Thr Homoplasmic H 
 ND5 G13759A 475 Ala-Thr -  
Fam. 2 ND1 T4172A 289 Leu-Gln Homoplasmic U6a 
 COII G7805A 74 Val-Ile -  
 ND6 C14568T 36 Gly-Ser Heteroplasmic  
 Cyt b G15221A 159 Asp-Asn -  
Fam. 3 ND1 T4216C 304 Tyr-His - J1c 
 ND3 A10398G 114 Thr-Ala -  
 ND5 G13708A 458 Ala-Thr -  
 ND5 C13934T 533 Thr-Met -  
 ND6 G14459A 72 Ala-Val Homoplasmic  
 Cyt b T14798C 18 Phe-Leu -  
 Cyt b C15452A 236 Leu-Ile   
Fam. 4 ND6 A14495G 60 Leu-Ser Heteroplasmic H 
Fam. 5 ATP6 A8944G 140 Met-Val - K1a 
 ATP6 G9055A 177 Ala-Thr -  
 ND3 A10398G 114 Thr-Ala -  
 ND6 G14258A 139 Pro-Leu Homoplasmic  
 ND6 A14582G 31 Val-Ala -  
 Cyt b T14798C 18 Phe-Leu -  
 
Tab. 10 Non-synonymous variants found in probands’ mtDNA from investigated families with relative 
amino acid substitutions. Rare or putative pathogenic mutations are reported in bold. 
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Fig. 24 Tree encompassing the complete mtDNA sequences observed in the investigated families. 
Nucleotide variants are shown on the branches; they are transitions unless the base change is explicitly 
indicated. Insertions are suffixed with a plus sign“+” and the inserted nucleotide; underlining indicates 
recurrent polymorphisms; “s” indicates synonymous mutations whereas “ns” indicates non-synonymous 
mutations, “h” indicates heteroplasmic mutations. Pathogenic LHON mutations are shown in red. 
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Family 1 
The mtDNA of II:1 from Family 1 has been completely sequenced and belongs to 
haplogroup H. Compared to revised Cambridge Reference Sequence (rCRS), only two 
non-synonymous nucleotide changes were found: G3700A/ND1 and G13759A/ND5. 
The ND1 variant cause the amino acid substitution Ala132Thr in ND1 protein sequence 
and has been previously reported as LHON pathogenic by Fauser and coll.316, whereas 
the ND5 nucleotide change is a common polymorphism reported in several haplogroups 
and diagnostic marker of haplogroup F1a1. The mutation load of G3700A/ND1 was 
assessed through a RFPL assay and the mutation resulted homoplasmic in DNA 
samples extracted from peripheral blood and urinary epithelium from II:1 (data not 
shown). 
 
Family 2 
The complete sequencing of mtDNA has been carried out on a DNA sample extracted 
from peripheral blood of IV:3 from Family 2. This mtDNA belongs to haplogroup U6a 
and harbors four non-synonymous nucleotide changes compared to rCRS.  We found 
the heteroplasmic mutation C14568T/ND6, that induces an amino acid substitution in 
ND6 at position 36 (Gly36Ser), previously reported in literature as LHON causative.316-
319
 Moreover, this mtDNA lineage is characterized by the variants T4172A/ND1, 
G7805A/COII and G15221A/cytb. The nucleotide change in COII gene defines the 
clade a of haplogroup U6, whereas the variant in cytb gene has been reported in 
association with five different haplogroups. Finally, nucleotide variant T4172A/ND1 
has been reported only once in another mtDNA belonging to haplogroup U6a and 
probably is the marker of a specific subclade of this haplogroup. This polymorphism 
induces the amino acid substitution Leu289Gln in ND1 protein. Interestingly, the same 
amino acid is substituted (Leu289Met) in presence of the mutation C4171A/ND1, 
reported as LHON pathogenic.320 In order to assess the mutational load of 
C14568T/ND6 mutation and its distribution on the maternal lineage, we performed an 
RFLP assay on DNA samples extracted from whole blood of several maternal relatives 
(III:2, III:3, III:4, IV:2, IV:5, IV:6, IV:7). In the investigated relatives only IV:5 harbor 
the LHON pathogenic mutation in heteroplasmic condition (Fig. 25B and C). Moreover, 
an analysis of heteroplasmy in DNA samples extracted from different tissues (whole 
 blood, platelets,
been performed (Fig. 25 A and C). In IV:3 mutant mtDNA reaches levels of about 90% 
in hairs, skeletal muscle and urinary epithelium, whereas in whole blood and platelet 
fraction is about 70%. In IV:5 mutated m
platelets and 70% in skeletal muscle.
The RFPL survey of all available DNA samples shows that the 4172/ND1 variant is 
homoplasmic in all maternal relatives and all available tissues from IV:3 and IV:5 
individuals (
 
Fig. 25
restriction enzyme AciI: the allele T remains uncut (298 bp) whereas the 
fragments. Panel A shows the RF
shows the same assay in DNA samples extracted from whole blood of all the available individuals of 
family 2. In panel C is shown the RFLP assay with the restriction enzyme BcgI: the alle
remains uncut, whereas the allele T (mutant) is cut in two fragments. The assay in panel C has been 
carried out in all the available samples (different individuals and different tissues). Abbreviations: B 
whole blood, U urinary epithelium,
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 RFLP analysis of C14568T/ND6 within F
 skeletal muscle, and, wh
 
 
LP assay in different tissues from individuals IV:3 and IV:5, panel B 
 P platelets, H hairs, M skeletal muscle.
en available urinary epithelium and hairs) has 
tDNA is about 50% in peripheral blood and 
amily 2. In panel A and B is shown the RFLP using the 
wild type allele C is cut in two 
 
Results
le C (wild type
 
85 
 
) 
 Family 3
We collected DNA samples from venous blood of seven individuals belonging to 
Family 3 (III:1, the proband, is a LHON patient, III:5 presents a complex disease 
characterized by 
are unaffected) and from skeletal muscle of III:5. The mtDNA of this family belongs to 
haplogroup J1c and is characterized by five variants in complex I genes (T4216C/ND1, 
A10398G/ND3, G1
pathogenic mutation G14459A/ND6 and two variants in 
C15452A). The pathogenic mutation in ND6 gene has been previously reported in some 
cases of LHON plus dystonia.
the only exception of that in position 13934, are common markers of haplogroup J1c. 
Available samples were investigated with RFLP for the G14459A mutation (Fig. 26
The two affected individuals, III:1 and III:5, an
the homoplasmic mutation G14459A, whereas II:2 harbored the heteroplasmic mutation 
in venous blood (about 90
wild type
Fig. 2
restriction enzyme MaeIII (139 and 25 bp), whereas the allele G remains uncut (164 bp). Abbreviations: 
B whole blood, SM skeletal muscle.
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 Family 
Family 4 shows a low penetranc
generations. The only available sample is extracted from peripheral blood of III:4, the 
analyzed proband. The mtDNA of Family 4 belongs to haplogroup H and harbors a 
single nucleotide change compared to r
A14495G/ND6, reported in literature by Chinnery et al.
heteroplasmic mutation, with about 50% of mutant molecules (Fig. 27).
Fig. 2
allele G generates a restriction site for NlaIII, whereas the 
 
Family 
Family 5 is composed of two related branches analyzed independently. The mtDNA 
sequencing in the t
presence of a common ancestor for both families and allowed their reconnection. The 
nucleotide variants present in the analyzed mtDNAs characterize haplogroup K1a. 
These polymorphisms are G90
Furthermore, other three non
gene (A8944G) and two in ND6 gene (G14258A and A14528G). The variant 
A14528G/ND6 is a common polymorphism associated with haplogroup H
reported also in other mtDNA backgrounds, such as haplogroup N9a, whereas the other 
two nucleotide changes are present 
of HmtDB (
family.
samples investigated from both branches (data not shown).
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Conservation analysis 
All the previously reported mtDNA nucleotide variants have been analyzed, in terms of 
amino acid position conservation in the three described data sets, and in terms of 
pathogenic potential, to establish whether they may have a functional effect. All the 
previously reported rare LHON mutations affect highly conserved amino acids, at least 
in mammals, being almost invariant. Furthermore, these amino acids are present in 
extremely conserved regions, suggesting a functional role for these domains (Fig. 28). 
In fact, G3700A/ND1 causes the substitution Ala-Thr in position 132 of ND1, very 
conserved from eukaryotes to mammals (from 80% to 93%), and is predicted to be 
pathogenic by SIFT and PMut (Tab. 10). This region in our ND1 model is located in the 
conserved loop CD, where another LHON putative mutation has been described in two 
unrelated pedigrees (G3733A/ND1).324 The mutations C14568T, G14459A and 
A14495G of ND6 gene affect invariant position in the two very conserved regions in 
ND6 subunit (helices B and C). The G14459A and A14495G mutations are predicted as 
pathogenic or probably damaging by all the used prediction tools (Tab. 11), whereas the 
C14568T mutation is predicted pathogenic only by PMut (Tab. 10).  
Interestingly, the polymorphism T4172A/ND1 of Family 2 affects the conserved amino 
acid Leu-289 (98.77% of conservation in mammals) in a very conserved region. The 
amino acid substitution induced by this variant (Leu289Glu) is predicted to be possibly 
pathogenic by the most restrictive prediction tool PolyPhen (PSIC score 1.899, Tab. 
11). Moreover, the same position is affected by the LHON reported pathogenic 
mutation C4171A, but this latter mutation induces a Leu289Met substitution, 
considered by PolyPhen benign (PSIC score 0.052).  
In the two branches of Family 5 we found two rare variants with a possible pathogenic 
potential (A8944G/ATPase6 and G14258A/ND6). The nucleotide change 
A8944G/ATPase6 affects amino acid Met-140, a position poorly conserved in 
vertebrates and eukaryotes, but invariant along mammals (Tab. 11). This amino acid 
resides in a very conserved region of ATPase a subunit, as shown in figure 28. 
Considering these features, this nucleotide change may have a functional role on ATP 
synthase activity and, consequently, a pathogenic potential in this family.  
The mtDNA variant G14258A/ND6 affects a poorly conserved amino acid in a poorly 
conserved region (amino acid Pro-139, see Tab. 11 and Fig. 28), even if is adjacent to a 
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invariant residue Gly-141. PolyPhen predicts both amino acid substitutions as benign, 
but we cannot exclude a functional role for both these mtDNA variants, especially for 
the nucleotide change in ATPase6 that may have a strong impact on protein function, 
affecting an invariant amino acid. 
 
Nucleotide change Amino acid 
change 
Conservation (%) PolyPhen  
(PSIC score) 
Family 
Mammals Vertebrates Eukaryotes 
G3700A/ND1  A132T 97.53  93.4  80  Benign (0.741) Fam. 1 
G13759A/ND5 A475T 52.63 41.18 21.74 Benign (0.816) Fam.1 
T4172A/ND1  L289Q 98.77  83.02  57.86  Possibly 
damaging  
(1.899)  
Fam. 2 
C4171A/ND1  L289M  98.77  83.02  57.86  Benign (0.052 )    
G7805A/COII V74I 84.57 83.15 64.69 Benign (0.479) Fam. 2 
C14568T/ND6  G36S  100  46.67  40.7  Benign (0.047) Fam. 2 
G15221A/cyt b  D159N  38.00 44.00 42.00 Benign (0.140)  Fam. 2  
T4216C/ND1  Y304H 61.73  68.87  48.2  Benign (0.825) Fam. 3  
A10398G/ND3  T114A 83.58  60.67  41.91  Benign (0.194) Fam. 3  
G13708A/ND5  A458T  44.74  52.94  34.38  Benign (0.610) Fam. 3  
C13934T/ND5  T533M 52.63  37.25  22.92  Benign (1.085) Fam. 3  
G14459A/ND6  A72V  100  69.33  67.44  Probably 
damaging  
(2.197)  
Fam. 3 
T14798C/cyt b  F18L  89.00 72.00 68.00 Benign (0.999) Fam. 3 
C15452A/cyt b  L236I 50.00 44.00 42.00 Benign (0.288) Fam. 3 
A14495G/ND6  L60S  100  100  95.35  Probably 
damaging  
(2.788)  
Fam. 4 
A8944G/ATP6 M140V 100 65.52 36.08 Benign (1.023) Fam. 5 
G9055A/ATP6  A177T  89.47  89.66  59.57  Benign (0.385) Fam. 5  
A10398G/ND3  T114A  83.58  60.67  41.91  Benign (0.194) Fam. 5  
G14258A/ND6  P139L  34.15  36  32.56  Benign (0.037) Fam. 5 
A14582G/ND6  V31A  46.34  74.67  69.77  Benign (0.195) Fam. 5 
T14798C/cyt b  F18L 89.00 72.00 68.00 Benign (0.999) Fam. 5 
 
Tab. 11 Sequence analysis of amino acid substitutions identified in LHON families 1-5. In table are 
reported the amino acid conservation along the three alignments (mammals, vertebrates and eukaryotes) 
and the pathogenicity prediction obtained using PolyPhen, PSIC score is indicated inside brackets.   
Results 
90 
 
 
Fig. 28 Global alignment of ND1, ND6 and ATPase6 protein sequences belonging to 11 different 
mammalian organisms. Amino acid residue with a percentage of conservation ranging between 70.0% 
and 79.9% are highlighted in light grey, those between 80.0% and 99.9% are highlighted in dark grey and 
those invariant (100%) are highlighted in black. Amino acid changes of interest are shown in bold. 
 
Determination of OXPHOS complexes activity 
To verify the impact of the reported mutations on the respiratory complexes function, 
we measured the specific activity of complex I, complexes II+III, complex III and 
complex IV, by using conventional spectrophotometric assays, in platelet fractions of 
available individuals and of a control group. We studied the probands from Family 2 
and Family 5a (respectively IV:3 and IV:1, see Appendix C) and two individuals from 
Family 3, III:1 (the LHON pure case) and III:5 (the LHON plus dystonia case).  
The prediction for these patients carrying ND6 gene mutations (C14568T/Family 2, 
G14459A/Family 3 and G14258A/Family 5) would be a defective complex I activity. 
 Conversely, as shown in figure 29 A
and in particular complex I, measured in probands from Family 2 and Family 5 were not 
significantly different from controls. In the case of Family 2, this is probably due to the 
high percentage of 
case of Family 5, the normal activity of complex I may be caused by a mild, not 
detectable, effect of this mtDNA variant on complex I activity, as for 14484/ND6,
by the lack of functional effect 
polymorphism. 
The two individuals from Family 3 showed a marked decrease of complex I activity 
(Fig. 29A), with a residual activity ranging from 35% in III:1 to 21% in III:5, 
demonstrating that the 
activity. Moreover, in III:5 a strong increase of all the other complexes activities was 
observed (Fig. 29AB), suggesting a compensatory response of cells to the energetic 
impairment caused by the ND
 
 
 
 
 
 
 
 
 
 
 
Fig. 29
to control group. Data are are reported as average±standard deviation. Asterisks indicate a reduction out 
of the 
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Role of mtDNA polymorphisms in LHON plus myoclonus 
In order to investigate the occurrence of myoclonus in two LHON families, we studied 
five patients and one unaffected carrier. All six individuals had myoclonus, elevated 
serum lactic acid and accumulation of lactic acid in ventricles. The RFLP survey in all 
maternal relatives investigated showed the 11778/ND4 mutation in Family A and the 
3460/ND1 mutation in Family B homoplasmic in blood, urinary epithelium, and skeletal 
muscle (data not shown). Based on the evidence of familial recurrence of myoclonus in 
these two families, which was strictly co-segregating with LHON on the maternal line 
in Family A, we sequenced the entire mtDNA extracted from skeletal muscle of 
individuals VI:15 from Family A and IV:2 from Family B (see Appendix C).  
 
Family A 
The mtDNA from Family A belongs to haplogroup T2 and, in addition to the 
11778/ND4 mutation, harbors five non-synonymous nucleotide changes commonly 
found in this haplogroup (Fig. 30). Three of the non-synonymous nucleotide changes 
(4136/ND1, 4216/ND1, and 4917/ND2) affect ND subunits of complex I, one 
(9139/ATPase6) the ATPase a subunit of complex V, and one (15452/cytb) the cyt b 
subunit of complex III. Those at nps 4216, 4917 and 15452 are ancient polymorphisms 
and characterize all haplogroup T mtDNAs. The two non-synonymous more recent 
variants of Family A (4136/ND1 and 9139/ATPase6) were surveyed by RFLP analysis 
in all available individuals and both were found homoplasmic in all tissues investigated. 
The rare 4136A>G/ND1 mutation has been previously found in three LHON families 
carrying an established primary mutation.242,325 A further case has been reported on a 
haplogroup A mtDNA in a study investigating a cohort of patients with Alzheimer’s 
disease of Japanese descent.326 The 9139G>A/ATPase6 transition is also rare and 
probably define a branch within T2 haplogroup. It was found also on L2d and L3f1 
haplogroups. 
 
Family B 
The mtDNA of Family B is a member of haplogroup U4a (Fig. 30). In this sequence 
only two non-synonymous changes are present, and both affect the cyt b subunit 
(15693/cytb, 15773/cytb). Of the two, only the change at nucleotide position 15693 is an 
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ancient polymorphism that characterizes all haplogroup U4 mtDNAs. The more recent 
variant of Family B (15773 G>A/cytb) has been rarely observed on different 
haplogroups (C1, T2b, H and V2). 
 
 
Fig. 30 Tree encompassing the complete mtDNA sequences observed in the investigated families. 
Nucleotide variants are shown on the branches; they are transitions unless the base change is explicitly 
indicated. Insertions are suffixed with a plus sign“+” and the inserted nucleotide; underlining indicates 
recurrent polymorphisms; “s” indicates synonymous mutations whereas “ns” indicates non-synonymous 
mutations. Pathogenic LHON mutations are in italic and possibly synergistic polymorphisms are 
indicated by an arrow.  
 
Conservation analysis 
To verify the possible functional significance of the non-synonymous changes found in 
the ND1, ND2, ATPase6 and cyt b genes, we analyzed their conservation and the 
prediction obtained with PolyPhen. The mammals alignments of the investigated 
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regions are reported in figure 31 and the percentages of conservation for each amino 
acid change are listed in table 12. 
The two LHON pathogenic mutations at positions 3460/ND1 and 11778/ND4 show 
59.4% and 99.2% of amino acid conservation in the alignment of eukaryotes, 
respectively, which increase to 97.5% and 100% (invariant position) when only 
mammals are considered. The position 277 of ND1 is highly conserved in both 
eukaryotes (78.6%) and mammals (98.7%). This feature – shared with the 11778/ND4 
and 3460/ND1 mutations – neatly distinguishes the 4136/ND1 mutation from the 
ancient polymorphism 4216/ND1 whose amino acid conservation in the mammals is 
only 60.8%. The other ancient polymorphism 4917/ND2 shows, instead, a moderate-
high conservation, ranging from 74.5% in eukaryotes to 93.5% in mammals. However, 
this amino acid resides in a poorly conserved region, probably with no functional role.  
The ATPase6 amino acid change A205T of Family A, due to the mutation at np 9139, 
despite being moderately conserved (76.0%) in eukaryotes, shows a conservation of 
94.7% in mammals, but is located in a highly conserved region. 
For Family B, the cyt b amino acid change M316T (15693/cytb) affects a poorly 
conserved position in eukaryotes (55%), which increased to a moderate conservation in 
mammals (71.0%) within a poorly conserved region of the protein. In contrast, the cyt b 
amino acid change V343M (15773/cytb) is a highly conserved amino acid position 
within a relatively conserved domain (Fig. 31, in eukaryotes 96% of conservation and in 
mammals 99%). 
The PolyPhen predictive analysis of pathogenicity defines as “probably damaging” the 
11778/ND4 mutation and “possibly damaging” the 3460/ND1 mutation, both being well 
established as pathogenic for LHON. The only other amino acid change scored as 
“possibly damaging” is V343M (15773/cytb) with a PSIC score difference of 1,570. 
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Nucleotide 
change 
Amino acid 
change 
Conservation (%) PolyPhen 
prediction 
(PSIC score) 
Family 
Mammals Vertebrates Eukaryotes 
G11778A/ND4 R340H 100 100 99.2 Probably 
damaging 
(2.520) 
Fam. A 
A4136G/ND1 
(possibly 
synergistic) 
Y277C 98.7 99.1 78.6 Benign Fam. A 
T4216C/ND1 Y304H 60.8 68.9 48.2 Benign Fam. A 
A4917G/ND2 N150D 93.5 87.5 74.5 Benign Fam. A 
G9139A/ATP6 
(possibly 
synergistic) 
A205T 94.7 96.5 76.0 Benign Fam A 
C15452A/cytb L236I 50.0 44.0 42.0 Benign Fam. A 
G3460A/ND1 A52T 97.5 70.1 59.4 Possibly 
damaging  
(1.553) 
Fam. B 
T15693C/cytb M316T 71.0 59.0 55.0 Benign Fam. B 
G15773A/cytb 
(possibly 
synergistic) 
V343M 99.0 98.0 96.0 Possibly 
damaging 
(1.570) 
Fam. B 
 
Tab. 12 Sequence analysis of all amino acid substitutions identified in LHON plus families. In table are 
reported the amino acid conservation along the three alignments (mammals, vertebrates and eukaryotes) 
and the pathogenicity prediction obtained using PolyPhen, PSIC score is indicated inside brackets.   
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Part 2 - Modifying factors in LHON: the role of mitochondrial 
biogenesis in variable penetrance 
 
Molecular characterization of LHON mutations 
In this study we have analyzed 179 individuals belonging to 57 different LHON Italian 
families and 64 individuals belonging to a single large Brazilian family of Italian 
ancestry (conventionally named SOA-BR).327 The family tree of SOA-BR is shown in 
Appendix C. Each individual has been previously investigated by RFLP analysis and 
characterized for LHON common mutations (11778/ND4, 14484/ND6 and 3460/ND1). 
Based on the clinical phenotype all subjects have been categorized in affected and 
carriers. In SOA-BR family, carrying the 11778/ND4 homoplasmic mutation, 25 
individuals were considered affected and 39 carriers (Tab. 13). Moreover, molecular 
characterization of Italian families, summarized in table 13, reveals that 123 individuals 
harbored the 11778/ND4 LHON mutation (58 affected and 65 carriers), 20 individuals 
had the 14484/ND6 mutation (10 affected and 10 carriers) and 36 individuals had the 
3460/ND1 mutation (19 affected and 17 carriers).  
Family Mutation Affected Carriers Total 
Brazilian (SOA-BR) 11778/ND4 25 39 64 
Italian 11778/ND4 58 65 123 
14484/ND6 10 10 20 
3460/ND1 19 17 36 
 
Tab. 13 LHON individuals investigated in this study: total number an differentiation in affected and 
carriers. 
 
DNA samples extracted from peripheral blood of these individuals have been analyzed 
and mtDNA haplogroups have been previously characterized. SOA-BR family belongs 
to haplogroup J, whereas the haplogroup distribution of Italian families is reported in 
table 14. 
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Haplogroup 11778 (n=37) 14484 (n=7) 3460 (n=13) 
H 24.32 0.00 53.85 
HV 5.41 0.00 0.00 
V 2.70 14.29 0.00 
U 13.51 0.00 7.69 
K 8.11 0.00 7.69 
J 21.62 71.43 15.38 
T 13.51 0.00 0.00 
Other 10.81 14.29 15.38 
 
Tab. 14 Distribution of mtDNA haplogroup within LHON italian families expressed as percentages.  
 
 
Determination of mtDNA content in LHON individuals 
 
The mtDNA copy number evaluation has been carried out on DNA samples extracted 
from peripheral blood of SOA-BR family members and selected individuals from the 
Italian families. This analysis has been approached in two different ways. The SOA-BR 
is very large (see Appendix C) and allows investigations within the family. We 
analyzed 64 individuals, 25 LHON affected and 39 LHON carriers. The control group 
was composed of 70 unrelated Brazilian individuals. Considering the Italian families, 
we performed a correlation study in selected individuals with homoplasmic LHON 
mutations, choosing to compare one affected individual, usually the proband, and one 
asymptomatic carrier on the same maternal lineage. Thus, we analyze 39 affected 
individuals, and their corresponding 39 carriers, 21 harboring the 11778/ND4 mutation, 
5 harboring the 11484/ND6 mutation and 13 harboring the 3460/ND1 mutation. In the 
last step of this study we also determined the mtDNA copy number in DNA samples 
extracted from skeletal muscle biopsies of 13 control and 31 LHON individuals (25 
affected and 6 carriers).  
In figure 32 we show the average values of mtDNA copy number/cell in DNA samples 
of peripheral blood of control individuals, LHON affected and carriers belonging to the 
SOA-BR Family. In the control group the average value of mtDNA copy number/cell is 
190±8, whereas SOA-BR family individuals show higher mtDNA/copy number values 
 (respectively affected 372±24 and carriers 516±30)
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In conclusion, all together these data indicate that the energetic  defect caused by LH
mutations is associated with induction of a compensatory mechanism triggering the 
mtDNA replication.
carriers, suggesting its involvement in LHON penetrance.
 
Study of the G1444A polymorphism
Based on the above results, we investigated the role of the functional polymorphism 
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mtDNA copy number.328 Thus, this polymorphic variant may play an important role in 
the modulation of mitochondrial biogenesis, triggered as a compensatory mechanism by 
the energetic dysfunction. We have therefore analyzed the distribution of the G1444A 
polymorphism in the previously described SOA-BR family (25 affected and 39 
carriers), in its control group and in all available individuals from Italian families (70 
affected and 92 carriers). The genotyping was carried out on DNA samples extracted 
from peripheral blood. Moreover, the possible correlation between PGC-1α genotype 
and mtDNA copy number has been tested. In table 15 the frequencies (expressed as 
percentages) of the three genotypes A/A, G/A and G/G are reported. Even if the “low 
copies” genotype G/G is under-represented in the carriers group, the three genotypes are 
not associated with the status of LHON affected or carrier, or to the status of LHON or 
control. 
 
 Brazil Italy 
 Affected Carriers Controls Affected Carriers Controls (HapMap) 
A/A 17% 23% 12% 15% 14% 20% 
G/A 50% 66% 46% 37% 48% 33% 
G/G 33% 11% 42% 48% 38% 47% 
Tab. 15 Distribution of genotypes of G1444A in PGC-1α gene in the Brazilian and Italian groups. 
 
Similar results have been obtained considering the frequencies of the alleles A or G 
within the investigated populations, or comparing the frequencies of the unfavorable 
genotype G/G to the other two (G/A plus A/A).  
In order to verify if there was a correlation between the nucleotide variants in position 
1444 of PGC-1α gene and mtDNA content, we also compared the mtDNA copy number 
divided for the three possible genotypes in each studied population. As shown in figure 
36 A and B, there is no association between mtDNA copy number and the PGC-1α 
genotypes. 
 Taken together these data demonstrate that the G1444A polymorphism does not 
influence the cellular mtDNA content, at least in Italian and Brazilian population, and 
does not play a role in the variab
 
Fig. 3
carriers) and control individuals, from the two sudied populations brazilian (A) and italian (B). Values are 
reported as average±SE
 
Gene expression assays for mitochondrial biogenesis regulators
Given the increased mtDNA copy number in LHON subjects, we decided to investigate 
the role of transcriptional coactivators belonging to the PGC
1β and PRC) and the 
determined the relative gene expression of these genes in five LHON individuals (3 
affected and 2 carriers), harboring the homoplasmic 11778/ND4 mutation, and 2 control 
individuals, using as referen
out on total RNA samples extracted from frozen skeletal muscle of these individuals. In 
figure 37, we show the results of comparison between LHON and control individuals. 
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 biogenesis regulators may therefore explain the raise of mtDNA observed in skeletal 
muscle of LHON subjects compared to controls (Fig. 35)
Figur
and carriers individuals, obtained with the qRT
reference. No differences were detected in the selected genes between the two groups. 
These
significant difference in mtDNA copy number was apparent in skeletal muscle of 
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 Fig. 3
skeletal muscle of LHON carriers and affected individuals, using 
are shown as fold of 
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R
e
la
ti
v
e
 e
x
p
re
ss
io
n
8 Relative gene expression of PGC
 
0,000
1,000
2,000
3,000
R
e
la
ti
v
e
 e
x
p
re
ss
io
n
(f
o
ld
 c
a
rr
ie
rs
 -
a
ff
e
ct
e
d
)
increse or decrese in LHON carriers compared to LHON affected and are reported as 
PGC-1a
-1α, PGC
PGC
-1β, PRC and Tfam in RNA samples extracted from 
 
-1b
β-actin (ACTB) as reference gene. Data 
PRC Tfam
Results
 
 
106 
Results 
107 
 
Part 3 – Activation of mitochondrial biogenesis as a therapeutic 
strategy for LHON 
 
According to the results reported above, induction of mitochondrial biogenesis might 
represent a compensatory mechanism activated in response to cellular energetic 
impairment caused by LHON mutations. A similar behavior has been previously 
reported for other mtDNA pathogenic mutations associated with more complex 
mitochondrial diseases (encephalomyopathies). To verify our hypothesis, we took 
advance of cellular models of LHON (cybrids), to analyze the effect of the PPARs pan-
activator bezafibrate, previously reported to induce mitochondrial biogenesis and to 
rescue mild and severe defects of the respiratory chain.329,330 We have investigated six 
different cybrids cell lines, two wild type, two 11778/ND4, two 14484/ND6 and two 
3460/ND1. Cybrid cell lines have the same nuclear background of osteosarcoma cell 
line 143B TK- and allow to test the effect of different mtDNA mutations. However, it 
has to be considered that these cell lines are immortalized and this may influence the 
cellular response to certain stimuli. We first assessed the biochemical defect 
discriminating LHON and wild type cybrids, as a baseline reference for the following 
experiments. 
 
Cell viability and energetic competence of LHON cybrids  
Determination of cell viability in a medium devoid of glucose and supplemented with 
galactose (galactose medium) was carried out. This assay allows evaluation of the 
mitochondrial energetic efficiency, since galactose slows down the glycolytic rate and 
cells are forced to rely on the ATP produced almost exclusively through oxidative 
phosphorylation. Accordingly, cells with defective respiratory chain cannot survive 
under these growth conditions. As reported in figure 39, all LHON cell lines failed to 
survive after 72h incubation in galactose medium, whereas control cell lines were still 
growing.  
These results are in agreement with previous reports, confirming the occurrence of a 
severe oxidative phosphorylation dysfunction in LHON cybrids.285-287  
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Moreover, the specific activity of NADH ubiquinone oxidoreductase (complex I) was 
measured by means of a spectrophotometric assay. Figure 40 shows that the 3460/ND1 
mutation only caused a significant reduction (-40%) in complex I specific activity 
compared to controls, whereas no difference was detected in the 11778/ND4 and 
14484/ND6 cell lines. This result is in agreeement with previous data reporting that the 
effect of LHON mutations on complex I activity is undetectable, except for the 
3460/ND1 mutation.273 
We also performed a polarographic analysis on digitonin-permeabilized cells. In this 
assay respiration driven by complex I substrates (pyruvate and glutammate) of LHON 
cells results invariably lower than controls, without reaching statistical significance 
(data not shown). Conversely, complex II driven respiration in LHON cells resulted 
comparable to controls.  
However, the rate of ATP synthesis, determined in digitonin-permeabilized cells and 
normalized for the citrate synthase activity, a marker of mitochondrial mass, was  
strongly reduced in LHON cybrids, when driven by the complex I substrates, malate 
and pyruvate. This reduction was 39% in 3460/ND1 cells, 51% in 11778/ND4 cells and 
71% in 14484/ND6 cells, respectively (Fig. 41). Conversely, we did not observe 
differences in ATP synthesis rate between LHON and wild type cybrids using the 
complex II substrate succinate plus rotenone (Fig. 41). These results clearly indicate a 
selective impairment in complex I in LHON cybrids. In conclusion, the assays of 
mitochondrial ATP synthesis and viabilty in galactose medium represent the most 
reliable outcome measures to evaluate the energetic deficit of LHON cybrids. 
 
 Fig. 3
reported as average±SEM. Asterisks indicate statistical significance (p<0.005).
 
 
Fig. 40
average±SEM. Asterisks indicate statistical significance (p<0.005).
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 Fig. 41
substrates, 
indicate statistical significance (p<0.005).
 
Dose
We then 
measuring cell viability and complex IV activity. 
increasing concentrations of bezafibrate (from 100 
corresponding DMSO volume, for different incubation times (0, 24, 48 a
Figure 42 shows the growth curve in complete medium supplemented with bezafibrate 
in different concentrations. After 48 and 72 hours of incubation, cells incubated with 
bezafibrate 200
bezafibrate 100
obtained with the same cells incubated with DMSO only (data not shown), suggesting a 
toxic effect of high DMSO concentration, particularly for long incubation time.
Figure 43, reveals that only 100 
increase in complex IV activity, whereas at higher concentrations bezafibrate had no 
effect. The increase in complex IV activity was due to bezafibrate, since treatment wi
DMSO only did not exert any effect (average 24.24±3.3 nmoles/min*mg protein). Thus, 
we decided to incubate cells with 100 
experiments.
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Fig. 43
bezafibrate for different times. Data are reported as average±SEM.
 
Effect of bezafibrate on mitochondrial biogenesis
We first tested the effect of bezafibrate on mitochondrial biogenesis activation. The 
mtDNA copy number/cell was evaluated in cells treated with bezafibrate and with 
DMSO. As shown in figure 44A, no effect on mtDNA content was determined after 
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 of treated cells ranged from 83% to 93% of DMSO
the relative gene expression of PGC
mRNA levels of ta
Furthemore, we performed a western blot analysis of several respiratory complexes 
subunits, nuclear or mitochondrial encoded, and of two structural proteins as control. 
These were three 
subunit (SDHA), three complex IV subunits (COX XI, COX IV and COX VIc) and one 
complex V subunit (ATPase a). The structural proteins actin and tubulin were used as 
controls for the densitometric a
proteins were not changed by bezafibrate treatment in all cell lines. 
Taken toghether, these data demonstrate that despite the effect on cell viability and 
complex IV activity, bezafibrate does no
replication or transcription in cybrid cells. 
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DMSO for 72 hours. Data are are reported as average±SEM.
 
Finally, we assessed the effect of bezafibrate on LHON and 
galactose medium. Cell viability was determined by means of the SRB assay. As shown 
in figure 47A,  wild type cybrids viability was not influenced by the presence of 
bezafibrate or vehicle. The bezafibrate treatment was also ineff
when compared to DMSO, with the only exception of a transient, weak and not 
statistically significant effect after 48 hours of incubation in galactose (Fig. 47 panels B, 
C and D).
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Fig. 47 Effect of incubation in galactose medium, plus bezefibrate 100 µM or equal volume of DMSO, on 
cell viability of control (panel A) and LHON cybrids (panels B, C and D). Data are reported as 
average±standard deviation. 
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Leber’s hereditary optic neuropathy (LHON) is a usually monosymptomatic disease 
characterized by a bilateral acute or sub-acute loss of central vision, caused by the 
selective degeneration of RGCs, leading to optic atrophy. It is now clear that LHON is 
one of the most common mitochondrial diseases. However, many aspects of this 
pathology are still unclear, such as the male prevalence, the incomplete penetrance and 
the selective involvement of a single cell type. Moreover, several new pathogenic 
mutations have been reported in the last years increasing the range of mutations that 
have to be screened in the diagnostic protocols. Finally, the pathogenic mechanism is 
still debated and no effective therapies are available for LHON patients. 
In this study we analyzed three aspects still unclear in LHON. At first, we investigated 
the role of rare mtDNA variants, mutations or polymorphisms, as causative or modifiers 
of LHON clinical phenotype. Second, we searched for a molecular feature able to 
distinguish affected and carrier subjects, within the same family or in different families, 
shedding light on the possible mechanism of variable penetrance. Lastly, we explored 
by a preliminary study, using the cellular model of LHON cybrids, the possibility of a 
pharmacologic therapeutic approach.  
 
LHON pathogenic mutations are located in defined and conserved domains of 
mtDNA encoded complex I subunits    
Complex I is the first enzyme of the respiratory chain and catalyzes the transfer of two 
electrons from NADH to ubiquinone, coupled to pumping of 4 protons across the 
membrane. This protein complex presents an L-shaped global structure, with a 
hydrophobic arm embedded in the membrane and a hydrophilic peripheral arm 
protruding in the mitochondrial matrix.331,332 Recently, the crystal structure of the 
hydrophilic arm has been solved, but currently there are only few data concerning the 
structural details of  hydrophobic arm subunits.43 We here propose new structural 
models for ND1-ND4 and ND4L complex I subunits, based on the analysis of 
hydropathy profiles generated starting from a wide global alignments of virtually all the 
available complete protein sequences. 
To date, the only exhaustive work predicting a structural model for each mitochondrial 
encoded complex I subunits has been published in 1992 by Fearnley and Walker.333  
Other structural models have been proposed for ND1, ND6 and ND4, in order to define 
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the possible role of newly identified pathogenic mutations or to explain the biochemical 
characterization of the common LHON pathogenic mutations.239,271,274,321,324 However, 
none of those is based on the great number of sequences currently available on generic 
and specialized data banks. Moreover, we analyzed three different data sets, 
corresponding to eukaryotes, vertebrates and mammals, to define either the most 
conserved regions, but also those regions particularly conserved in mammals that may 
be crucial for protein function. All the sequences are characterized by long hydrophobic 
segments, generally of 20 or more amino acids, probably folded in membrane spanning 
regions. These TMHs are connected by short hydrophilic loops, although some of them 
may be organized in extra-membrane domains.   
Our analysis on average conservation and fraction of conserved amino acids, confirms 
that ND1 is invariably the most conserved subunit and that ND6 is the most divergent, 
as previously reported by Fearnley and Walker.333 However, the other ND subunits have 
a different overall conservation within the three data sets. Considering the single ND 
subunits, our analysis on ND3 and ND4L reveals that these very short proteins are 
extremely hydrophobic and are folded in three TMHs, as previously reported.333  In 
previous works, ND6 subunit was predicted to have 5 or 6 α-helices.333,274,321 We here 
propose for ND6 subunit a structural model with 5 TMHs, similar to Fearnley and 
Walker and to Carelli et al, 1999.333,274 In fact, we do not predict as membrane 
embedded the short region from amino acid 116 to 120, being too short to be considered 
a transmembrane helix. For ND1at least two different models have been proposed. The 
first one represents ND1 with 8 membrane spanning domains239,333, whereas Carelli et 
al., 1997, and Valentino et al., 2004, proposed a structural model characterized by only 
5 transmembrane segments and an extra-membrane domain with an hydrophobic region 
(helix E).271,324 The model here proposed for ND1 is very similar to that one, with the 
only exception of the C-terminal, where we recognized another transmembrane domain. 
In fact, our model maintains 5 TMHs and one hydrophobic extra-membrane domain, 
probably an amphipatic helix on the positive side of the membrane, but presents another 
TMH (helix G in our model) in the C-terminal of the polypeptide chain. The structure of 
the ND4 subunit has been also predicted with 11 or 12 TMHs.333,271 Our new model 
predicts 10 clearly defined TMHs and 2 additional helices that can be either 
transmembrane or located in extra-membrane domains. Furthermore, the topology of 
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ND4 across the membrane cannot be clearly defined, being the net charge on the two 
sides of the protein positive and very similar. Finally we proposed for ND2 a structural 
model with 8 TMHs and one uncertain helix and for ND5 a model with 13 TMHs and 
one unclear helix, whereas Fearnley and Walker predicted 10 and 15 α-helices for ND2 
and ND5, respectively.333 
The differences between the proposed models may be due to different approach or 
hydropathy scales. In fact, models can be derived from a sequence from a single 
organism or from alignments of several sequences from different organisms. Moreover, 
the number of sequences and their divergence may influence the overall hydropathy, if 
the model is generated on the average hydrophobicity along the alignment, or the 
generation of a consensus sequence (see results). The choice of the hydropathy scale 
and the hydrophobicity threshold may also influence the structural models, when the 
template structure is unknown. As suggested by Degli Esposti el al., in several integral 
proteins the hydrophobicity scales based on statistical analysis correlate better that those 
based on transmembrane distribution of the residues, in several integral proteins.309,334 
Thus, commonly used hydropathy scales, such as that of Kyte and Doolittle, may lead to 
wrong predictions for the folding of transmembrane proteins folding, even if their 
performance on globular protein are optimal.334,335 Furthermore, an integration of 
different and appropriate predictive methods is recommended, since every single 
method is prone to errors.309  
Prediction methods based exclusively on hydropathy scales can be now combined with 
up to date methods based on different parameters, such as sequence profile analysis 
using amino acid properties, neural network (NN) and Hidden Markov Models (HMM) 
trained on transmembrane proteins with known structure (for reviews see Punta et al., 
2007, and Simon et al., 2001).336,337 Thus, in a future step we will use different 
prediction tools to ND1-ND6 and ND4L protein sequences, to generate an “ensemble” 
prediction of the protein structures. This approach, recently applied in different papers, 
for example Martelli et al., 2003, combining a NN and two different HMM predictors, 
is probably the best approach to ab-initio structure predictions.338,339 
We used these models and some tools available on line for the prediction of 
pathogenicity to analyze the possible impact of mitochondrial mutations on the protein 
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function and to identify structural regions with a functional role and specific patterns for 
LHON pathogenic mutations. 
Establishment of the pathogenic potential for an mtDNA mutation is still controversial. 
The classical criteria proposed by DiMauro and Schon are currently used to determine 
the pathogenic potential of a novel mtDNA nucleotide variant.340 However, in 2006 a 
new score system has been introduced by Mitchell and coll.304 This score system is 
based on a weighted analysis of the canonical criteria, the functional evidence of 
pathogenicity and the multiple and independent reports of pathogenicity of a 
mitochondrial mutation. Instead, our predictions represent an in-silico approach based 
exclusively on conservation analysis. Although our approach takes into account less 
parameters, it can be a “cheap and easy” tool for the initial screening of mitochondrial 
sequence variations, together with a careful search for the putative mutation in 
specialized data banks of mtDNA variation, such as HmtDB or Mitomap 
(www.hmtdb.uniba.it, www.mitomap.org). 
Our analysis reveals that 25/39 nucleotide variants, reported on Mitomap as pathogenic 
for LHON, are predicted as probably damaging at least by 3/4 methods. All the 
mutations reported as “confirmed” on Mitomap are predicted as pathogenic by every 
used method, with the only exception of 14568/ND6 mutation that is predicted as 
unclear. Similar results were obtained applying the score system that predicts as 
probably or possibly pathogenic all these mutations, whereas 14568/ND6 was still 
considered neutral. Other 19 nucleotide variants, cited on Mitomap as “reported”, are 
predicted as pathogenic, whereas 2 are uncertain, being predicted as pathogenic by 2/4 
methods. Instead, the score system recognizes as probably or possibly pathogenic 12 of 
the reported mutations. Thus, our approach probably is more prone to recognize some 
unclear variant as probably pathogenic, but none of the common non-synonymous 
polymorphisms, associated in the general population with mtDNA haplogroups, is 
predicted as pathogenic.  
We also analyzed the position of the reported “primary” mutations and of some 
polymorphisms on the previously generated structural model of ND1-ND6 and ND4L 
subunits. This approach allows us to define some protein regions, usually characterized 
by local high conservation, with probable functional roles for these proteins. ND1 is a 
mutational hot spot of LHON and all the pathogenic (predicted or confirmed) mutations 
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are located in extra-membrane loops protruding in the mitochondrial matrix. 
Interestingly, these loops are the most conserved zones of the ND1 polypeptide and 
probably define a functional domain, as previously suggested by our group.271,324 In 
ND4 only two mutations are considered pathogenic (G11778A and C11874A) and both 
are located in the loops facing the positive side of the membrane in the boundaries of 
the helix J, predicted as amphipatic. Concerning ND5, two regions particularly affected 
by pathogenic mutations can be defined. Similar to ND1 and ND4, extra-membrane 
loops are affected; the first region is defined by the loops DE and FG on the matrix side 
of the membrane, whereas the second is located on the positive side of the membrane 
(intermembrane space) and involves the loops JK and LM. The other hot spot for 
LHON pathogenic mutations is ND6 and the structural model here proposed clearly 
defines that only the helices B and C are affected by pathogenic LHON mutations.   
 
Confirmation of pathogenic LHON rare mutations 
Five unrelated Italian families have been investigated. All of them fulfilled the clinical 
criteria to be diagnosed as LHON, but they were negative at the screening for the three 
LHON common mutations. Thus, complete sequencing of mtDNA has been carried out 
in DNA samples from the probands and we found four rare LHON mutations, 
previously reported, and two rare mtDNA variants with pathogenic potential (for 
discussion of these see next paragraph). We found one mutation in ND1 gene (G3700A) 
and three mutations in ND6 gene (C14568T, G14459A and A14495G), all of them 
previously reported at least once.  
The mutation G3700A/ND1 was reported in a single case of LHON in 2002 by Fauser 
and coll., in a screening of 14 LHON patients negative for common mutations.316 In that 
case the authors suggested that this mutation may have a pathogenic role for LHON 
within the family, but could not confirm this hypothesis because the mutation was found 
only in a single family. Our findings support that initial results, confirming that G3700A 
change is a rare primary LHON mutation, now identified in two LHON unrelated 
families and not present in over 3400 control sequences of HmtDB data bank. Our 
conservation analysis reveals that the amino acid substitution Ala132Thr affects a very 
conserved residue within a conserved extra-membrane loop of ND1, with possibly 
implicated in the quinone binding. Furthermore, the Ala to Thr change is non-
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conservative, with a switch from a neutral and hydrophobic to polar and hydrophilic 
amino acid and an increase in steric volume. The pathogenicity of G3700A/ND1 
mutation is also supported by the identification of another pathogenic mutation located 
in the same loop (G3733A, Glu143Lys) in two unrelated families by Valentino et al., 
2004.324 
In Family 2 we identified the heteroplasmic rare transition C14568T/ND6. This 
mutation induces the amino acid substitution Gly36Ser in the ND6 subunit and was 
previously found in two unrelated families in homoplasmic condition.316-319 In our 
family the mutation was heteroplasmic, at different loads, in all the investigated tissues 
from two siblings (IV:3 and IV:5). Another sibling (IV:2) and the mother (III:2) were 
virtually wild type; however, in particular for the mother, it is possible that the 
percentage of mutant mtDNA was under the detection threshold for a standard RFLP 
analysis. Thus, a more sensitive approach, such as hot last cycle PCR or cloning and 
sequencing of the PCR fragment, have to be applied in these cases. The conservation 
analysis shows that Gly-36 is a divergent amino acid in eukaryotes and vertebrates, but 
reaches an absolute conservation within mammals. The Gly-Ser substitution is a non-
conservative change in terms of hydrophobicity but does not affect the steric volume, 
being both amino acids are very small. Notwithstanding, glycine is hydrophobic and 
neutral, whereas serine is hydrophilic and polar. This amino acid resides in helix B of 
ND6, one of the best conserved regions of the protein probably involved in the quinone 
binding site. Furthermore, this mtDNA lineage harbors also the homoplasmic nucleotide 
variant T4172A/ND1. This nucleotide substitution has been reported once and probably 
is the marker of a specific subclade of haplogroup U6a. This polymorphism induces the 
amino acid substitution Leu289Gln in the ND1 protein. Interestingly, the same amino 
acid is substituted (Leu289Met) in presence of the mutation C4171A/ND1, reported as 
pathogenic for LHON.320 In fact, Kim et al., 2002, reported this mutation in two 
unrelated LHON families belonging to haplogroup A (Korean ancestry), with a good 
visual prognosis and a high frequency of visual recovery. The amino acid position 289 
in the ND1 subunit is well conserved in vertebrates and mammals and affects a 
conserved extra-membrane loop protruding on the matrix side. Surprisingly, the 
pathogenic change Leu289Met is predicted benign by all the used tools (PolyPhen, 
SIFT and PMut), whereas the polymorphic change Leu289Gln is predicted as 
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pathogenic. This may be explained by the substitution type. In fact, the substitution 
Leu289Met is conservative, being both leucine and methionine large, hydrophobic and 
neutral amino acids, whereas the Leu289Gln is non-conservative, being glutamine 
smaller and polar. Thus, the latter may have a stronger impact on ND1 function. 
Moreover, the biochemical effect of both variants on complex I activity is not evident in 
respiratory chain complexes activity assays. This could be explained by the high 
percentage of wild type mtDNA in the platelet fraction or by a mild effect on complex I 
activity, similar to the 14484/ND6 mutation.273 
Taken singularly, the homoplasmic 14568/ND6 and 4171/ND1 mutations are usually 
associated with LHON phenotypes with good visual prognosis. Our family also shows a 
partial recovery of visual acuity, but it is characterized by a heteroplasmic mutation. 
However, the presence of the 4172/ND1 variant may modulate the pathogenicity of the 
14568/ND6 mutation.  
The 14459/ND6 mutation, found in Family 3, has been frequently reported in literature 
often associated with a variable clinical phenotype ranging from LHON, to LHON plus 
spastic dystonia, to Leigh syndrome.234,238,341-346 This variability is also evident in our 
family, where the mutation was homoplasmic at least in three of the investigated 
subjects, being one unaffected carrier (III:2), one LHON affected (III:1) and one 
affected with spastic dystonia only (III:5). The fact that these three individuals were all 
homoplasmic, but discordant for their clinical expression, strongly suggests the 
influence of nuclear/environmental factors as modifiers. This nucleotide change induces 
the Ala72Val substitution. Along eukaryotes and vertebrates alignments, this position is 
very divergent, whereas in mammals is invariant and is located in the extremely 
conserved helix C of the ND6 subunit. This amino acid change is conservative, being 
alanine and valine very similar. Biochemical evaluations confirm a severe impairment 
of complex I. Interestingly, the subject with the most severe phenotype (III:5) shows an 
increase in complex II, complex III and complex IV activities, probably due to a 
compensatory mitochondrial proliferation. Even if this mutation is often associated to 
LHON plus spastic dystonia, our cases demonstrate that the mutational screening has to 
be carried out also in patients with pure LHON phenotype, negative for the common 
mutations. 
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We also identified the third LHON case associated with the heteroplasmic 
A14495G/ND6 mutation. The analysis of the complete mtDNA sequence revealed that 
this family is unrelated to the families reported by Chinnery et al., 2001, even if they all 
belong to haplogroup H.321 We found this mutation with a heteroplasmic load of about 
50% in peripheral blood. The same heteroplasmic load was found in one affected 
individual in the British family previously reported.321 The authors proposed that 
mutational load may be higher in other tissues, or that some environmental factors may 
enhance the pathogenicity of the mutation or that the threshold level for this particular 
mutation may be lower than for the others. The A14495G mutation induces the amino 
acid change Leu60Ser. This amino acid position is extremely conserved and is part of 
the hyper-conserved helix C of ND6. Moreover, the amino acid substitution is non-
conservative; in fact, leucine is a hydrophobic large amino acid, whereas serine is small, 
polar and usually exposed on the protein surface. 
In conclusion, we here confirm the pathogenicity of four rare LHON mutations 
(G3700A/ND1, C14568T/ND6, G14459A/ND6 and A14495G/ND6) and suggest their 
inclusion in the diagnostic protocols. Furthermore, we also confirm that ND1 and ND6, 
in particular some hyper-conserved regions, are common hot spots for LHON 
mutations.   
 
Novel putative pathogenic LHON mutations 
We here report two branches of a single family independently investigated and then 
reconnected through their mtDNA lineage. The two probands showed a typical LHON 
clinical phenotype but RFLP survey for LHON common mutations resulted negative. 
Thus, we sequenced the entire mtDNA molecule and we found two rare variants with 
pathogenic potential. This mtDNA lineage belongs to haplogroup K1a and harbors, in 
addition to haplogroup specific polymorphisms, the nucleotide variants 
A8944G/ATPase6 and G14258A/ND6.  
All the confirmed LHON mutations affect mitochondrial encoded complex I subunit 
genes (see Mitomap), thus at our first analysis the variant 14258/ND6 seemed to be the 
most probable pathogenic mutation. However, conservation analysis, pathogenicity 
prediction and localization of the affected amino acid all suggest that this variant should 
not interfere with complex I function or assembly. In fact, the amino acid substitution 
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Pro139Leu affects a very divergent residue in a poorly conserved ND6 region (the 
extra-membrane loop DE). Two other putative mutations have been previously reported 
in the same loop.256,347 The mutation T14325C was found in a Dutch pedigree, negative 
for LHON common mutations, with a single affected individual and hits the amino acid 
position Asn-117 (change to Asp). The authors proposed this variant as a candidate 
mutation but suggested further studies to prove its real pathogenicity. In the same loop 
is also located the mutation G14279A that induces the amino acid substitution 
Ser132Leu. Both these changes affect poorly conserved residues of ND6 and are 
predicted as neutral at least by PolyPhen and SIFT. Moreover, no biochemical 
assessments of complex I function have been carried out on patients or cell models 
harboring these mutations. Similarly, the 14258/ND6 variant is predicted as neutral by 
PolyPhen and SIFT and pathogenic by PMut, but with a low score and a low reliability. 
The measurement of complex I activity on platelet fraction shows a specific activity 
comparable to controls. This result may suggest that this variant is a polymorphism that 
does not influence complex I activity or it may be explained by considering that mild 
mutations often do not cause a detectable complex I impairment.273 We also analyzed 
the presence of this variant in the general population. In HmtDB this variant is present 
only once in one mtDNA sequence belonging to haplogroup H and it was also reported 
in five individuals, from India and Nepal, by Semino et al., 1991.323,348 Moreover, we 
also found this nucleotide variant in heteroplasmic condition in an LHON patient 
harboring the 14484/ND6 mutation on haplogroup L2.349 However, it is still reasonable 
that 14258/ND6 change is a mild pathogenic mutation; in fact, no clinical details were 
provided on the individuals identified by the population studies of Herrnstadt et al., 
2002, and Semino et al., 1991, and a mild mutation might have only subclinical 
effects.323,348 
The other nucleotide change with a pathogenic potential is A8944G/ATPase6 and 
induce the amino acid substitution Met140Val. Our analysis reveals that the affected 
position is invariant in mammals and is predicted as pathogenic with high score by 
PMut. The affected region is extremely conserved in mammals and may play a role in 
ATP synthase function. Moreover, the A8944G variant has been reported only once on 
a L3 haplogroup background.322 ATPase6 gene is usually a hot spot for Leigh 
syndrome, but some mutations have been reported in this gene in LHON pedigrees. 
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Abu-Amero and Bosley reported the nucleotide changes G8950A in a LHON plus 
dystonia patient, with a decrease in mitochondrial respiratory activity. However, no 
other details about that patient were provided.350 The same authors identified the 
A8836G mutation, predicted as pathogenic by PolyPhen, but assessment of 
mitochondrial respiratory activity for this case was not available.351 Moreover, in this 
study the increase of mtDNA content is suggested as a marker of pathogenicity, but in 
the sample characterized by A8836G mutation the relative mtDNA content was lower 
than the proposed threshold (1.27 versus 1.76 of threshold).351 The heteroplasmic 
mutation A9016G was found in a LHON pedigree harboring the primary 14484/ND6 
mutation. The authors defined the A9016G a secondary mutation able to induce a 
complete penetrance of the primary mutation in males.352 However, the sequences 
reported in this study contain many errors as shown by successive analysis.353 Quoting 
Bandelt et al., 2007, “it is still an open question whether the heteroplasmic mutation 
A9016G is real and (...) could be blamed for the high penetrance of LHON in that 
family”.353 Another variant reported in ATPase6 gene is T9101C and causes a reduction 
in ATP synthase activity, even if the affected amino acid is poorly conserved.354 Thus, 
the role of these mutations is still unclear and debated. We also found in an LHON 
pedigree, negative for common mutation and belonging to haplogroup C, the rare 
variant T8555C/ATPase6 (data not shown, analysis still in progress). This mutation may 
affect an important functional domain of ATPase a subunit, being predicted by 
PolyPhen as possibly damaging (classified as “improper substitution in the 
transmembrane region”), and also by PMut, despite it affects a poorly conserved amino 
acid. 
In conclusion, we here propose for Family 5 two candidate pathogenic mutations 
(A8944G/ATPase6 and G14258A/ND6), but further studies are necessary, in particular 
biochemical investigations aimed to determine their real role on complex I and ATP 
synthase function. 
 
Rare mtDNA variants are associated to LHON plus myoclonus 
We here report the recurrence of myoclonus in two Italian LHON families as a feature 
of central nervous system involvement besides the optic nerve. Since myoclonus was 
strictly maternally inherited in Family A, we sequenced the entire mtDNA and found 
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that there was an accumulation of non-synonymous variants in both families, similar to 
what was recently reported for the modifying effect of haplogroup J on LHON 
penetrance.327 Occurrence of myoclonus in association with LHON has been previously 
reported in a few cases.355-357 In our families, myoclonus seemed to be a feature 
independent from optic neuropathy, being present also in one individual not visually 
affected. The complete mtDNA sequencing, in conjunction with the conservation 
analysis of the observed variants, provided new clues to explain myoclonus in these two 
LHON families. The 4136/ND1 mutation in Family A is of particular interest because it 
was previously reported only four times, of which three were LHON families carrying 
one of the primary mutations (the QLD1 family from Australia and two Italian 
families).242,325 The QLD1 family showed the co-occurrence, within the same maternal 
genealogy, of classical cases with LHON, cases of infantile encephalopathy with early 
deaths and features resembling Leigh syndrome, and cases of LHON and late onset of 
“spastic dystonia”.358 This mtDNA was a member of haplogroup U4 and carried the 
14484/ND6 LHON mutation, in conjunction with the 4160/ND1 mutation, which 
affects a very conserved amino acid position, the latter being implicated as responsible 
for the “plus” clinical features.242 In the QLD1 family the 4136/ND1 mutation 
characterized only a branch of the maternal lineage and was thus considered a de novo 
event. In contrast, the two 4136/ND1 LHON families from Italy harbored the 
11778/ND4 LHON mutation.325 Similar to our Family A, their mtDNAs were members 
of haplogroup T2. Furthermore, they were characterized by a control-region motif 
(16126-16153-16293-16294-16296-16519-73-150) identical to that seen in our Family 
A.327 The shared regional origin (Apulia) of the three Italian LHON families, and the 
fact that they also share a rare control-region motif (seen in only 1 out of 3087 Italian 
controls) indicate that the three T2 families are indeed related and share both the 
11778/ND4 and the 4136/ND1 mutations by descent from a common maternal ancestor. 
This scenario is further supported by the finding that the single mtDNA with an 
identical control-region motif found in the control subjects is also a member of 
haplogroup T2, but does not harbor either the 4136/ND1 or the 11778/ND4 mutations. 
The fact that the 11778/ND4 mutation in one of the three LHON families was still 
heteroplasmic, while all samples investigated from Family 1 (10 individuals), as well as 
the other two haplogroup T2 LHON probands were homoplasmic mutant for the 
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4136/ND1 mutation, reveals that the 4136/ND1 mutational event predated the 
11778/ND4 mutation.  
Thus, the 4136/ND1 mutation has the potential for a functional relevance and a 
deleterious effect on complex I activity. Its conservation and recurrent association with 
LHON pedigrees strongly indicate that its co-occurrence with the canonical 11778/ND4 
mutation may act synergistically to further impair complex I function, leading to a 
LHON “plus” phenotype. Furthermore, the same scenario applies to the 9139/ATPase6 
variant in Family A, which also shows similar features of conservation and could 
synergistically affect mitochondrial function. 
Sequence analysis in Family B revealed a novel combination of known non-
synonymous cytb amino acid changes. In particular, the 15773/cytb variant showed a 
remarkable conservation in mammals, and was predicted as “possibly damaging” by 
PolyPhen. Thus, it can be envisioned that in the presence of the 3460/ND1 mutation, the 
15773/cytb variant alone or the combination 15693/cytb+15773/cytb contribute to the 
clinical expression of the LHON “plus” phenotype – an effect analogous to that played 
by the cytb amino acid changes of haplogroup J in LHON patients in combination with 
the 11778/ND4 and 14484/ND6 mutations.327 The rationale for this functional effect is 
that complex I co-assembles with complex III to form a supercomplex, and 
accumulation of amino acid changes induced by non-synonymous polymorphisms may 
affect this process. Obviously, we cannot exclude at this time that further genetic 
variability in the nuclear genome may contribute to the “plus” phenotype in these 
patients. However, the co-segregation of myoclonus and other adjunctive features in 
Family A along the maternal line more consistently suggests a major role for mtDNA. 
 
Increased mtDNA content as a compensatory mechanism in LHON 
The increase of mtDNA content has been considered a compensatory response to the 
impaired function of the respiratory chain in aging and in some mitochondrial diseases. 
Several authors hypothesized that a reduced activity of the respiratory chain and the 
consequent ATP deficit, due to aging or mtDNA mutations, can induce a retrograde 
signaling pathway that results in increased mtDNA content to compensate the decreased 
cellular ATP levels. This hypothesis is supported by the increase of mtDNA copy 
number reported in different tissues of aged individuals, such as brain, skeletal muscle 
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or lung.359-361 Moreover, it has been shown that NRF-1 and Tfam, two major players in 
mtDNA transcription, are up-regulated at least in skeletal muscle of aged subjects.362 In 
MELAS and MERRF affected individuals it has been shown that the mtDNA copy 
number is significantly increased in leukocytes of young subjects compared to controls, 
whereas it is lower in old affected individuals.363 The compensatory mechanism in these 
diseases is also evident by the presence of RRFs in the skeletal muscle, generated by the 
subsarcolemmal accumulation of aberrant mitochondria. 
Conversely, skeletal muscle biopsies from LHON affected patients failed to reveal the 
presence of RRFs, even if in LHON/MELAS overlap syndromes they may be 
present.364  However, some signs of mitochondrial proliferation are apparent in skeletal 
muscle biopsies from LHON patients, for example the increased subsarcolemmal SDH 
activity.324,365 In LHON patients with the 11778/ND4 mutation, an increased succinate-
cytochrome c reductase activity, with normal complex III activity, has been reported in 
blood cells mitochondria, suggesting the occurrence of a nuclear compensatory effect 
for defective respiratory chain.366 Moreover, an increased mtDNA copy number in blood 
cells of LHON affected and asymptomatic carrier individuals harboring the 11778/ND4 
and 14484/ND6 mutations, has also been reported.367,368  
We analyzed the mtDNA content in peripheral blood cells and skeletal muscles of 
LHON affected and asymptomatic carriers belonging to the large 11778/ND4 Brazilian 
pedigree and to 39 Italian families harboring homoplasmic 11778/ND4, 14484/ND6 and 
3460/ND1 mutations. In the SOA-BR family we found a significant increase of blood 
cells mtDNA copy number in LHON individuals, both affected and carriers. 
Interestingly, asymptomatic carriers showed a significantly higher mtDNA copy 
number also compared to the affected. This result has also been confirmed by analysis 
of mtDNA content in Italian LHON blood samples, comparing affected to carrier 
individuals. In skeletal muscle we found an increase of mtDNA in both LHON affected 
and carriers compared to controls, but no differences were found between the two 
LHON groups. In fact, LHON carriers presented a higher mtDNA copy number 
compared to controls, but this difference was not statistically significant.  We believe 
that the increased mtDNA copy number may vary in different LHON individuals, being 
influenced by genetic and/or environmental unknown factors. The subjects with an 
efficient compensatory response have a high mtDNA copy number and may not develop 
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the disease (asymptomatic carriers), whereas those characterized by a lower mtDNA 
copy number cannot completely compensate for the energy defect and will be more 
prone to develop LHON (affected). We can neatly differentiate the LHON affected from 
asymptomatic carriers, setting a threshold for mtDNA copy number, and this parameter 
may now be considered a prognostic factor for developing LHON.   
We did not find any correlation between mtDNA content and age or sex. However, 
within the carrier group we found a different distribution of mtDNA copy number 
between males and females. In fact, female asymptomatic carriers show a lower mtDNA 
copy number compared to males. This effect can be explained if the compensatory 
response is assumed as a multifactorial mechanism, in which mtDNA copy number 
operates in conjunction with other factors. In this model, the mtDNA content threshold 
could be lower in females, but the compensatory mechanism could still remain efficient 
due to the involvement of other stimuli or factors, for example estrogens. 
Mitochondrial biogenesis is a complex and finely tuned process characterized by the 
coordinated expression of mitochondrial and nuclear genes. Several transcription factors 
are involved in this process, such as Tfam, NRF-1, NRF-2 and ERRα and the master 
regulators PGC-1α/β and PRC.129-131 In particular PGC-1α is the most studied and the 
best known transcriptional coactivator of this pathway. The polymorphism Gly482Ser 
has been associated to a variety of pathologies, such as hypertension, diabetes mellitus 
and insulin resistance. A recent study demonstrates that PGC-1α variant with Gly/Gly at 
482nd amino acid impairs Tfam transcription, thus lowering mtDNA replication.328 In 
particular, Choi et al., 2006, analyzed the mtDNA copy number of leukocytes from 
patients affected by diabetes mellitus and control individuals, reporting a 20% decrease 
of mtDNA in the homozygous variant G (Gly/Gly) of this polymorphism compared to 
the Ser/Ser variant.328 Thus, this polymorphic variant may influence mitochondrial 
biogenesis triggered as a compensatory mechanism by the energetic dysfunction in 
LHON. We performed a genotyping analysis on DNA samples from blood cells of all 
the available individuals (LHON and controls) and we evaluated the distribution of the 
G1444A (Gly482Ser) polymorphism and its possible correlation with mtDNA copy 
number. The Gly482Ser polymorphism was equally distributed in the different groups 
(LHON affected, LHON carriers and controls) and was not associated to differences in 
mtDNA copy number. Therefore, in our hands this variant does not influence the 
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mtDNA content in the analyzed populations and is not involved in the variable 
penetrance in LHON. 
The relative mRNA levels of PGC-1α/β, PRC and Tfam in skeletal muscle were also 
investigated. All these genes were upregulated in LHON skeletal muscle compared to 
controls, suggesting their involvement in the mitochondrial biogenesis induction in 
LHON subjects. Conversely, no differences in mRNA levels were found between 
LHON affected individuals and asymptomatic carriers. These results may simply reflect 
the lack of significant difference in mtDNA content between affected and carriers in 
skeletal muscle. They may also suggest an alternative mechanism in the increase of 
mtDNA content in asymptomatic carriers, for example an increase in Tfam or POLγ 
activity that may induce mtDNA replication also without the complex activation of 
PGC-1 dependent mitochondrial biogenesis. Thus, further investigations are necessary 
to understand the molecular mechanism that underlies the activation of mitochondrial 
biogenesis. In particular, a systematic analysis of mitochondrial proteome, 
transcriptome and functional studies in affected and carrier LHON subjects, may reveal 
new clues on LHON pathogenesis. 
 
Bezafibrate does not improve the energetic function of LHON cybrids 
Recently, several studies demonstrate that PGC-1 coactivators have a major role in 
mitochondrial biogenesis regulation, both in physiological and pathological conditions. 
Srivastava et al., 2007, demonstrated that PGC-1α/β overexpression can induce 
mitochondrial biogenesis, stimulates OXPHOS activity and mitochondrial respiration in 
cells harboring ND5 and COI nonsense mutations, suggesting a possible role of this 
pathway for an alternative therapeutic approach in respiratory chain deficiencies.369 
Moreover, PGC-1α overexpression in cell lines stimulates mitochondrial respiration, 
ATP production and mitochondrial mass, and, after the exposure to oxidant injury, 
accelerates the recovery of mitochondrial function.370 The overexpression of PGC-1α, 
induced by transgenic expression in skeletal muscle, stimulates the mitochondrial 
proliferation and prevents the energetic failure in a mouse model of myopathy.329 The 
authors demonstrate that induction of mitochondrial biogenesis successfully stimulates 
the respiratory chain function and ATP production, improving the mitochondrial 
myopathy phenotype, in terms of delayed onset and prolonged lifespan.329 Interestingly, 
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similar results have been obtained by oral administration of bezafibrate, a commercially 
available drug currently used in the pharmacological treatment of metabolic 
disorders.329 Bezafibrate is a PPARs pan-activator shown to induce PGC-1α expression, 
via PPARδ, at least in skeletal muscle (in cell lines and mice).371 Furthermore, 
bezafibrate-induced mitochondrial biogenesis compensates moderate respiratory chain 
defects in fibroblasts and myoblasts derived from patients with different respiratory 
chain dysfunction caused by mutations in nuclear genes (enzyme subunits or assembly 
factors).330  
However, bezafibrate effects on the respiratory chain are still debated; in a cell model 
and at high concentration (1 mM), this drug exhibits cytotoxic effects, induces lactate 
and acetate production and inhibits in vitro complex I activity.372 This latter result has 
also been confirmed at lower concentration of bezafibrate, but in this case the drug does 
not influence cellular oxygen consumption and has milder effects on respiratory chain, 
compared to other fibrates or thiazolidinediones.373 Conversely, Brunmair et al., 2004, 
showed that bezafibrate did not reduce complex I activity in skeletal muscle and liver 
homogenates.374  
We here characterized the bioenergetic function of LHON mutant cybrids and their 
response to bezafibrate treatment. In our model, bezafibrate was not able to induce 
mitochondrial biogenesis, in terms of mtDNA replication or steady-state respiratory 
chain protein levels, and did not influence the ATP synthesis rate or protect LHON 
cybrids from galactose induced apoptosis. This result may be due to the tumoral nature 
of cybrid cell lines, which are derived from the 143B TK- osteosarcoma parental cell 
line, and, furthermore, to the continous passages and selection in culture of these cells. 
Parental osteosarcoma or cybrid cell lines may accumulate chromosomal rearrangments 
(deletions, duplications or inversions) and consequently some assets in gene expression 
(for example genes belonging to the PGC-1 pathway) may be modified. Moreover, it 
has been demonstrated that multidrug resistance, mediated by ABC transporters, is 
present in several osteosarcoma cell lines, including 143B.375 This phenomenon may 
cause a lower uptake of bezafibrate or the efflux of the drug from the treated cells. 
Primary cell lines from LHON patients, such as fibroblasts or myoblasts, may therefore 
represent a better model for these studies. 
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Since 1988, when the first mtDNA mutation has been demonstrated to be the cause of 
Leber’s hereditary optic neuropathy, this pathology has been intensively studied, even 
though to date many questions are still open. In fact, main features of LHON, such as 
male prevalence, variable penetrance and tissue selectivity, are still under investigation 
and the underlying pathogenic mechanisms are still unknown. 
The results here reported contributed to the definition of new pathogenic LHON 
mutations and tried to clarify some aspects of the still unknown question of variable 
penetrance. The main concluding remarks of this thesis can be summarized as follows: 
- Novel structural models for ND1-ND4 and ND4L complex I subunits have been 
generated and conservation analysis and pathogenicity prediction have been 
carried out for all LHON reported mutations (confirmed and candidates). This 
in-silico approach allowed us to locate LHON pathogenic mutations in defined 
and conserved protein domains, in particular for ND1, ND4, ND5 and ND6. 
Moreover, this approach can be a useful tool in the analysis of novel mtDNA 
variants with unclear pathogenic/functional role. 
- Four rare LHON pathogenic mutations, two reported only once, have been 
identified. This study confirms that the ND1 and ND6 genes are mutational hot 
spots for LHON. All mutations were previously described at least once and we 
validated their pathogenic role, suggesting the need for their screening in LHON 
cases negative for the common mutations. Moreover, two novel mtDNA variants 
with a possible pathogenic role have been identified in two independent 
branches of a large pedigree. Functional studies are necessary to define their 
contribution to LHON in this family. 
- The combination of mtDNA rare polymorphic variants in complex I, ATP 
synthase or cytochrome b genes, has been shown to be relevant in determining 
the maternal recurrence of myoclonus in unrelated LHON pedigrees. Thus, we 
suggest that particular mtDNA backgrounds and /or the presence of specific rare 
mutations may increase the pathogenic potential of the primary LHON 
mutations, thereby giving rise to the extraocular clinical features characteristic 
of the LHON “plus” phenotype. 
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- We identify the first molecular parameter that clearly discriminates LHON 
affected individuals from LHON asymptomatic carriers, the mtDNA copy 
number. This provides a valuable mechanism for future investigations on 
variable penetrance in LHON. However, the increased mtDNA content in 
LHON individuals was not correlated to the functional polymorphism G1444A 
of PGC-1α, the master regulator of mitochondrial biogenesis, but may be due to 
gene expression of genes involved in this signaling pathway, such as PGC-1α/β 
and Tfam. 
Future studies will be necessary to identify the biochemical effects of rare 
pathogenic mutations and to validate the novel candidate mutations here described, 
in terms of cellular bioenergetic characterization of these variants. Moreover, we 
were not able to induce mitochondrial biogenesis in cybrids cell lines using 
bezafibrate. However, other cell line models are available, such as fibroblasts 
harboring LHON mutations, or other approaches can be used to trigger the 
mitochondrial biogenesis. For example, we showed that virus-mediated PGC-1α/β 
overexpression, can improve OXPHOS defects caused by mutations in nuclear 
genes or mtDNA (Srivastava S et al., Hum Mol Genet, in press).  
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Appendix A – Abbreviations (in alphabetical order) 
 
ADP: adenosine diphosphate 
AIF: apoptosis inducing factor 
AMP: adenosine monophosphate 
AMP07: average membrane preference 
AMPK: AMP activated protein kinase 
ANT: adenosine nucleotide translocator 
Apaf1: apoptotic protease activating factor 1 
ATF2: activating transcription factor 2 
ATP: adenosine triphosphate 
B17.2L: NDUFA assembly factor 2 
BAT: brown adipose tissue 
Bcl-2: B cell lymphoma 2 
BF: bezafibrate 
BH: Bcl-2 homology 
BIR: baculovirus inhibitor repeats 
BSA: bovine serum albumin 
CAD/DFF: caspase activated DNase/DNA 
fragmentation factor 
CamK: Ca2+/calmodulin dependent protein 
kinase 
CARD: caspase recruitment domains 
CBP: CREB binding protein 
cGMP: cyclic guanosine monophosphate 
CMT2A: Charcot-Marie-Tooth type 2A 
CoQ: coenzyme Q 
CoQH2: reduced coenzyme Q 
CPEO: Chronic Progressive External 
Opthalmoplegia 
CREB: cAMP response element binding 
protein 
Cyt b: cytochrome b 
Cyt c: cytochrome c 
DGUOK: deoxyguanosine kinase 
DMEM: Dulbecco’s modified Eagle medium 
DMSO: dimethyl sulfoxide 
DOA: Dominant Optic Atrophy 
DRIP: vitamin D receptor interacting proteins 
Drp1: Dynamin-related protein 
EDTA: ethylenediaminetetraacetic acid 
EGTA: ethylene glycol tetraacetic acid 
ER: estrogen receptor 
ERR: estrogen related receptor 
ERRE: Estrogen related response element 
FADH2: reduced flavin adenine dinucleotide 
FAK: focal adhesion kinase 
FBS: Fetal bovine serum 
FMN: flavin mononucleotide 
FoxO: forkhead box O 
Fzo1p: fuzzy onion 1 
GPx: gluthatione peroxidase 
HAT: histone acetyl transferase 
hFis1: human Fis 
HMG: high mobility group 
HMM: Hidden Markov Models 
HNF4: hepatocyte nuclear factor 4 
IAP: inhibitors of apoptosis protein 
ICAD: inhibitor of caspase activated DNase 
IMM: inner mitochondrial membrane 
KSS: Kearn Sayre Syndrome 
LHON: Leber’s hereditary optic neuropathy 
LRPPRC: Leucine-rich PPR-motif containing 
protein 
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MAC: mitochondrial apoptosis induced 
channel 
MEF2: myocite enhancer factor 2 
MELAS: Mitochondrial Encephalomyopathy 
Lactic Acidosis and Stroke-like episodes 
MERRF: Myoclonus, Epilepsy and Ragged-
Red Fibers 
Mfn1: mitofusin 1 
Mfn2: mitofusin 2 
Mgm1p: mitochondrial genome maintenance 
MILS: Maternally Inherited Leigh Syndrome 
MNGIE: Mitochondrial 
NeuroGastroIntestinal Encephalomyopathy 
MnSOD: Mn superoxide dismutase 
MPH: membrane propensity for 
haemoproteins 
MRI: Magnetic Resonance imaging 
MRS: Magnetic Resonance Spectroscopy 
MST1: mammalian sterile-20 
MT: microtubules 
mtDNA: mitochondrial DNA 
mTERF: mitochondrial termination factor 
mtRPOL: mitochondrial RNA polymerase 
mtSSB: mitochondrial single-stranded DNA 
binding protein 
Myb: v-myb myeloblastosis viral oncogene 
homolog 
NAD+: nicotinamide adenyndinucleotide 
NADH: reduced nicotinamide 
adenyndinucleotide 
NARP: Neuropathy, ataxia, retinitis 
pigmentosa 
nDNA: nuclear DNA 
NDUFA: NADH dehydrogenase (ubiquinone) 
1α subcomplex 
NDUFB: NADH dehydrogenase (ubiquinone) 
1β subcomplex 
NDUFS: NADH dehydrogenase (ubiquinone) 
Fe-S protein 
NDUFV: NADH dehydrogenase (ubiquinone) 
flavoprotein 
NFL: Nerve Fiber Layer 
NN: neural network 
NRF: nuclear respiratory factor 
Omi/HtrA2: HtrA serine peptidase 2 
OMM: outer mitochondrial membrane 
Opa1: optic atrophy 1 
OXPHOS: Oxidative Phosphorylation 
PBS: Phosphate buffered saline 
PCD: programmed cell death 
PDCH: pyruvate dehydrogenase complex 
PGC-1: peroxisome proliferator associated 
receptor γ coactivator 1 
PKA: protein kinase A 
PMSF: phenyl methyl sulphonyl fluoride 
Polγ: polymerase γ 
PPAR: peroxisome proliferator associated 
receptor 
PPRE: peroxisome proliferator associated 
receptor response element 
PRC: PGC-1 related coactivator 
PS: Pearson Syndrome 
PSIC: Position specific independent counts 
PTP: Permeability Transition Pore 
RAO-AR: Rao Argos 
rCRS: revised Cambridge reference sequence 
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RFLP: Restriction fragment length 
polymorphism 
RGCs: Retinal Ganglion Cells 
RMM: RNA recognition domain 
ROS: reactive oxygen species 
RRF: Ragged Red Fiber 
RRM2B: ribonucleotide reductase M2 B 
(TP53 inducible) 
RS: serine-arginine-rich domain 
RXR: retinoid acid X receptor 
SANDO: Sensory-Ataxia Neuropathy, 
Dysarthria and Opthalmoplegia 
SC35: splicing component 35kDa 
SDH: succinyl dehydrogenase 
SDS: sodium dodecyl sulphate 
SOX9: sex determining region Y box 9 
SRB: sulforodhamine B 
SRBP1: sterol regulatory element binding 
protein 
SRC-1: steroid receptor coactivator 1 
SRp:Ser/Arg protein 
SUCLA2: succinylCoA synthetase 
TCA: trichloroacetic acid 
Tfam: mitochondrial transcription factor A 
TFB1M: mitochondrial transcription factor 
B1 
TFB2M: mitochondrial transcription factor 
B2 
TK2: Thymidine Kinase 2 
TMH: transmembrane helix 
TNF: tumor necrosis factor 
TP: thymidine phosphorylase 
TRAIL: TNF related apoptosis inducing 
ligand 
TRAP: TR-associated proteins 
TZD: thiazolidinedione 
UCP: uncoupling protein 
VEGF: vascular endothelial growth factor 
YY1: YingYang1 
 
Appendix B – Primer sequences and PCR conditions 
 
163 
 
Appendix B – Primers sequences and PCR conditions 
 
LHON 11778 
Fw: 
5’-GAATGTAGGAGTAATGATAAG-3’ 
Rv: 
5’-ATTATCGAAAAACTACTGAAC-3’ 
1 cycle 25 cycles 1 cycle 
94°C x 5’ 94°C x 30’’ 
55°C x 60’’ 
72°C x 2’30’’ 
72°C x 7’ 
 
LHON 14484 
Fw: 
5’-ATCATATAGGTTTCTGTTGGT-3’ 
Rv: 
5’-GGGACTGGGGGTACGGAGTC-3’ 
1 cycle 25 cycles 1 cycle 
94°C x 5’ 94°C x 30’’ 
49°C x 60’’ 
72°C x 2’30’’ 
72°C x 7’ 
 
LHON 3460 
Fw: 
5’-AAGTGTTTCGCGGAAGGGGG-3’ 
Rv: 
5’-GAGTAACATGGGTAAGATTA-3’ 
1 cycle 30 cycles 1 cycle 
94°C x 5’ 94°C x 30’’ 
55°C x 30’’ 
72°C x 2’30’’ 
72°C x 7’ 
 
LHON 14495 
Fw: 
5’-AGTATATCCAAAGACAACCATCATTCCCCAT-3’ 
Rv: 
5’-ATGGGGGTTTAGTATTGATTGTTAGCGGTG-3’ 
1 cycle 25 cycles 1 cycle 
94°C x 5’ 94°C x 30’’ 
56°C x 30’’ 
72°C x 30’’ 
72°C x 7’ 
 
LHON 14459 
Fw: 
5’-ATGCCTCAGGATACTCCTCAATAGCCGTC-3’ 
Rv: 
5’-ATGGGGGTTTAGTATTGATTGTTAGCGGTG -3’ 
1 cycle 25 cycles 1 cycle 
94°C x 5’ 94°C x 30’’ 
56°C x 30’’ 
72°C x 30’’ 
72°C x 7’ 
 
LHON 3700 
Fw: 
5’-TGAAGCCTGAGACTAGTTCGG-3’ 
Rv: 
5’-ACTACAACCCTTCGCTGACG-3’ 
1 cycle 32 cycles 1 cycle 
96°C x 1’ 94°C x 15’’ 
56°C x 30’’ 
72°C x 15’’ 
72°C x 7’ 
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LHON 14568 
Fw: 
5’- CAAGACCTCAACCCCTGA-3’ 
Rv: 
5’-CATTGGTCGTGGTTGTAGTCCGTGC-3’ 
1 cycle 25 cycles 1 cycle 
94°C x 5’ 94°C x 30’’ 
55°C x 60’’ 
72°C x 2’30’’ 
72°C x 7’ 
 
Candidate pathogenic mutation 14528 
Fw: 
5’-CCTACTCCTAATCACATAACCTA-3’ 
Rv: 
5’-CATTGGTCGTGGTTGTAGTCCGTGC-3’ 
1 cycle 25 cycles 1 cycle 
95°C x 5’ 94°C x 30’’ 
59°C x 60’’ 
72°C x 2’30’’ 
72°C x 7’ 
 
Candidate pathogenic mutation 4172 
Fw: 
5’-ACGACCAACTCATACACCTG-3’ 
Rv: 
5’-TTACTCTATCAAAGTAACTCT -3’ 
1 cycle 25 cycles 1 cycle 
94°C x 5’ 94°C x 30’’ 
56°C x 60’’ 
72°C x 2’30’’ 
72°C x 7’ 
 
mtDNA polymorphism 4136 
Fw: 
5’-CCTGAACTCTACACAACA-3’ 
Rv: 
5’-TTACTCTATCAAAGTAACTCT-3’ 
1 cycle 25 cycles 1 cycle 
94°C x 5’ 94°C x 30’’ 
56°C x 60’’ 
72°C x 2’30’’ 
72°C x 7’ 
 
mtDNA polymorphism 9319 
Fw: 
5’-GCCTAACCGCTAACATTACT-3’ 
Rv: 
5’-CTGGAGTGGTAAAAGGCTCA-3’ 
1 cycle 25 cycles 1 cycle 
94°C x 5’ 94°C x 30’’ 
56°C x 60’’ 
72°C x 2’30’’ 
72°C x 7’ 
 
mtDNA polymorphism 15773 
Fw: 
5’-CAGAATAATAACACACCCGA-3’ 
Rv: 
5’-GGAGTTGCAGTTGATGTGTG-3’ 
1 cycle 25 cycles 1 cycle 
94°C x 5’ 94°C x 30’’ 
56°C x 60’’ 
72°C x 2’30’’ 
72°C x 7’ 
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PGC-1α polymorphism 1444 
Fw: 
5’-TGCTACCTGAGAGAGACTTTG-3’ 
Rv: 
5’- CTTTCATCTTCGCTGTCATC-3’ 
1 cycle 30 cycles 1 cycle 
94°C x 5’ 94°C x 60’’ 
60°C x 60’’ 
72°C x 60’’ 
72°C x 10’ 
 
 
Real Time PCR assays 
PGC-1α Fw: 
5’-ACACAGTCGCAGTCACAACAC-3’ 
Rv: 
5’-GGAGTGGTGGGTGGAGTTAGG-3’ 
PGC-1β Fw: 
5’-CAGACAGAACGCCAAGCATC-3’ 
Rv: 
5’-TCGCACTCCTCAATCTCACC-3’ 
PRC Fw: 
5’-CAAGCAGAAACAGAAGAGAGAAG-3’ 
Rv: 
5’-GGTGGGATGACAAGACAAGG-3’ 
Tfam Fw: 
5’-AACAACGAAAATATGGTGCTGAGG-3’ 
Rv: 
5’-CAAGTATTATGCTGGCAGAAGTCC-3’ 
Actin B Fw: 
5’-ACTATGACTTAGTTGCGTTACCA -3’ 
Rv: 
5’-GCCATGCCAATCTCATCTTG -3’ 
PREINCUBATION AMPLIFICATION MELTING CURVE 
1 cycle 45 cycles 1 cycle 
95°C x 10’ 95°C x 30’’ 
56°C x 20’’ 
72°C x 25’’ 
Acquisition of fluorescence signal 
95°C x 5’ 
65°C x 1’ 
65°C - 97°C (ramp rate 0.11°C/s) 
Acquisition of fluorescence in continous  
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C – Family trees of the investigated pedigrees
 
 
Appendix C – Family trees
166
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3. Myoclonic Italian  LHON pedigrees
4. SOA-BR family 
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Appendix D – Raw data from complete mtDNA sequencing 
 
Family 1  - Haplogroup H 
Position Map Locus Nucleotide change relative to rCRS  Amino acid change Notes 
150 D-loop C to T -  
263 D-loop A to G -  
315+C D-loop Insertion C -  
750 12S rRNA A to G -  
1438 12S rRNA A to G -  
3107d 16S rRNA Deletion C -  
3700 ND1 G to A Ala to Thr  
4769 ND2 A to G Synonym  
8856 ATPase6 G to A Synonym  
8860 ATPase6 A to G Thr to Ala +8858HhaI 
13759 ND5 G to A Ala to Thr  
15326 Cyt b A to G Thr to Ala  
16192 D-loop C to T -  
16261 D-loop C to T -  
16289 D-loop A to G -  
16519 D-loop T to C -  
 
Family 2  - Haplogroup U6a 
Position  Locus Nucleotide change relative to rCRS  Amino acid change Notes 
73 D-loop A to G -  
263 D-loop A to G -  
309+C D-loop Insertion C -  
315+C D-loop Insertion C -  
523+CA D-loop Insertion CA -  
750 12S rRNA A to G -  
1438 12S rRNA A to G -  
2706 16S rRNA A to G -  
3107d 16S rRNA Deletion C -  
3348 ND1 A to G Synonym  
3369 ND1 G to A Synonym  
4172A ND1 T to A Transversion Leu to Gln  
4769 ND2 A to G Synonym  
7028 COI C to T Synonym  
7805 COII G to A Val to Ile  
8860 ATPase6 A to G Thr to Ala +8858HhaI 
11467 ND4 A to G Synonym -11465MseI  
11719 ND4 G to A Synonym -11718HaeIII 
11722 ND4 T to C Synonym  
11938 ND4 C to T Synonym  
12308 tRNA Leu2 A to G -  
12372 ND5 G to A Synonym  
14179 ND6 A to G Synonym  
14568 ND6 C to T Gly to Ser heteroplasmic 
14766 Cyt b C to T Thr to Ile +14766MseI 
14926 Cytb A to G Synonym  
15221 Cytb G to A Asp to Asn  
15326 Cyt b A to G Thr to Ala  
16172 D-loop C to T -  
16183C D-loop A to C Transversion -  
16189 D-loop T to C -  
16219 D-loop A to G -  
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Family 2  - Haplogroup U6a                                                                                                                     (continue) 
Position  Locus Nucleotide change relative to rCRS  Amino acid change Notes 
16239 D-loop C to T -  
16278 D-loop C to T -  
 
 
Family 3 – Haplogroup J1c 
Position Map Locus Nucleotide change relative to rCRS  Amino acid change Notes 
73 D-loop A to G -  
185 D-loop G to A -  
189 D-loop A to G -  
228 D-loop G to A -  
263 D-loop A to G -  
295 D-loop C to T   
315+C D-loop Insertion C -  
462 D-loop C to T   
489 D-loop T to C   
750 12S rRNA A to G -  
1438 12S rRNA A to G -  
2706 16S rRNA A to G -  
3010 16S rRNA G to A   
3107d 16S rRNA Deletion C -  
4216 ND1 T to C Tyr to His +4216NlaIII 
4769 ND2 A to G Synonym  
7028 COI C to T Synonym  
8860 ATPase6 A to G Thr to Ala  
10398 ND3 A to G Thr to Ala +10394DdeI 
11251 ND4 A to G Synonym -11251Tsp509I 
11719 ND4 G to A Synonym  
12612 ND5 A to G Synonym  
13708 ND5 G to A Ala to Thr -13704BstOI 
13934 ND5 C to T Thr to Met  
14459 ND6 G to A Ala to Thr  
14766 Cyt b C to T Ile to Thr  
14798 Cyt b T to C Phe to Leu  
15326 Cyt b A to G Thr to Ala  
15452A Cyt b C to A Transversion Leu to Ile  
16069 D-loop C to T -  
16114 D-loop C to T -  
16126 D-loop T to C -  
 
Family 4  - Haplogroup H 
Position Map Locus Nucleotide change relative to rCRS  Amino acid change Notes 
195 D-loop T to C -  
263 D-loop A to G -  
315+C D-loop Insertion C -  
750 12S rRNA A to G -  
1438 12S rRNA A to G -  
2060 16S rRNA A to G -  
3107d 16S rRNA Deletion C -  
4769 ND2 A to G Synonym  
7337 COI G to A Synonym  
8860 ATPase6 A to G Thr to Ala  
14495 ND6 A to G Leu to Ser  
15326 Cyt b A to G Thr to Ala  
16129 D-loop G to A -  
16248 D-loop C to T -  
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Family 5 – Haplogroup K1a                                                                                                                         
Position Map Locus Nucleotide change relative to rCRS  Amino acid change Notes 
73 D-loop A to G -  
263 D-loop A to G -  
315+C D-loop Insertion C -  
497 D-loop C to T -  
750 12S rRNA A to G -  
1189 12S rRNA T to C   
1438 12S rRNA A to G -  
1811 16S rRNA A to G -  
2281 16S rRNA A to G -  
2706 16S rRNA A to G -  
3107d 16S rRNA Deletion C -  
3480 ND1 A to G Synonym  
4769 ND2 A to G Synonym  
6137 COI T to C Synonym  
6329 COI C to T Synonym  
7028 COI C to T Synonym +7025AluI 
8860 ATPase6 A to G Thr to Ala +8858HhaI 
8944 ATPase6 A to G Met to Val  
9055 ATPase6 G to A Ala to Thr  
9698 COIII T to C Synonym  
10398 ND3 A to G Thr to Ala  
10550 ND4L A to G Synonym  
11038 ND4 A to G Synonym  
11299 ND4 T to C Synonym  
11467  ND4 A to G Synonym -11465MseI 
11719 ND4 G to A Synonym -11718HaeIII 
12308 tRNA Leu2 A to G - +12308HinfI 
12372 ND5 G to A Synonym  
14167 ND6 C to T Synonym   
14258 ND6 G to A Pro to Leu  
14582 ND6 A to G Val to Ala  
14766 Cyt b C to T Thr to Ile +14766MseI 
14798 Cyt b T to C Phe to Leu  
15253 Cyt b A to G Synonym  
15326 Cyt b A to G Thr to Ala  
16129 D-loop G to A -  
16224 D-loop T to C -  
16311 D-loop T to C -  
16519 D-loop T to C -  
 
Family A – Haplogroup T2 
Position Map Locus Nucleotide change relative to rCRS  Amino acid change Notes 
73 D-loop A to G -  
150 D-loop C to T -  
263 D-loop A to G -  
309+C D-loop Insertion C -  
315+C D-loop Insertion C -  
523+CA D-loop Insertion CA -  
709 12S rRNA G to A -  
750 12S rRNA A to G -  
1438 12S rRNA A to G -  
1888 16S rRNA G to A -  
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Family A – Haplogroup T2                                                                                                                       (continue) 
Position Map Locus Nucleotide change relative to rCRS  Amino acid change Notes 
2706 16S rRNA A to G -  
3107d 16S rRNA Deletion C -  
4136 ND1 A to G Tyr to Cys  
4216 ND1 T to C Tyr to His +4216NlaIII 
4769 ND2 A to G Synonym  
4917 ND2 A to G Asn to Asp +4917BfaI 
6026 COI G to A Synonym  
7028 COI C to T Synonym +7025AluI 
8222 COII T to C Synonym  
8697 ATPase6 G to A Synonym  
8860 ATPase6 A to G Thr to Ala +8858HhaI 
9139 ATPase6 G to A Ala to Thr  
10463 tRNA Arg T to C -  
11251 ND4 A to G Synonym -11251Tsp509I 
11719 ND4 G to A Synonym -11718HaeIII 
11778 ND4 G to A Arg to His  
11812 ND4 A to G Synonym  
13368 ND5 G to A Synonym -11718HaeIII 
14233 ND6 T to C Synonym -11718HaeIII 
14766 Cyt b C to T Thr to Ile +14766MseI 
14905 Cyt b G to A Synonym  
15326 Cyt b A to G Thr to Ala  
15452A Cyt b C to A Transversion Leu to Ile  
15607 Cyt b A to G Synonym +15606AluI 
15928 tRNA Thr G to A - -15925MspI 
16126 D-loop T to C -  
16153 D-loop G to A -  
16293 D-loop A to G -  
16294 D-loop C to T -  
16296 D-loop C to T -  
 
Family B – Haplogroup U4a                                                                                                                       
Position Map Locus Nucleotide change relative to rCRS  Amino acid change Notes 
73 D-loop A to G -  
195 D-loop T to C -  
247 D-loop G to A -  
263 D-loop A to G -  
309+C D-loop Insertion C -  
315+C D-loop Insertion C -  
499 D-loop G to A -  
523+4CA D-loop insertion CACACACA -  
750 12S rRNA A to G -  
801 12S rRNA A to G   
1438 12S rRNA A to G -  
1811 16S rRNA A to G -  
2706 16S rRNA A to G -  
2792 16S rRNA A to G -  
3107d 16S rRNA Deletion C -  
3460 ND1 G to A Ala to Thr  
4646 ND2 T to C Synonym  
4769 ND2 A to G Synonym  
5999 COI T to C Synonym  
6047 COI A to G Synonym  
6665 COI C to T Synonym  
6929 COI A to G Synonym  
7028 COI C to T Synonym +7025AluI 
8065 COII G to A Synonym  
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Family B – Haplogroup U4a                                                                                                                      (continue)                                                                                                     
Position Map Locus Nucleotide change relative to rCRS  Amino acid change Notes 
8818 ATPase6 C to T Synonym  
8860 ATPase6 A to G Thr to Ala +8858HhaI 
11332 ND4 C to T Synonym  
11467  ND4 A to G Synonym -11465MseI  
11719 ND4 G to A Synonym -11718HaeIII 
12308 tRNA Leu2 A to G - +12308HinfI 
12372 ND5 G to A Synonym  
14620 ND6 C to T Synonym  
14766 Cyt b C to T Thr to Ile +14766MseI 
15326 Cyt b A to G Thr to Ala  
15693 Cyt b T to C Met to Thr  
15773 Cytb G to A Val to Ala  
16356 D-loop T to C -  
16362 D-loop T to C -  
16519 D-loop T to C -  
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